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ABBREVIATIONS 
 
ACC: acetyl coenzyme A carboxylase. 
Acetyl CoA: acetyl coenzyme A. 
ALT: alanine aminotransferase. 
AMPK: AMP activated protein kinase. 
ApoB: apolipoprotein B 100. 
AST: aspartate transaminase. 
ATP: adenosine triphosphate. 
BA: bile acid. 
BCLC: Barcelona clinic liver cancer. 
BDL: bile duct ligation. 
BHMT: betaine homocysteine S-methyltransferase. 
BMI: body mass index. 
BN-PAGE: blue native-polyacrylamide gel electrophoresis. 
BSEP: bile salt export pump. 
BrdU: bromodeoxyuridine. 
CA: cholic acid. 
CBS: cystathionine-beta-synthase. 
CCL: C-C motif chemokine ligand. 
CCR: C-C motif chemokine receptor. 
CDCA: chenodeoxycholic acid. 
ChREBP: Carbohydrate-responsive element-binding protein. 
CPT: carnitine palmitoyltransferase. 
CXCL: C-X-C motif chemokine ligand. 
CXCR: C-X-C motif chemokine receptor. 
CYPs: cytochrome P450. 
Cyt c: cytochrome c. 
DCA: deoxycholic acid. 
DCR: disease control rate. 
DGAT: diacylglycerol acyltransferase. 
DMEM: Dulbecco’s modified eagle medium.  
MicroRNAs in liver disease 
24 
 
DNMT: DNA methyltransferase. 
DR5: death receptor 5. 
ECM: extracellular matrix. 
EGF: epidermal growth factor 
EGFR: epidermal growth factor receptor 
EMT: epidermal mesenchymal transition. 
ETC: electron transport chain. 
ER: endoplasmic reticulum. 
EZH2: enhancer of zeste homolog 2. 
FA: fatty acid. 
FAO: fatty acid oxidation. 
FASN: fatty acid synthase. 
FBS: fetal bovine serum. 
FGF: fibroblast growth factor. 
FGFR: fibroblast growth factor receptor. 
FFA: free fatty acid. 
FXR: farnesoid X receptor. 
FD: fructose diet. 
FADH2/FAD: Flavin adenine dinucleotide. 
GNMT: glycine N-methyltransferase. 
Gnmt-/-: Gnmt-knock out. 
GSH: glutathione. 
HAT: histone acetyltransferase. 
HBV: hepatitis B virus. 
HCC: hepatocellular carcinoma. 
HCD: high cholesterol diet. 
HCV: hepatitis C virus. 
HCY: homocysteine. 
HDAC: histone deacetylase. 
HDL: high density lipoprotein. 
HFD: high fat diet. 
HSC: hepatic stellate cell. 
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IL-6: interleukin 6. 
IP: immunoprecipitated protein. 
i.v.: intravenously. 
JAK: janus kinase. 
JNK: c-Jun N-terminal kinase. 
KB: ketone body. 
KC: Kupffer cell. 
LCA: lithocholic acid. 
LDL: low density lipoprotein. 
LC-MS: liquid chromatography-mass spectrometry.  
MAT: methionine adenosyltransferase. 
MeCP2: Methyl-CpG Binding Protein 2. 
MBD: methyl binding domain. 
MCDD: methionine choline deficient diet. 
MCP-1: monocyte chemoattractant protein-1. 
MDMC: medium deficient in methionine and choline. 
MDR: multi drug resistance. 
MEM: minimum essential medium. 
MiR, miRNA: microRNA. 
MMP: metalloproteinase. 
MOC: mechanisms of chemoresistance. 
MRP: multidrug resistance associated protein. 
MS: methionine synthase. 
MTA: 5’-methylthioadenisine. 
MTHFR: methylenetetrahydrofolate reductase. 
MTHFS: methenyltetrahydrofolate synthetase. 
mTOR: mammalian target of rapamycin. 
MVUH: Marqués de Valdecilla University Hospital 
NADH/NAD+: nicotinamide adenine dinucleotide. 
NAFL: non-alcoholic fatty liver. 
NAFLD: non-alcoholic fatty liver disease. 
NASH: non-alcoholic steatohepatitis.  
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NF-κB: nuclear factor kappa-light-chain-enhancer of activated B cells. 
NK: natural killer. 
NOS: nitric oxide synthase. 
NPC2: Niemann-Pick type C2 protein. 
NT: non-tumor. 
OA: oleic acid. 
OCR: oxygen consumption rate. 
OS: overall survival. 
OXPHOS: oxidative phosphorylation. 
PBC: primary biliary cholangitis; primary biliary cirrhosis. 
PBS: Phosphate buffered saline. 
PC: phosphatidylcholine. 
PCR: polymerase chain reaction. 
PDGF: platelet-derived growth factor 
PDGFR: platelet-derived growth factor receptor. 
PE: phosphatidylethanolamine. 
PEMT: phosphatidylethanolamine N-methyltransferase. 
PIAS: protein inhibitor of activated STAT. 
PPAR: peroxisome proliferator-activated receptors. 
PSC: primary sclerosing cholangitis. 
PSG: penicillin, streptomycin and glutamine. 
PUMA: P53 upregulated modulator of apoptosis. 
RNA: ribonucleic acid. 
ROS: reactive oxygen species. 
RT: room temperature. 
RT qPCR: quantitative real-time reverse transcription polymerase chain reaction. 
RTS: radiological time of progression. 
SAH: S-adenosylhomocysteine. 
SAHH: S-adenosylhomocysteine hydrolase. 
SAMe: S-adenosylmethionine. 
SDH: succinate dehydrogenase. 
Sf: sorafenib. 
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SHARP: sorafenib hepatocellular carcinoma assessment randomized protocol. 
SHP: small heterodimer partner. 
SiRNA: small interfering RNA. 
SLC: solute carrier. 
SOCS: suppressor of cytokine signaling. 
SOD: superoxide dismutase. 
SREBP-1c: sterol regulatory element-binding protein 1. 
STAT: signal transducers and activators of transcription. 
T: tumor. 
TACE: transarterial chemoembolization. 
TCA: tricarboxylic acid. 
TET: ten-eleven translocation.  
TG: triglyceride. 
TGFβ: transforming growth factor beta. 
TIMP: tissue inhibitor of metalloproteinase. 
TKR: tyrosine kinase receptor. 
TNF: tumor necrosis factor. 
TRAIL: TNF-related apoptosis inducing ligand. 
TTSP: time to symptomatic progression. 
UN: Universidad de Navarra. 
VEGF: vascular endothelial growth factor. 
VEGFR: vascular endothelial growth factor receptor. 
VLCFA: very long-chain fatty acid. 
VLDL: very low-density lipoprotein. 
αSMA: alpha smooth muscle actin. 
5mC: 5-methylcytosine. 
5hmC: 5-hydroxymethylcitosine. 
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SUMMARY 
Chronic liver disease refers to a large group of pathologies generally characterized 
by a slow progression and the final development of cirrhosis and hepatocellular 
carcinoma. It can be caused by several damaging agents that affect liver function, such as 
alcohol and drug abuse, hepatitis virus infection, autoimmune and hereditary disorders 
and non-alcoholic fatty liver disease. Chronic liver disease is one of the most frequent 
cause of mortality in the United States and Europe. The increasing amount of emerging 
risk factors associated with chronic liver disease and the lack of effective therapies to 
treat it highlight the necessity of the better characterization of the molecular mechanism 
underlying this disease. 
During the last years, increasing evidence have indicated dysregulations of 
methionine and S-adenosylmethionine (SAMe) metabolism and of those enzymes 
participating in the methionine cycle are implicated in different manifestations of chronic 
liver disease. Studies carried out by our group and others have identified frequent 
downregulation of Glycine N-methyltransferase (GNMT), the most important enzyme 
implicated in SAMe catabolism, in liver pathologies such as NAFLD, cholestasis, 
fibrosis, cirrhosis and hepatocellular carcinoma. These studies have revealed GNMT 
deficiency as an important mechanism driving liver disease and affecting several hepatic 
functions. Despite the importance of GNMT for normal liver function avoiding liver 
disease development, the mechanisms mediating GNMT downregulation have been 
poorly addressed and present several limitations concerning their implication in liver 
disease. 
Parallel, the recent discovery of the microRNAs has led to understand many 
biological processes and diseases. MicroRNAs are small non-coding RNAs that regulate 
gene expression at the posttranscriptional level by mRNA targeting and repression. Since 
the microRNAs discovery, the expression of many miRNAs has been described 
deregulated in liver disease, contributing to understand liver pathobiology and emerging 
as new targets for the design of liver therapies. 
The main objective of this project is to study the general mechanism mediating 
GNMT downregulation in different chronic liver disease scenarios: NAFLD, cholestasis 
and fibrosis and HCC. We hypothesize that GNMT is targeted and repressed by 
dysregulated microRNAs in the liver. 
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NAFLD is one of the most frequent chronic liver diseases in develop countries, 
where it is associated with metabolic syndrome risk factors and can range from simple 
steatosis (lipid accumulation) to steatohepatitis (NASH). GNMT is frequently 
downregulated in NAFLD patients and murine models and the Gnmt-/- mouse 
spontaneously develops hepatic steatosis and steatohepatitis without body mass gain. We 
show miR-873-5p is upregulated in human NAFLD patients and in murine dietary 
models, correlating GNMT downregulation. Inhibition of miR-873-5p results in normal 
expression of GNMT in the liver and in concrete in the mitochondrion. Mitochondrial 
GNMT levels are essential for the maintenance of SDH Complex II activity in the ETC, 
avoiding ROS generation, mitochondrial dysfunction and reduction in fatty acid β-
oxidation and OXPHOS. 
We have further investigated the role of miR-873-5p in cholestasis, fibrosis and 
cirrhosis, diseases characterized by GNMT downregulation and aggravated in the absence 
of this enzyme. MiR-873-5p upregulation correlates with GNMT downregulation in 
human and murine fibrotic models. Anti-miR-873-5p treatment in mice inhibits miR-873-
5p mediated repression of GNMT. Recovery of GNMT in hepatocytes and other hepatic 
cell types protects from hepatocyte apoptosis, ductular proliferation, inflammation and 
fibrogenesis. Normal GNMT levels restores SAMe metabolism, avoiding aberrant DNA 
and histone methylation, highlighting the importance of maintaining homeostatic 
methionine and SAMe metabolism in the liver. 
Chronic liver disease can evolve to hepatocellular carcinoma (HCC). HCC is the 
fifth most common cancer and the second cause of cancer related death, due to the high 
heterogeneity of the tumor and the presence of several molecular pathways converging 
within the tumor. HCC is a very poor prognosis cancer with difficult treatment and low 
success of the unique anticancer drug approved for systemic therapy (sorafenib), due to 
the above mentioned characteristics that frequently leads to drug resistance. Upregulation 
of miR-518d-5p correlates with GNMT downregulation in HCC. We have demonstrated 
that serum miR-518d-5p levels are increased in patients considered as non responders to 
sorafenib treatment in a prospective cohort. Therefore miR-518d-5p appears as a 
predictor biomarker for Sorafenib response. Sorafenib resistance in hepatoma cells is 
resolved by miR-518d-5p inhibition, which results in GNMT and c-Jun upregulation, 
both of them direct targets of the microRNA. MiR-518d-5p regulation of sorafenib 
induced apoptosis is mediated by increasing ROS and mitochondrial dysfunction. 
 Summary 
33 
 
In conclusion our results show the importance of the GNMT in the maintenance 
of liver health. The microRNAs miR-873-5p and miR-518d-5p are implicated in GNMT 
downregulation in different stages of chronic liver disease, affecting different cellular 
processes and emerging as interesting therapeutical targets. 
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2 INTRODUCTION 
2.1 CHRONIC LIVER DISEASE 
Chronic liver disease is a term that includes a broad group of hepatic pathologies 
from different etiology that last longer than 6 months and are commonly ended in 
cirrhosis and hepatocellular carcinoma (HCC) (Mishra and Younossi, 2012; Riley and 
Bhatti, 2001; Vernon et al., 2011). Chronic liver disease is one of the leading cause of 
mortality in the United States and Europe and it can be caused by different pathologies, 
including  viral infection of hepatitis B and C, toxins, alcohol and drug abuse, some 
autoimmune liver disease (primary sclerosis cholangitis and primary biliary cirrhosis), 
hereditary diseases and Non-Alcoholic Fatty Liver Disease (NAFLD) (Mishra and 
Younossi, 2012; Riley and Bhatti, 2001; Vernon et al., 2011). Despite the different 
etiology of these pathologies termed as chronic liver disease, most of them are 
characterized by a slow progression, frequently over 20 to 40 years, from hepatitis to 
cirrhosis and finally HCC (Riley and Bhatti, 2001). 
2.1.1 NON-ALCOHOLIC FATTY LIVER DISEASE  
NAFLD is emerging as one of the most frequent causes of chronic liver disease 
worldwide (Vernon et al., 2011) and, particularly, as the main manifestation in Western 
countries, with and incidence of 20-30% in general population, becoming a major health 
problem in the world (Bellentani et al., 2010; Loomba and Sanyal, 2013). NAFLD is a 
clinical syndrome that includes a spectrum of hepatic disorders ranging from simple lipid 
accumulation within the hepatocytes (steatosis or non-alcoholic fatty liver; NAFL) to 
hepatic steatosis with inflammation and, occasionally, fibrosis (steatohepatitis or non-
alcoholic steatohepatitis; NASH). 
NAFLD is closely associated to obesity, type 2 diabetes, insulin resistance, 
dyslipidemia and hypertension (Adams and Lindor, 2007; Adams et al., 2005; Calzadilla 
Bertot and Adams, 2016; Loomba and Sanyal, 2013; Noureddin and Rinella, 2015; Teli 
et al., 1995; Utzschneider and Kahn, 2006; Vernon et al., 2011), all of them considered 
risk factors for the development of metabolic syndrome (Siegel and Zhu, 2009). 
Moreover, NAFLD prevalence (accounted for a 20-30% in general population in western 
countries) is increased to 30-50% in diabetic patients and presented in 80-90% in obese 
people, tuning almost universal when combining both factors (Bellentani et al., 2010). In 
the case of children, NAFLD prevalence has risen up from 3-10% to 40-70% (Bellentani 
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et al., 2010). The increase prevalence of NAFLD during the last years is expected to rise 
up in the near future as patients with metabolic syndrome are increased; hence, NAFLD 
represent an incoming global health problem (Loomba and Sanyal, 2013; Mishra and 
Younossi, 2012). 
The progression of NAFLD requires a set of steps usually studied as the “two-hit 
hypothesis” (Day and James, 1998; Sanyal, 2005) (Figure 2.1). First, an initial “hit” in 
the liver is given to start a process of adipose tissue lipopisis leading to fatty acids (FAs) 
accumulation in the liver, developing steatosis/NAFL. Steatosis is frequently considered 
a benign disease with good prognosis that is commonly reversible by changing underlying 
causes of the disease like unhealthy lifestyle (Mishra and Younossi, 2012). Despite the 
good prognosis of steatosis, about a 10%-30% of the patients with simple steatosis 
progress NASH, with 20% of them developing cirrhosis within the next 10 years (Farrell 
and Larter, 2006; Harrison et al., 2003; Marrero et al., 2002) and, finally, liver failure and 
HCC (4-27%) (Takuma and Nouso, 2010). For this initial progression from steatosis to 
NASH, a second “hit” is required. Different possible second “hits” have been proposed 
by researchers, being the most commonly accepted the activation of endoplasmic 
reticulum (ER) stress and the increase oxidative stress by overproduction of reactive 
oxygen species (ROS) and/or decreased  antioxidant defences (Day and James, 1998; 
Sanyal, 2005). The continue overproduction of ROS leads to mitochondrial dysfunction 
(Berson et al., 1998), release of proinflammatory cytokines (Day, 2006; Kershaw and 
Flier, 2004) and hepatocyte apoptosis , contributing to the development of hepatitis and 
fibrosis (Berson et al., 1998; Sanyal, 2005).  
 
Figure 2.1. Liver disease progression from NAFLD to HCC. Steatosis develops as a consequence of 
lipid storage in the liver due to different causes (1st “hit”). 2nd “hit” in form of reactive oxygen species 
(ROS), lipotoxicity and endoplasmic reticulum stress can be presented in the liver, leading to non-
alcoholic steatohepatitis (NASH) in 10%-30% of NAFLD patients. Sustained damage results in fibrotic 
 Introduction 
 
39 
 
response and cirrhosis in 25% of patients. Finally, 4-27% of cirrhotic patients can develop hepatocellular 
carcinoma (HCC), the most common manifestation of liver cancer. 
 
Despite the common use of this “two-hit” hypothesis to refeer to the progression 
of NAFLD, nowadays it is becoming more evident that different factors may converge at 
the same time synergistically contributing to the development of the disease, which is 
known as the “multiple-hit” hypothesis. In the next two sections the mechanisms 
implicated in the initiation (alterations in lipid homeostasis, “first hits” or “factors”) and 
the progression (ROS production and mitochondrial dysfunction “second hits”) required 
for the development of NAFLD will be described.  
2.1.1.1 Alterations in lipid homeostasis 
As mentioned before, hepatic steatosis is characterized by lipid accumulation in 
the liver that results from an imbalance between processes involved in production and 
turnover. Increased fatty acid uptake and/or de novo lipogenesis and defective triglyceride 
export and lipid degradation will lead to this lipid accumulation in the hepatocytes (Figure 
2.2). 
 
Figure 2.2. Main pathways implicated in triglyceride accumulation in the liver and disease 
progression. NAFLD is characterized by TG accumulation in lipid droplets. This can be the 
consequence of increased FA uptake from the diet or adipose tissue, enhanced lipogenesis in the liver, 
decreased VLDL secretion and impairment in β-oxidation. Lipid accumulation can predispose the liver 
to mitochondrial dysfunction, with increased ROS, which later promotes inflammation and apoptosis in 
hepatocytes, leading to disease progression (NASH). 
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2.1.1.1.1 Increased de novo lipogenesis and fatty acid uptake 
De novo lipogenesis is a process regulated mainly by the enzymes acetyl 
coenzyme A (acetyl CoA) carboxylase (ACC) and fatty acid synthetase (FASN) that 
constitutes an important source of FAs in the liver. De novo lipogenesis contribution to 
hepatic TG content in normal individuals is estimated at less than 5% while it has been 
described to be increased in NAFLD patients accounting for 15-23%, even during fasting 
stages (Diraison et al., 2003; Donnelly et al., 2005; Lambert et al., 2014). In this context, 
nutrients coming from the diet are very relevant contributors to de novo lipogenesis in the 
liver. Not only FAs but also carbohydrates and fructose constitute important sources of 
FAs to the global liver pool. 
Finally, the FA pool in the liver can be also altered by an excess of free fatty acids 
(FFAs) supply from the white adipose tissue. White adipose tissue is the major source of 
FA in the body. Under specific circumstance, TG contained in the adipose tissue are 
hydrolysed releasing FFAs that are delivered to the liver. This process has been found to 
be upregulated in NAFLD (Fabbrini et al., 2010). 
De novo lipogenesis must be tightly regulated by several molecular mechanisms 
that implicates different enzymes (ACC1/2, FAS, stearoyl-CoA desaturase 1 (SCD1) and 
diacylglycerol acyltransferase (DGAT) 1/2)) involved in the conversion of acetyl CoA to 
palmitate and TG. These enzymes are, in turn, transcriptionally regulated by several 
transcription factors, particularly the sterol regulatory element-binding protein-1 isoform 
c (SREBP-1c) (Shimano et al., 1997; Shimomura et al., 1999) and the carbohydrate 
response element-binding protein (ChREBP) (Yamashita et al., 2001), stimulated by 
insulin and glucose, respectively. Other transcription factors implicated in de novo 
lipogenesis regulation are liver X receptor α (LXRα), farnesoid X receptor (FXR) and 
peroxisome proliferator-activated receptor γ (PPARγ)(Fabbrini et al., 2010; Sanyal, 2005; 
Strable and Ntambi, 2010) (Figure 2.3). 
 
Figure 2.3. De novo lipogenesis. Principal steps implicated in TG synthesis from simple precursors 
(acetyl-CoA). De novo lipogenesis is frequently augmented in NAFLD, and it is controlled by different 
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transcription factors that regulates the expression of different enzymes implicated in different steps of 
lipogenesis. 
 
2.1.1.1.2 Impaired VLDL secretion 
Exceeding FAs in the liver are transformed to TGs, which can be stored or secreted 
into VLDL to the circulation for their delivery to peripheral tissues. VLDL are 
macromolecular complexes mainly formed by TGs and cholesteryl esters surrounded by 
an envelope of phospholipids and unesterified cholesterol, all stabilized by a molecule of 
apolipoprotein B 100 (apoB). Increased VLDL production is a common feature in 
NAFLD, however, the increased production of VLDL cannot compensate the increased 
TGs synthesis that is produced in the liver (Fabbrini et al., 2010; Kawano and Cohen, 
2013). Moreover, it has been reported that oxidative stress and endoplasmic reticulum 
stress, both characteristics of NASH, contribute to the degradation of apoB by 
proteasomal and non-proteasomal mechanisms, impairing TG secretion from the liver and 
contributing to fatty liver (Ota et al., 2008; Pan et al., 2004). 
2.1.1.1.3 Impaired fatty acid β-oxidation. 
The liver has the ability to degrade FFAs through mitochondrial fatty acid β-
oxidation (FAO) in a series of steps critical to produce energy in form of ATP and ketone 
bodies. FAO is regulated by different mechanism (Figure 2.4). First, carnitine 
palmitoyltransferases 1/2 (CPT1/2) are the limiting enzymes to translocate FAs into the 
mitochondrion. CPT1 is negatively regulated by malonyl CoA produced from acetyl CoA 
during de novo lipogenesis (Fabbrini et al., 2010). Thus, de novo lipogenesis can regulate 
FAO inhibiting the entrance of FAs to the mitochondrion. On the other hand, CPT1 can 
be positively regulated by PPARα, which promotes the transcription of malonyl CoA 
decarboxylase, implicated in the degradation of malonyl CoA (Lee et al., 2004). PPARα 
is also implicated in the regulation and transcription of most of the enzymes implicated 
in FAO, being a master regulator of mitochondrial β-oxidation (Mandard et al., 2004; 
Mello et al., 2016; Rakhshandehroo et al., 2010). Finally, FAO is regulated by AMPK 
phosphorylation, which inactivates de novo lipogenesis through ACC and SREBP1c 
phosphorylation and increases β-oxidation directly binding and activating PPARα. FAO 
is linked to other mitochondrial functions such as the TCA cycle and the electron transport 
chain (ETC), regulating the reduction power production in the mitochondrion and the 
energy production as ATP (see section 2.1.1.2.3). 
MicroRNAs in liver disease 
42 
 
 
Figure 2.4 Mitochondrial β-oxidation. FAs are degraded through β-oxidation in the mitochondria. 
First, FAs are transformed to acyl-CoA to be internalized into the mitochondria, where they undergo a 
series of sequential oxidation reactions to produce acetyl-CoA. This acetyl-CoA can be directed to the 
TCA cycle to produce energy and reduction power or used to produce ketone bodies (ketogenesis). 
 
The importance of FAO oxidation in NAFLD is not well described, since NAFLD 
studies in patients have reported both downregulation and upregulation of mitochondrial 
β-oxidation (Fabbrini et al., 2010; Sanyal et al., 2001; Satapati et al., 2012). It has been 
proposed that β-oxidation may be increased NAFLD initiation to compensate increased 
fat accumulation in the liver, however during the preogression of the disease, 
mitochondrial failure may affect the β-oxidation capacity of the cell. Despite the 
controversy of these studies, decreased mitochondrial function is considered a common 
event in NAFLD, in part due to the fact that mitochondrial abnormalities in structure and 
function are frequently found in NAFLD (Caldwell et al., 1999; Sanyal et al., 2001). 
2.1.1.2 Progression to NASH 
As mentioned before, simple steatosis can progress to steatohepatitis when a 
second “hit” is given in the liver, resulting in a damaging situation. Different agents in 
the liver can lead to the progression of the disease, being the primary event and the most 
common one the presence of ROS; although there are other important factors, as 
lipotoxicity and ER stress and mitochondrial dysfunction. The mechanism implicated in 
NASH progression will be discussed in the next section: 
2.1.1.2.1  Reactive Oxygen Species (ROS) 
ROS are chemically reactive compounds that are normally generated in the liver 
and other tissues as a consequence of cellular metabolism of oxygen. ROS have an 
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important role on cell signalling and can mediate many reactions in the cell, affecting 
lipids, proteins and DNA (Freeman and Crapo, 1982). There are different ROS 
components such as hydrogen peroxide (H2O2), superoxide (O2-), hydroxyl radical (OH) 
and single oxygen (Thannickal and Fanburg, 2000). Under normal conditions, ROS 
produced in the cells are buffered by the antioxidant machinery (mainly superoxide 
dismutase (SOD), catalases and glutathione (GSH); however, when the production of 
ROS overcomes the capacity of its detoxification a situation of oxidative stress is 
produced in the cell, becoming cytotoxic. 
Cellular ROS can come from different sources, mainly mitochondria, endoplasmic 
reticulum and peroxisomes (Sanyal, 2005). Mitochondria represents the most important 
producer of ROS: when FAO and TCA cycle are linked to electron transport chain (ETC), 
a series of reaction of oxidative phosphorylation (OXPHOS) are produced to form ATP. 
During OXPHOS, e- and H+ are transported through the different components of the ETC 
(each one with higher reduction capacity than the previous one) with the last e- directed 
to reduce O2, finally reduced to water in normal conditions. However, during ETC, it is 
estimated that about 1-2% of the e- can leak the ETC leading to superoxide radical 
formation(Boveris and Chance, 1973). 
In the pathogenesis of NAFLD, different sources are implicated in ROS overload: 
increased CYP2E1 expression (a ROS producing enzyme located in the ER and the 
mitochondria) (Zangar et al., 2004), increased peroxisomal FAO, implicated in H2O2 
production (Begriche et al., 2006) and, importantly, an excessive flow of e- derived to the 
ETC due to increased mitochondrial FAO during NAFLD initiation. The increase in ROS 
production may induce tumor necrosis factor TNF signalling, that enhances lipid 
peroxidation, which, in turn, results in increase e- overproduction, mitochondrial 
dysfunction and ROS sustained production (Nassir and Ibdah, 2014; Pessayre et al., 2002) 
2.1.1.2.2  Lipotoxicity and Endoplasmic Reticulum Stress and inflammation 
In the recent years, hepatic lipotoxicity has been regarded as an important 
contributor to NASH development (Cusi, 2012; Neuschwander-Tetri, 2010). Despite the 
fact that TG accumulation is the first common step produced in NAFLD, most of the 
recent studies indicates that TG accumulation itself is not toxic in the liver (McClain et 
al., 2007). However, besides the amount of FAs, the toxicity in the liver is determined by 
the relative amount of FA species: while monounsaturated FA (MUFA) do not induced 
toxicity, saturated FA (SFA) they do (Alkhouri et al., 2009; Listenberger et al., 2003). On 
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the other hand, several studies have described a role of FFA in the induction of hepatocyte 
lipoapoptosis through the upregulation of death receptors, such as FAS, TRAIL and DR5, 
leading to initiation of the extrinsic apoptotic pathway (Feldstein et al., 2003a; Malhi et 
al., 2007). Upregulation of death receptors is an important feature in liver from NASH 
patients (Alkhouri et al., 2009; Feldstein et al., 2003b). 
In the recent years ER stress has been proposed as an important mechanism 
implicated in the development and progression of NASH (Malhi and Kaufman, 2011; 
Ozcan et al., 2004; Puri et al., 2008). By one side, steatosis leads to ER stress as a 
consequence of FAs and very long chain fatty acid (VLCFA) accumulation and, at the 
same time, ER stress response contributes to liver damage and NASH progression. ER 
stress related signalling is linked to lipotoxicity, insulin resistance, inflammation and 
hepatocyte cell death. ER stress was first described in mouse models of NAFLD has been 
described (Ozcan et al., 2004; Rahman et al., 2007) and later characterized in NAFLD 
and NASH human patients (Gregor et al., 2009; Puri et al., 2008). First, during steatosis, 
ER stress response is implicated in increased insulin resistance and lipogenesis while 
impairs VLDL secretion contributing to lipid accumulation (Dara et al., 2011; Zhang et 
al., 2014). During the progression of NASH, ER stress is strongly associated to 
inflammation by different mechanism (ROS production, activation of NF-κB, JNK and 
ChREBP transcription factor signalling) and hepatocyte apoptosis (mainly via CHOP 
induction and JNK/TRAF signalling) (Dara et al., 2011; Zhang et al., 2014). 
2.1.1.2.3 Mitochondrial dysfunction 
During the development of NAFLD many metabolic adaptations are necessary to 
counteract the increase of fat in the liver. Mitochondria, as the most important metabolic 
organelles within the cell, show increased FAO during the initial steps of NAFLD, 
however, this can lead increased ROS that ends up in mitochondrial dysfunction and ETC 
deficiency, contributing to the development of NASH. In these sections, a brief 
introduction of the main metabolic function of the mitochondrion in the liver and its 
dysfunction in NAFLD will be presented. 
a) Mitochondrial role in metabolism  
Mitochondria are the main source of energy in hepatocytes and most cells. These 
organelles are the responsible of generating energy as ATP and reduction power as 
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NADH and FADH2 through the metabolism of nutrients implicating three converging 
different pathways: β-oxidation and ketogenesis, TCA cycle and ETC. 
TCA cycle 
The TCA cycle is the central pathway of metabolism, linking carbohydrate, lipid 
and protein metabolism through the catabolism of acetyl-CoA. TCA cycle consists of 8 
oxidative steps in which acetyl-CoA is oxidized to CO2 producing ATP, NADH and 
FADH2 that can be subsequently used as reduction power for the oxidative 
phosphorylation. 
Β-oxidation and ketogenesis 
FAs are mainly catabolized by β-oxidation in the mitochondria. Dietary lipids can 
be stored as TGs in the adipose tissue or directly metabolized, depending on the metabolic 
state. Under certain circumstances such as fasting, TGs stored in the adipose tissue are 
mobilized to the liver and metabolized for energy production. Once in the hepatocytes, 
FAs must be activated into acyl-CoA and translocated to the mitochondria, where they 
undergo cycles, each of four sequential reactions until the FAs are converted into several 
acetyl-CoA molecules and, in case of impair FAs into acetyl-CoAs and propionil-CoA.  
Acetyl-CoA at this point can either enter the TCA cycle to produce ATP or be 
condensated to synthesize ketone bodies (KBs), which are generally oxidized in 
extrahepatic tissues (Begriche et al., 2013). In the reaction implicated in acyl-CoA 
catabolism to acetyl-CoA NADH and FADH2 are produced, directly linking 
mitochondrial FAO with ETC (Figure 2.4). 
ETC 
As already mentioned in this section, both TCA and FAO converge into the ETC 
through the production of reduction power NADH and FADH2. These molecules are 
reoxidized during the oxidative phosphorylation (OXPHOS) reactions that take place in 
the electron transport chain. OXPHOS are the final step of metabolism, producing ATP 
in a series of steps controlled by the different components of the ETC: the complexes I, 
II, II, IV and V (known as ATP synthase) (Berg et al., 2002; Lodish et al., 2000) (Figure 
2.5).  
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Complex I: NADH-ubiquinone oxidoreductase is the complex responsible of 
NADH oxidation to NAD+. In this process, two e- are transferred to the ubiquinone (Q) 
while four H+ are translocated to the intermembrane space generating the proton gradient. 
Complex II: succinate dehydrogenase (SDH) complex is involved both in the 
ETC and in the TCA cycle. In the ETC, SDH oxidizes FADH2 to FAD. In this complex, 
two extra e- are delivered to the ubiquinone (Q), however, in this case, no H+ protons are 
pumped to the intermembrane space.  
Complex III: ubiquinone-cytochrome-c oxidoreductase complex is involved in 
the reduction of cytochrome c oxidizing the ubiquinol to ubiquinone and contributing to 
the proton gradient releasing four H+ to the intermembrane space.  
Complex IV: cytochrome c oxidase complex is linked to Complex III, transferring 
four e- from Complex III to oxygen, producing water and pumping four H+ the 
intermembrane space. 
Complex V: the ATP synthase couple the ETC to the oxidative phosphorylation, 
using the proton gradient created across the ETC to generate ATP. This complex acts as 
an inverted pump that redrives the H+ to the matrix, using the free energy to produce ATP  
 
Figure 2.5 Electron Transport Chain. The ETC is composed by a series of complexes that transfer 
electrons from FADH2 and NADH to the oxygen that is finally reduced to water. During the process, 
hydrogens are pumped from the mitochondrial matrix to the intermembrane space creating a gradient. 
Finally, ATP is produced in this process. 
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b) Mitochondrial dysfunction in NASH 
During the last years, increasing studies have pointed NAFLD and NASH 
progression as a mitochondrial disease. Despite the fact that it is still not clear whether 
mitochondrial dysfunction observed in NASH is a cause or a consequence of the disease, 
several studies have clearly shown a link between mitochondrial dysfunction and NASH 
both in human patients and murine models (Begriche et al., 2013; Nassir and Ibdah, 
2014). NASH mitochondrial dysfunctions refer to common events observed such as 
impairment in ETC complexes activity and reduction in OXPHOS and ATP production. 
It was first observed in NASH patients the presence of mitochondrial abnormalities 
(enlarged and swollen and loss of cristae and paracristalline inclusion bodies) (Caldwell 
et al., 1999; Sanyal et al., 2001). However, in animal model there are some controversies 
in the way that mitochondrial dysfunctions affect NASH: 
Referring FAO, some studies have described increased, unchanged or decreased 
FAO in different NAFLD murine models (Begriche et al., 2013). However, PPARα 
reduced expression seems to be a common event in NAFLD, being progressively reduced 
correlating with NASH progression. Moreover, other studies have described decreased 
expression of proteins implicated in mitochondrial biogenesis and ETC (PGC1α, NRF1 
and Tfam) (Aharoni-Simon et al., 2011; Begriche et al., 2013). In this sense, it seems that 
mitochondrial FAO is progressively decreased with the severity of NASH. 
Similarly, alterations in ETC complexes activity and OXPHOS and ATP 
production have been described in human patients and murine NASH models. ETC 
complexes activity was reduced in NASH patients, inversely correlating with plasma 
TNFα and further decreasing with the higher the progression to fibrosis (García-Ruiz et 
al., 2013; Pérez-Carreras et al., 2003). Later, similar results showing decreased activity 
of the different ETC complexes have been reported in NASH murine models (Bruce et 
al., 2009; García-Ruiz et al., 2006, 2014; Ramirez-Tortosa et al., 2009). These studies 
highlight the importance of ETC in mitochondrial dysfunction in NASH, potentially 
linking it with the progressive decrease in energy status and ATP levels in this disease 
(Cortez-Pinto et al., 1999; Serviddio et al., 2008; Szendroedi et al., 2009). 
Potential mechanism implicated in the decrease activity of ETC and FAO during 
NAFLD include ROS and RNS damaging effect over different complexes; increased 
inflammatory TNF and interferons signalling implicated in ETC complex impairment, 
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mtDNA damage and PPARα inhibition; and also lipotoxicity, which can be implicated in 
ETC enzyme inhibition and even apoptosis (Begriche et al., 2013). 
2.1.1.3 NAFLD progression to fibrosis, cirrhosis and HCC 
As previously mentioned, the progression of steatosis to NASH and fibrosis and 
HCC is highly variable and depends on a wide variety of factors, with 10-30% of patients 
developing NASH, among which 20% progress to cirrhosis and a final 4-27% of the 
cirrhotic patients ends suffering HCC. Among important factor that influence the grade 
and time of progression of the disease, there are increasing evidence pointing out the 
importance of genetic factors that can condition for example the grade of ROS production, 
the immune system control and the inflammatory response managing the presence and 
activity of inflammatory cell in the liver, with the concomitant contribution to hepatic 
stellate cell activation (HSCs) implicated in cell proliferation and extracellular matrix 
(ECM) deposition. Altogether, factors that can final lead to HCC by different mechanism 
(Baffy et al., 2012; Calzadilla Bertot and Adams, 2016; Feldstein et al., 2009; Vernon et 
al., 2011) (Figure 2.1). 
2.1.1.4 NAFLD therapies 
Despite representing the most common representation of chronic liver disease, to 
date, there is still no effective treatment approved or effective for NAFLD, being the most 
frequent recommendation for NAFLD patients focused in changing unhealthy lifestyle 
(Chalasani et al., 2012; Palmer and Schaffner, 1990; 2002). However, some 
pharmacological approaches have emerged during the last years. The goal of these 
pharmacological approaches would be to reduce liver inflammation and injury, overcome 
insulin resistance and target fibrotic mechanism (Ratziu et al., 2015). Some relevant 
pharmacological agents are the following: 
2.1.1.4.1 Insulin sensitizers 
Insulin resistance is present in almost all NASH patients, thus, many 
pharmacological studies have been focused on the development of insulin sensitizer. 
Glitazones are the best studied and have the strongest data for the treatment of NASH. 
Glitazones are compounds that promote differentiation of insulin-resistant large pre-
adipocytes into proliferative insulin-sensitive adipocytes thtough the direct activation of 
PPARγ, enhancing FA uptake in these adipocytes instead of their delivery to the liver. 
Glitazones also induces insulin sensitivity and adiponectin, increasing FAO in the liver. 
Moreover, they show some anti-inflammatory effect in Kupffer cells. The best study 
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glitazone, Pioglitazone, has shown improved individual histological benefits, 
transaminase (ALT) reduction and correction of insulin resistance in NASH (Ratziu et 
al., 2015; Sanyal et al., 2010). However, glitazones beneficial effects have resulted short-
living after treatment interruption and undesired side effects have been reported (weight 
gain and bone loss) (Lutchman et al., 2007; Ratziu et al., 2015). 
Metformin is an activator of AMP-activated protein kinase (AMPK) that reduces 
the hepatic glucose production promoting glucose use in peripheral tissues and insulin 
sensitization. Although it is approved for diabetes 2 treatment, is not recommended for 
NASH, due to the lack of effectiveness beyond insulin sensitization, it has not shown 
histological or transaminase beneficial effect in NASH (Chalasani et al., 2012; Zhou et 
al., 2001). 
Finally, other novel insulin sensitizers are being developed as agonist of different 
metabolic pathways activators. Agonists of the transcription factor FXR (implicated in 
cholesterol and bile acid metabolism and homeostasis) have shown beneficial effects in 
insulin sensitization, decreased lipogenesis, increased β-oxidation and reduction of 
inflammatory processes in murine models, with promising results also in NASH patients 
(Neuschwander-Tetri et al., 2015; Wagner et al., 2008; Watanabe et al., 2004). Similarly, 
agonists for the PPARα/δ have been shown to inhibit hepatic lipogenesis and increase 
fatty acid oxidation, reducing also liver inflammation and fibrosis. PPARα/δ agonist in 
NASH trials have shown improvement in insulin resistance, dyslipidemia, inflammation 
and liver function tests (Cariou et al., 2013; Staels et al., 2013).  
2.1.1.4.2 Hepatoprotective agents 
Antioxidant agents are important to overcome oxidative stress underlying NASH 
progression in many patients. Vitamin E, protects hepatocytes against mitochondrial 
toxicity and apoptosis, presenting also antioxidant properties. However, Vitamin E 
benefit in NASH patients has been only shown in one study and it is not well described 
whether it may present benefits or not for the treatment of NASH (Hoofnagle et al., 2013; 
Ratziu et al., 2015; Soden et al., 2007; Sokol et al., 1998). 
2.1.1.5 Animal models of NAFLD 
The study of NAFLD has been performed in different animal models mimicking 
the progression of the disease. NAFLD models should reflect the histopathological 
features presented in NAFLD patients (steatosis, inflammation, hepatocyte ballooning 
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and fibrosis); however, different models fail to completely address these features. 
Researchers have used genetic and dietary models to study NAFLD. 
2.1.1.5.1 Genetic models of NAFLD 
Most important genetic models are based on the absence (Ob/ob) or deficiency 
(Db/db) of leptin signaling, the hormone that regulates appetite and lipogenesis. Ob/ob 
mice have a mutation in the leptin gene and develop steatosis, hyperglycemia, 
hyperinsulinemia, insulin resistance and obesity. However, these mice do not progress 
spontaneously to steatohepatitis and are resistant to fibrosis development, and, 
importantly, leptin mutations are not a common feature in NAFLD patients (Takahashi et 
al., 2012). The Db/db mice have a mutation in the leptin receptor, being resistant to this 
hormone. These mice are obese and insulin resistant and present hepatic steatosis. 
However, Db/db mice do not develop steatohepatitis without an extra condition 
(Wortham et al., 2008). Other important genetic models to study the implication of 
concrete signalling in steatosis are the Srebp1-c overexpressing mice, PPARα knock out 
mice, AOX null mice, which differentially develop steatosis through the disruption of the 
processes in which they are implicated (lipogenesis, FAO and peroxisomal β-oxidation, 
respectively). 
Finally, two important knock-out models are based on the disruption of the 
methionine cycle and S-adenosylmethionine (SAMe) metabolism, the Mat1a-/- (Lu et al., 
2001) and the Gnmt-/- (Martínez-Chantar et al., 2008). Alterations in this pathway and the 
enzymes implicated in the cycle have been described in NAFLD patients. Both models 
are characterized by spontaneous development of steatosis and steatohepatitis at different 
ages, implicating the disruption of different processes differentially contributing to the 
development of the disease. Mat1a-/- and Gnmt-/- and their contributions to NAFLD and 
liver disease are described in detail in Section 2.2.2 and 2.2.3. 
2.1.1.5.2 Dietary models of NAFLD 
There are different dietary models extensively used for the study of NAFLD 
progression: the methyl-choline deficient diet (MCDD), the high-fat diet (HFD), the high 
cholesterol diet (HCD) and the fructose diet (FD) (Anstee and Goldin, 2006; Hebbard and 
George, 2011; Takahashi et al., 2012). 
MCD diet is characterized by the absence or deficiency of methionine and choline, 
in the diet, two essential amino acids that are precursors of SAMe and 
 Introduction 
 
51 
 
phosphatidylcholine (PC), respectively. This deficiency compromises important 
processes such as VDLD formation, methylation reactions and the antioxidant machinery 
(see section 2.2.1 for detailed functions of methionine and SAMe in the liver). MCDD 
rapidly induces steatosis, inflammation, cell death, transaminases and fibrosis. Reduced 
β-oxidation and mitochondrial dysfunctions alongside with increased oxidative stress are 
characteristic in mice fed the MCD diet. Moreover, MCDD mice is a useful model for the 
study of NASH specifically in the liver, without other tissue implications. However, these 
mice differ from human NASH pathology regarding some aspects of the disease, MCDD 
mice do not gain weight and are not resistant to insulin, while humans NASH are 
frequently characterized by increased body weight and insulin resistance. 
In the HF diet most of the nutrients are derived from dietary fats (71%). HFD 
induces steatosis, insulin resistance, oxidative stress and inflammation. Therefore, HF is 
closely related to metabolic syndrome. However, the animals under HFD develop low 
NAS score, being highly dependent on the mice strain used. 
2.1.2 LIVER FIBROSIS AND CIRRHOSIS 
As mentioned, NAFLD is a progressive disease that can evolve from the simple 
steatosis to NASH and fibrosis, being estimated that about 20% of patients suffering 
NASH finally progress to fibrosis/cirrhosis, a more advanced stage of liver disease 
(Figure 2.1).  
Liver fibrosis is characterized by an excessive extracellular matrix (ECM) 
deposition in the liver as a result chronic and sustained liver damage with the concomitant 
sustained wound healing response. The accumulation of ECM proteins alters the normal 
hepatic architecture of the parenchyma leading to fibrotic scar formation and generation 
of hepatocyte regeneration nodules, finally leading to cirrhosis. The wound healing 
response can be initiated in the liver as a reaction to an acute liver damage, but a chronic 
exposure to the damaging agent is necessary for the fibrosis progression. Damaging 
agents can be different, including viral infections, autoimmune disorders, alcohol and 
drug abuse and cholestatic and metabolic diseases. Liver fibrosis can evolve rapidly 
(weeks or months) in some cases, but normally is a very low progressive disease that take 
over decades to end up in cirrhosis (Friedman, 2003, 2008a). Cirrhosis is considered as 
an end-stage of liver disease characterized by distortion of liver parenchyma, nodule 
formation and hepatic dysfunction or insufficiency, accompanied by decreased 
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intrahepatic blood flow resulting in portal hypertension (Bataller and Brenner, 2005; 
Friedman, 2003; Schuppan and Afdhal, 2008). 
The architecture of a healthy liver is characterized by a sinusoid surrounded by 
hepatocytes lined over a membrane of permeable connective tissue called the space of 
Disse. The inactivated hepatic stellate cells (HSC) reside in the space of Disse while the 
inflammatory macrophages (Kupffer cells, KC) are located in the sinusoid. During 
fibrosis, apoptotic hepatocytes activate KCs, which release inflammatory cytokines that 
activate HSCs. HSCs are the major contributors to fibrosis, once activated secrete large 
amounts of ECM that fills the space of Disse and remodel the sinusoid, replacing damaged 
and dead hepatocytes by fibrotic scar tissue. This remodelling of the sinusoid also leads 
to its capillarization and to the mentioned alteration in hepatic vascularization and portal 
hypertension, which underlies the main cause leading to cirrhosis complications (e.g. 
ascites, renal failure, hepatic encephalopathy and varicelar bleeding) correlating with 
diminished liver functions (Bataller and Brenner, 2005; Schuppan and Afdhal, 2008; Van 
Beers et al., 2003) (Figure 2.6).  
As mentioned, fibrosis can evolve to cirrhosis chronically and, in many cases, 
asymptomatically. If the liver presents normal or not decreased hepatic functions is 
known as compensated cirrhosis. Compensated cirrhosis is followed by a progression to 
decompensated cirrhosis, characterized by the rapid development of different 
complications associated to hypertension and liver dysfunction that can be accelerated by 
HCC development and is generally associated to short survival rates. 
The diagnosis of cirrhosis still finds its most reliable technique in liver biopsy, it 
can identify the underlying mechanism of the disease and more accurately set the grade 
of the progression of cirrhosis. However, it is a very invasive method and it cannot be 
completely reliable. Alternative diagnostic methods are used, as serum biomarkers and 
transient elastography (Fibroscan), nevertheless, these new methods present 
inconveniences as thee do not identify the causes of the disease (Castéra et al., 2005; 
Pinzani et al., 2005; Schuppan and Afdhal, 2008; Ziol et al., 2005). 
Historically, liver fibrosis has been though as an irreversible disease with scar 
formation being a unidirectional pathway. However, since the late 90’s, it has started to 
be considered as reversible. The most effective therapy for fibrosis is still to eliminate the 
causative agent underlying the disease (section 2.1.2.3); however, there are 
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implementation treatments that have shown important improvements in fibrosis 
regression in patients (Bataller and Brenner, 2005; Benyon and Iredale, 2000; Bonis et 
al., 2001; Friedman, 2007). The enhancement in the development of effective therapies 
for liver cirrhosis necessarily pass through the characterization of the major cellular 
mechanism driving the disease, given the complex interplay of hepatic cells that is known 
to take place during liver fibrosis. 
2.1.2.1 Cell population contribution and fibrogenesis 
As mentioned, during liver fibrosis, a complex interplay between different hepatic 
cellular populations is established (Figure 2.6). In this section, the major contribution of 
these hepatic cells to liver fibrosis will be presented. 
2.1.2.1.1 Hepatocytes 
Hepatocytes are the predominant hepatic cells in terms of volume and function. 
Hepatocytes are generally the most important cells in the initiation of the fibrogenic 
response. Many damaging and cytotoxic agents (alcohol and drugs metabolites, lipids, 
bile acids, viruses, etc.) target the hepatocytes, promoting hepatocyte injury. After this 
initial insult, injured hepatocytes release ROS and cytokines, including inflammatory 
mediators (interleukins, TNF) and fibrogenic agents (TGFβ), stimulating inflammatory 
cells recruitment (KCs) and myofibroblast tissue repair activation (HSCs), respectively. 
Moreover, severe injuries can drive hepatocyte apoptosis, leading to the release of 
apoptotic bodies from the death hepatocytes. These apoptotic bodies can be phagocyted 
both by KCs and HSCs, activating them and inducing their production of cytokines, 
including TNF, TRAIL, FAS-ligand and TGFβ, cytokines that initiate inflammatory and 
fibrogenic processes in the liver and also increase apoptotic signalling in the hepatocytes 
(Canbay et al., 2003a, 2004; Higuchi and Gores, 2003; Savill and Fadok, 2000). 
2.1.2.1.2 Kupffer cells and immune system 
Kupffer cells are the resident macrophages of the liver that are located within the 
sinusoid and have a high endocytic and phagocytic capacity (including endotoxins and 
pathogens and apoptotic bodies). These cells are in contact with gut derived and bacterial 
products that can induce their activity. Upon liver damage, KCs secrete molecules and 
cytokines (ROS, NOS, TNF, chemokines, etc.) mediating the inflammatory response in 
the liver and immune system regulation via antigen presentation; and secrete also 
important death ligands (TRAIL and FAS) enhancing hepatocyte apoptosis. KCs 
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activation, thus, leads to liver inflammation, hepatocyte apoptosis and also to hepatic 
stellate cell activation (Canbay et al., 2003a; Gressner et al., 1993). 
As Kupffer cells, there are also other members of the immune system described 
to play a role in liver fibrosis. During hepatic inflammation, innate immune cells 
(including monocytes, neutrophils, dendritic cells (DC) and natural killer (NK) cells and 
adaptive immune cells (T and B cells) are recruited to the liver, playing different roles in 
inflammatory response and fibrogenic development/resolution (Maher, 2001; Winau et 
al., 2007; Xu et al., 2012). 
2.1.2.1.3 Hepatic Stellate Cells  
Hepatic stellate cells (HSC; previously known as Ito cells, lipocytes and 
perisinusoindal cells) are the main contributors to liver fibrosis independently of its 
etiology, being the major producers of ECM and the amplification of the fibrogenic 
response (Bataller and Brenner, 2005; Friedman, 2008a; Mederacke et al., 2013). In 
normal healthy liver, HSCs reside in the space of Disse in contact with the hepatocytes 
and upon liver injury HSCs get activated and differentiated into myofibroblast-like cells 
characterized by proliferation, contraction, inflammatory and fibrogenic capacity. 
Activated HSCs migrate across the liver and accumulate in damaged sites, replacing 
injured and dead hepatocytes and secreting ECM. HSCs contribution to fibrosis is defined 
in three sequential steps: initiation, perpetuation and resolution. 
 
Figure 2.6 Liver architecture and fibrosis. Healthy liver (left panel) is composed by hepatocytes lined 
on a loose basal membrane (space of Disse) surrounding the sinusoid. In the space of Disse also are 
found the hepatic stellate cells (HSC) in a quiescent state. Finally, Kupffer cells (KC) are located in the 
sinusoid. Upon liver injury, fibrosis is initiated in the liver (right panel). Hepatocyte become apoptotic, 
releasing cytokines that activate both KCs and HSCs. Activated HSCs produce extracellular matrix 
proteins (ECM) to replace dead hepatocyte and repair tissue. Sustained liver damage, perpetuates 
interplay between hepatocytes, KCs and HSCs, leading to ECM excessive deposition and parenchymal 
architecture disruption.  
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a) Initiation 
The initiation phase consists in early and rapid changes in HSCs phenotype and 
in ECM composition. HSCs become activated very rapidly in response to ROS and 
cytokines mainly derived from injured hepatocytes, KCs and cholangiocytes. The most 
important cytokines known to activate HSCs are TGFβ, PDGF and EGF. Another 
important mechanism of HSCs activation is the engulfment of apoptotic bodies derived 
from hepatocytes. Similarly to KCs, HSCs have the ability to recognize and engulf these 
apoptotic bodies from the hepatocytes and also DNA from dead cells (damage/danger-
associated molecular patterns, DAMPs), resulting in their activation and proliferation 
(Canbay et al., 2003b, 2004; Jiang et al., 2009). 
Changes in the ECM in this phase consists in changes in collagen composition 
(from collagen IV as the major component to collagen I and III), changes in membrane 
receptors (e.g. integrins) (Shafiei and Rockey, 2006; Yang et al., 2003; Zhang et al., 2006) 
that drives the ability of HSCs to migrate across the matrix, the actin cytoskeleton 
promotes migration and contraction (Choi et al., 2006; Yee, 1998) and matrix 
metalloproteases get activated releasing additional growth factors that increase fibrogenic 
signalling (Schuppan et al., 2001). 
b) Perpetuation 
Once activated, the HSCs may respond to cytokines and growth factors that 
enhance their fibrogenic capability through the maintenance and regulation of its 
proliferation, chemotaxis, fibrogenesis, contractility, proinflammatory signalling and 
matrix degradation. 
Proliferation. HSCs are able to induce their own proliferation by paracrine and 
autocrine mechanisms involving mainly PDGF, the most potent mitogen described for 
HSCs (Pinzani, 2002; Pinzani et al., 1994). PDGF regulates proliferation by activating 
PI3K and MAPK/ERK pathways. Other mitogens responsible for HSCs proliferation are 
EGF, VEGF and FGF (Friedman, 2008a; Yoshiji et al., 2003; Yu et al., 2003). 
Chemotaxis. Hepatic stellate cells are able to migrate across the matrix to the 
injured place driven by chemoattractants (Ikeda et al., 1999). Potent chemoattractants for 
HSCs include PDGF, MCP-1 and CXCR ligands (Bonacchi et al., 2001; Kinnman et al., 
2000; Marra et al., 1999). HSCs migration is inhibited by the high levels of adenosine at 
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the place of injury, regulating their fixation and fibrogenesis in the right site (Hashmi et 
al., 2007). 
Fibrogenesis. The main function of activated HSCs is to produce ECM. 
Fibrogenesis is mainly regulated by TGFβ autocrine/paracrine signalling. TGFβ 
signalling is intracellular mediated by the Smad2 and 3 receptors (which activate target 
gene expression associating to transcription factors and coactivators) and Smad7 (which 
inhibits TGFβ signalling) (Breitkopf et al., 2006; Inagaki and Okazaki, 2007).  
Contractility. During liver fibrosis, HSCs presents features characteristics of 
smooth muscle-like cells, such as the expression of α smooth muscle actin (αSMA) and 
myosin filaments that mediate contractile activity in these cells (Rockey et al., 1992; Saab 
et al., 2002). This contractility is one of the major causes of hepatic portal hypertension. 
Proinflammatory signalling. Activated HSCs contributes to liver inflammation 
releasing different cytokines (e.g. CCLs, CXCLs, MCP-1, CCRs, and TNF) that can 
activate themselves, hepatocytes and other immune cells. Moreover, HSCs are able to 
interact with immune cells and modulate their response through antigen presentation 
(Bomble et al., 2010; Friedman, 2008b; Hellerbrand et al., 1996; Lee and Friedman, 2011; 
Sahin et al., 2010; Wasmuth et al., 2010). Thus, HSCs have the ability to amplify and 
establish a positive loop of inflammatory signalling that contributes to liver fibrosis. 
Matrix degradation. During fibrogenesis matrix remodelling is an important event 
where HSCs play a major role. In early stage of fibrosis, HSCs release matrix-
metalloproteinases (MMPs) MMP-2 and MMP-9 that degrades collagen IV specifically, 
leading to disruption of the basal membrane in the liver (Arthur et al., 1992; Han et al., 
2007). HSCs also release inhibitors of MMPs, TIMPs, important during advance fibrosis 
as they mainly inhibit metalloproteinases implicated in collagen I and III degradation (e.g. 
MMP-1), contributing to the perpetuation of liver fibrosis (Benyon et al., 1996; Iredale et 
al., 1992). Particularly, TIMP-1 is known to inhibit MMP-1 and to have survival effect in 
HSCs (Murphy et al., 2002). The modulation of TIMPs and MMPs activities is and 
attractive target to study the reversal of liver fibrosis. 
c) Resolution. 
During resolution of fibrosis, the excessive ECM deposited in the liver is removed 
and liver recovers its normal architecture and function. The resolution process requires 
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HSCs to stop their fibrogenic activity, which occur when HSCs become senescent, 
inactive or apoptotic (Tacke and Trautwein, 2015). During the resolution there are 
common events frequently found, such as, decreased production of TIMPs (allowing 
increase in ECM degradation and collagenase activity (Henderson and Iredale, 2007; 
Iredale et al., 1998)) changes in the immune system (leading to apoptosis of HSCs, mainly 
mediated by NKs (Fasbender et al., 2016; Gao et al., 2007; Radaeva et al., 2006). 
2.1.2.1.4 Non-hepatic stellate cells 
Despite the evidence identifying HSCs as the major contributors to liver fibrosis 
independently of its etiology (Mederacke et al., 2013), the use of different animal models 
has allowed to identify other important contributors for the initiation and perpetuation of 
the fibrotic process. Other sources of myofibroblast in the liver are portal fibroblast 
(Beaussier et al., 2007; Dranoff and Wells, 2010; Hinz et al., 2007; Iwaisako et al., 2012), 
bone marrow derived mesenchymal cells (Forbes et al., 2004; Russo et al., 2006) and cells 
undergoing epithelial-mesenchymal transition (EMT) (Xia et al., 2006) (however, the 
contribution of the last ones remains controversial (Chu et al., 2011; Scholten et al., 2010; 
Taura et al., 2010). Particularly, portal fibroblast and epithelial-mesenchymal cells 
contribution to myofibroblast pool is of special interest in the development of cholestatic 
disease (an increasing leading cause of cirrhosis beyond alcohol abuse and viral hepatitis 
B and C) described in detail in the following section (Poupon et al., 2000). 
2.1.2.2 Cholestatic liver disease 
Cholestatic liver diseases include a wide variety of heterogeneous disorders 
characterized by the defective bile acid flow from the liver to the intestine, leading to the 
accumulation of hydrophobic bile acids (BAs) in the liver. This BA accumulation causes 
initial damage in biliary epithelial cells (named cholangiocytes) and in hepatocytes that 
can conclude in liver inflammation, liver failure and cirrhosis. Cholestasis can derive 
either from an impairment in the bile formation in the hepatocytes or from a defective 
mechanism of secretion at the bile duct (Trauner and Boyer, 2003; Trauner et al., 1998; 
Zollner and Trauner, 2008). The more frequently causes leading to cholestasis are 
inflammation, viral infection, drug, hormones, pregnancy and genetic and autoimmune 
disorders. In adults, cholestatic disorders are more frequently found as chronic primary 
biliary cholangitis (PBC) or as primary sclerosis cholangitis (PSC); while in children 
biliary atresia (BA) and Alagille syndrome (ALS) are the most common forms of 
cholestasis (Bassett and Murray, 2008; Boonstra et al., 2012; Carey et al., 2015; Poupon 
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et al., 2000; Turnpenny and Ellard, 2012). Cholestatic liver disorders related mortality is 
not very high, however are relatively common and present lack of effective treatment 
(surgery being the most frequent option) and frequent evolution to more complicated liver 
situations (2017). Better understanding of cholestatic liver disease driving mechanisms is 
necessary to improve therapies and avoid complications 
2.1.2.2.1 Pathways implicated in cholestasis 
Cholestasis can result from different causes, however, once established, the 
mechanism and progression underlying this disease are frequently similar, including, 
alteration in hepatobiliary synthesis, metabolism and transport, biliary epithelial cells 
damage, hepatocyte apoptosis and inflammation and fibrosis progression, all as a 
consequence of toxic BA accumulation in the liver. These general features present in 
cholestasis will be described in this section:  
2.1.2.2.2 Bile acids regulation in the liver 
Bile acids are the most abundant biliary component and have an important role as 
regulators of bile flow and the absorption of lipids and other nutrients in the intestine. 
BAs are generated in the liver as primary BAs (cholic acid, CA and chenodeoxycholic 
acid, CDCA) through the oxidation of cholesterol and conjugated to glycine or taurine 
amino acids to form bile salts that can be exported to the intestine through the bile ducts. 
Once in the intestine, conjugated BAs are partially dehydroxilated and processed by 
intestinal bacteria, generating secondary BAs (deoxycholic acid, DCA and lithocholic 
acid, LCA, from cholic acid and chenodeoxycholic acid, respectively) that can return to 
the liver through the enterohepatic circulation (Chiang, 2013; Russell, 2003).  
Alterations in BAs synthesis, export and metabolism drive excessive BAs 
accumulation in the liver, becoming toxic BAs. Bile acids mainly cause hepatocyte 
toxicity, but also have strong effect on the biliary epithelial cells (cholangiocytes). In 
general terms, BAs grade of toxicity correlates with hydrophobicity, the more 
hydrophobic the BA, the more toxic. Most toxic BAs described are: LTA, DCA, CDCA, 
GCDCA and TCDCA (Attili et al., 1986; Chiang, 2013; Delzenne et al., 1992). 
a) Regulation of bile acid synthesis,  metabolism and transport 
As just mentioned, BAs are synthetized in the liver as primary BAs. The synthesis 
of BAs is produced as part of the cholesterol metabolism and is mainly regulated by the 
enzyme CYP7A1 (a rate limiting enzyme for BAs synthesis) through a negative feedback 
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mechanism regulated by the BAs pool in the liver. Low BAs returned to the liver induce 
CYP7A1 activity while, high BA levels inhibit its enzymatic activity (Chiang, 2013). BAs 
have been described to act as natural ligands of nuclear receptor, regulating its own 
metabolism. In the process of BA regulation the nuclear receptor transcription factor 
FXR/NR1H4 play a central through the regulation of the expression of different target 
genes implicated in BA synthesis, secretion and absorption (Eloranta and Kullak-Ublick, 
2008; Makishima et al., 1999; Parks et al., 1999; Wang et al., 1999) (Figure 2.7).  
FXR is activated in the liver by different BAs (CDCA, LCA, CA and DCA) and 
regulates different target genes. One of the main regulatory mechanisms mediated by 
FXR is the activation of the small heterodimer partner (SHP) that inhibits CYP7A1 
activity, thus impeding BA synthesis.  Other nuclear receptors are also implicated in the 
regulation of BA synthesis through the repression of CYP7A1, such as PXR and VDR. 
FXR is also implicated in the regulation of BA transporters. At the transcriptional 
level FXR induces the expression of the bile salt exporting pump (BSEP/ABCB11), the 
most important exporter of bile acids; the multidrug resistance protein (MDR2), 
responsible for phosphatidylcholine secretion into the bile and ABCG5/8, implicated in 
cholesterol secretion. In the intestine, FXR induces the transcription of the organic solute 
transporter α/β (OST α/β), responsible of the BAs secretion to the blood. Finally, in the 
hepatocytes FXR is responsible of the inhibition of the NTCP, which mediates BA uptake 
in the hepatocytes from the blood. Thus, FXR appears as a master regulatory transcription 
factor that senses BAs levels to regulate its liver synthesis and secretion, intestinal 
reabsorption and secretion and BA uptake into the hepatocytes (Chiang, 2013; Zollner 
and Trauner, 2008).  
The importance of FXR in cholestasis is further highlighted in studies describing 
mutations in its gene affecting either the levels or the transcriptional functionality of FXR 
(with the consequent reduction of its target genes) in human cholestatic diseases such as 
intrahepatic cholestasis of pregnancy and cholesterol cholestasis (Kovacs et al., 2008; 
Van Mil et al., 2007). Additionally, in other hereditary diseases, such as progressive 
familiar intrahepatic cholestasis (PFIC), mutations and defects in BA transporters have 
been described (Zollner and Trauner, 2008). Nevertheless, such mutational defects are 
barely frequent in general population and the regulation in BA synthesis and transporters 
is more frequently found downregulated and upregulated, respectively, indicating 
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adaptive mechanism to counteract the toxic accumulation of BAs (although not sufficient 
in most of the cases) (Zollner and Trauner, 2008). 
 
Figure 2.7 FXR and BA regulation. In the hepatocytes, BAs activates FXR transcriptional activity, 
which activates a set of genes implicated in BA transport, metabolism and synthesis. FXR inhibits BA 
synthesis through the repression of Cyp7a1. FXR induce the expression of BA exporters (BSEP and 
MDR2), facilitating the removal of BAs from the liver to the circulation through the bile ducts. In the 
intestine BA absorption and secretion is also regulated by FXR. Finally, BAs reabsorption from the 
circulation in the hepatocytes is allowed or impeded by FXR depending on the internal hepatic BA levels. 
Thus, FXR is a master regulator of BA content in the liver, which functions sensing BA levels. 
 
2.1.2.2.3 Biliary epithelial cell, cholangiocytes 
Cholangiocytes are the cells lining the intrahepatic biliary tree that play an 
important role in bile duct formation and bile acid metabolism and detoxification (Alpini 
et al., 1988, 1989, 1996; LeSage et al., 1999). During cholangiopathies (e.g. PBC, PSCS), 
cholangiocytes represent the primary target cell, showing both increase proliferation and 
apoptosis due to toxicity of BAs. BAs effect in cholangiocytes is highly dependent on the 
apical bile acid transporter (ABAT) in these cells (Lazaridis et al., 1997), which mediates 
BAs uptake by the cells with the consequent effect of BAs in cholangiocyte proliferation 
and BAs secretion (Alpini et al., 1999).  
Cholangiocyte proliferation is one of the most important feature in cholestasis and 
animal models of cholestatic fibrosis (Alpini et al., 1988; Marucci et al., 1993; Roberts et 
al., 1997) and it does not only depend on bile acids but also on other factors such as 
intestinal hormones, estrogens, inflammatory cytokines, growth factors and cAMP 
(LeSage et al., 2001). Resulting cholangiocyte proliferation and malfunction in 
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cholestasis leads to activation of portal fibroblast and fibrosis initiation, probably by the 
enhanced cytokine secretion of “activated” cholangiocytes and the recruitment of immune 
cells (Desmoulière et al., 1997; LeSage et al., 2001; Tuchweber et al., 1996). Several 
studies have shown the important contribution of cholangiocytes to liver fibrosis, 
initiating the transformation of portal fibroblast to myofibroblast and recruiting HSCs 
through the production of several cytokines, such as PDGF (Grappone et al., 1999; 
Kinnman et al., 2000, 2003), MPC-1 (Lamireau et al., 2003; Marra et al., 1998), TGFβ 
(Lamireau et al., 1999; Milani et al., 1991) and CTGF (Sedlaczek et al., 2001). 
2.1.2.2.4 BA-induced hepatocyte apoptosis 
Hepatocytes are the most abundant cells in the liver and the primary target cells 
in cholestasis alongside cholangiocytes. The accumulation of excessive bile acids in the 
hepatocytes becomes toxic, resulting in BA-induced apoptosis and necrosis. Different 
mechanisms have been proposed to contrite to apoptosis in hepatocytes, including FAS 
and TRAIL-R2 (DR5) mechanism, ROS induction, TNF signalling and ER stress (Figure 
2.8). 
BAs have been shown to initiate FAS induced apoptosis both in a FAS-ligand 
independent and dependent manner. FAS receptor can be directly activated by BAs 
mediating its aggregation on the plasma membrane. Following FAS activation, the 
caspase cascade is initiated by Caspase 8 and continued by the protease Cathespin B 
amplifying the apoptotic signalling (Faubion et al., 1999). Similarly, BAs induce 
apoptosis by induction and aggregation of the TRAIL-receptor2/DR5, leading to the 
activation of caspase 8 in a Fas-independent way (Higuchi et al., 2001, 2004). These death 
receptor mechanisms of apoptosis is followed by cleavage and mitochondrial 
translocation of the proapoptotic protein Bid, which alters mitochondrial membrane 
potential, leading to depolarization and release of cytochrome c to the cytosol, activating 
the caspase signalling cascade and leading to irreversible cell death (Yin and Ding, 2003). 
Another mechanism of BA-induced apoptosis is mediated by ROS. BAs have been 
demonstrated to induce ROS production in the mitochondria (Sokol et al., 1993, 1995). 
ROS induction its implicated in the activation of JNK and the protein kinase C, which 
finally phosphorylates FAS, inducing its localization into the plasma membrane 
(Sodeman et al., 2000). Parallel, PKC have been proposed to induce cathespin activation 
and Mg2+ entrance in the cell with the following endonuclease activity and DNA cleavage 
(Patel et al., 1994). On the other hand, ROS also induces the intrinsic mitochondrial 
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pathway of apoptosis. BA accumulation increases mitochondrial ROS and leads to 
mitochondrial membrane depolarization and release of proapoptotic proteins such as Cyt 
c and the caspase cascade initiation. The direct implication of ROS and membrane 
depolarization in BA-induced apoptosis has been further demonstrated by the reduction 
of apoptosis when using ROS and membrane depolarization inhibitors (Botla et al., 1995; 
Yerushalmi et al., 2001). 
Finally, another mechanism implicated in bile acid-induced apoptosis has been 
recently described. BAs mediates upregulation of CHOP, which is an important mediator 
of the ER stress induced apoptosis, leading to hepatocyte cell death(Tamaki et al., 2008). 
In summary, hepatocyte apoptosis is a well-documented event occurring during 
cholestasis (in vitro and in vivo) playing an important role in the progression of the 
disease, contributing to liver dysfunction and increasing the inflammatory and fibrogenic 
processes associated to BA accumulation in the liver. 
 
Figure 2.9 Pathways implicated in BA-induced apoptosis. BA accumulation in the liver become toxic 
and induced apoptosis by the extrinsic and intrinsic pathways. BAs engage FASr and TRAIL-receptor2 
(DR5) activating caspase cascade. BAs also induce mitochondrial ROS, triggering JNK activation, loss 
of mitochondrial membrane potential (MMP), cyt-c release and apoptosis. 
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2.1.2.3 Liver fibrosis therapies  
Nowadays, there is no effective and standard treatment for the intervention of liver 
fibrosis. Most effective current treatment implicates the removal of the causative agents 
underlying the disease. The recent success achieved in blocking and reversing the 
progression of liver fibrosis with antiviral treatments has opened the possibility of 
treatment liver fibrosis. However, considering the high prevalence of fibrosis progression 
from NASH patients, there are still some major challenges for the development of new 
therapeutical approaches: I) better characterization of the disease and molecular pathways 
underlying; II) non-invasive markers for the diagnostic of the disease and III) 
establishment of continued studies for the progression of the disease in treated patients. 
Some of the targets of current research in fibrosis treatment include: anti-
inflammatory drugs to avoid inflammation contribution to progression of the disease; 
targeted therapy against HSCs to inactive them or to induce their apoptosis; antioxidants 
therapies to protect the hepatocytes from ROS induced damage; synthetic transcription 
factor ligands (PPARs and FXR); and the use of the non-toxic ursodeoxycholic bile acid 
(UDCA) for the treatment of BA-induced fibrosis (Bataller and Brenner, 2005; Trautwein 
et al., 2015). 
2.1.2.4 Animal models of fibrosis 
Animal models have been extensively used in fibrosis research, greatly 
contributing to the understanding of the disease. There are several animal models of liver 
fibrosis, however, all of them present different characteristics that needs to be accounted, 
contributing unequally to the disease (genetic background, immune system contribution, 
differential gene expression, etc.) Some of the most animal models used for the study of 
liver fibrosis are based on chemical toxins, such as carbon tetrachloride (CCl4); surgical 
procedures, the bile duct ligation (BDL); diet models, the MCDD; and some genetic 
models (Md2-/- and Gnmt-/-). 
Carbon tetrachloride (CCl4) is a chemically induced model of fibrosis.  CCl4 is 
intraperitoneally administrated and transformed into CCL3- by CYP2E1in the liver. CCL3- 
radical leads to an acute phase of hepatocyte cell death, necrosis, inflammation and 
activation of fibrogenesis. Sustained administration leads to fibrogenesis and even HCC 
development (Scholten et al., 2015). Other chemical-based models of fibrogenesis use 
ethanol, DMN and DEN compounds, which are also CYP2E1 related toxins (Starkel and 
Leclercq, 2011; Yanguas et al., 2016). 
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Bile duct ligation (BDL) is a surgical procedure that involves the ligation of the 
bile duct, leading to obstructive cholestasis. The ligation of the bile duct leads to bile acid 
accumulation in the liver, which cannot be secreted. The excess of bile acids promotes 
hepatocyte apoptosis, inflammation and fibrogenesis. BDL model is characterized by the 
implication of portal myofibroblast in the fibrogenic response as well as by the 
proliferation of the cholangiocytes and the intrahepatic bile ducts. These characteristics 
make BDL an excellent model frequently used to study biliary cirrhosis. The invasiveness 
and difficulty of the procedure and the high mortality associated to the process are the 
major disadvantages of BDL model (Tag et al., 2015). 
Animal models of diet induced fibrosis includes the MCDD. As mentioned in 
section 2.1.1.5.2, this diet induces the progression of steatosis to NASH and fibrosis by 
disrupting the methionine cycle and the glutathione synthesis and increasing oxidative 
damage. Another important diet that induces cholestatic fibrosis is a high content bile acid 
diet, which promotes toxic bile acid accumulation and cholangiocyte proliferation, 
resembling the BDL mouse model. 
Finally, genetic models are also important in the study of liver fibrosis. In this 
sense, the most important is the Mdr2-/- mouse (Popov et al., 2005). This mouse lacks the 
Mdr2 protein that is responsible for the secretion of phospholipids into the bile from the 
liver and spontaneously develops severe biliary fibrosis and HCC. The previously 
mentioned Gnmt-/- mouse has been also used for the study of fibrosis, as these mice 
spontaneously progress from steatosis to NASH, fibrosis and HCC (section 2.2.3.1). In 
this mouse, the characteristic chronic excess of SAMe contributes to alterations in the 
immune system during NASH and fibrosis, leading to overactivation of NK/NKT cells, 
which promote TRAIL-induced apoptosis in hepatocytes, highlighting the contribution 
of SAMe metabolism and immune system and TRAIL to liver injury (Fernández-Álvarez 
et al., 2015; Gomez-Santos et al., 2012).  
2.1.3 HEPATOCELLULAR CARCINOMA 
2.1.3.1 Epidemiology and etiology  
Liver cancer is an important cause and morbidity and mortality over the world. It 
is the fifth most common cancer and the second most common cause of cancer-related 
cell death, being HCC the most frequent presentation of liver cancer (70-85%) (Govaere 
and Roskams, 2015; Jemal et al., 2011). Other liver cancer types are cholangiocarcinoma, 
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hemangiosarcoma and hepatoblastoma. The etiology of HCC is heterogeneous and 
multifactorial and the major risk factor for the development of HCC are chronic hepatitis 
B and C, alcoholism, aflatoxin B1 intoxication and NAFLD (described in more detail in 
the next section) (McGlynn and London, 2011; Mittal and El-Serag, 2013). HCC is 
frequently asymptomatic in early stages of the disease being diagnosed at late stages, 
when it is already presented as multifocal and alongside a cirrhotic surrounding 
environment, making HCC of difficult treatment and a poor prognosis cancer (Attwa and 
El-Etreby, 2015; El-Serag et al., 2008; Llovet and Bruix, 2003). At the moment of 
diagnosis very few patients are eligible for therapeutic intervention (liver transplantation 
or tumor resection). Survival rates of HCC patients ranges between 6-20 months after 
diagnosis. Tumor recurrence after therapeutically intervention is frequent and may be 
enhanced by the convergence of different signalling pathways contributing to the 
malignant transformation of the HCC, difficulting the efficacy of conventional systemic 
therapies (Forner et al., 2012). Better understanding of molecular pathways driving 
hepatocellular carcinoma is needed for the development of new strategies for HCC 
treatment. 
2.1.3.1.1 NAFLD and HCC 
As previously mentioned, there is approximately a 4-27% of cirrhotic patients that 
develops HCC (Figure 2.1). The increase of NAFLD incidence in the last years and its 
expected continued rise in the next future is positioning NAFLD-associated HCC as one 
of the second leading causes of HCC and the most increasing one, countering the recent 
progress achieved in the treatment in HBV/HCC-derived HCC (Khan et al., 2015; 
Michelotti et al., 2013; Wong et al., 2014). Many risk factors mentioned before for 
NAFLD development are also risk factors for HCC (metabolic syndrome, dyslipidemia, 
diabetes, etc.) and almost universally presented at least in one form in NAFLD-derived 
HCC (Michelotti et al., 2013; Welzel et al., 2011). One important feature of NALFD-
derived HCC is the possibility of developing HCC without cirrhosis (Alexander et al., 
2013; Ertle et al., 2011; Guzman et al., 2008). Despite these particular features 
characterizing this type of HCC, the mean survival is similar to other etiologies. 
Improvement in understanding and diagnosing HCC and NAFLD-derived HCC would 
help to reduce HCC increased incidence during the last years, with NAFLD rising 
popping up as the major contributor for this increase in HCC (Khan et al., 2015; Wong et 
al., 2014).  
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2.1.3.2 Molecular pathways in HCC 
One of the principal features that makes HCC a highly difficult to treat and a very 
poor prognosis cancer is its particular heterogeneity, with many different molecular 
signalling pathways activated at the same time and contributing to the development of the 
cancer. Some important frequent alterations found in HCC are the following: 
2.1.3.2.1 Signalling pathways in HCC 
HCC is driven by a variety of signalling pathways implicated in the regulation of 
cell growth and proliferation, differentiation, angiogenesis, inflammation and apoptosis. 
a) Tyrosine kinases receptor (TKRs) pathway 
TKRs include a group of receptor whose activation involves different growth and 
migration pathways. Most important pathways responding to TKRs activation are Ras-
MAPK (Ras/Raf/MEK/ERK), PI3K/Akt, VEGF, EGFR, c-MET and c-Myc. Ras-MAPK 
and PI3K/Akt are frequently overactivated in early HCCs and in almost all advanced HCC 
(Bhat et al., 2013; Calvisi et al., 2006; Schmidt et al., 1997). Ras-MAPK is activated by 
different TKRs as IGFR, EGFR, PDGFR and FGFR and lead to the activation of 
transcription factors and proliferation genes. On the other hand, PI3K/Akt is activated by 
IGFR1 and other TKRs and activates the mTOR signalling pathway. PI3K/Akt pathway 
is also regulated by inactivation by PTEN, which frequently downregulated in HCC by 
loss of function, mutations or epigenetic silencing (Figure 2.9). 
b) VEGF angiogenic pathway 
HCC is a highly vascular tumor in which the formation of new vessel to sustain 
vascularization is very important. However, HCC, as well as many other solid tumors, is 
characterized by the presence of hypoxic regions that induces an angiogenic response to 
generate the growth of new vessel from the surrounding parenchyma into the tumor. The 
angiogenic necessities in HCC and the response to hypoxic conditions is mainly mediated 
by the overexpression of VEGF, the major player in tumor vascularization (Kim et al., 
1998; Muto et al., 2015).  
c) JAK/STAT pathway 
JAK/STAT signalling pathway is frequently found overexpressed in HCC and 
promotes transcription of genes implicated in proliferation, migration and differentiation. 
JAK/STAT pathway is autoregulated in a negative feedback loop in which JAK/STAT 
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activation induces the transcription of SOCS proteins, which binds to JAK to inhibit the 
pathway. The frequent overexpression of JAK/STAT signalling in HCC is associated to 
the high methylation of different SOCS promoter, preventing the negative autoregulation 
of the pathways (Calvisi et al., 2006). 
d) Epigenetics: DNA methylation and microRNAs  
Epigenetics is a term used to define a variety of mechanism implicated in the 
control of gene expression without affecting genomic sequences. Epigenetic regulatory 
mechanisms include DNA methylation, histone acetylation/methylation, microRNAs, 
transcription factors and chromatin remodeling. Alterations in the regulation of this 
mechanisms are highly involved in HCC development and prognosis. Basically, 
epigenetic modification contribute to cancer development by enhancing tumor oncogenic 
gene expression or downregulating tumor suppressor genes. Epigenetics in liver disease 
and HCC are described in more detail in section 2.3.  
e) Other pathways 
Other important pathways contributing to HCC are the WNT/β-catenin and the 
TGFβ pathways. WNT/β-catenin is implicated in the regulation of proliferation 
associated genes and is frequently activated in HCC mainly responding to different 
mutations (Thompson and Monga, 2007). TGFβ plays a dual role in HCC development, 
acting as a tumor suppressor during HCC initiation and being implicated in invasiveness, 
angiogenesis and metastasis in advanced HCC (Roberts and Wakefield, 2003).  
2.1.3.3 HCC treatment, sorafenib and drug resistances 
Hepatocellular carcinoma is still considered as a very poor prognosis cancer due 
to the difficult and low effective therapeutic options still available for its treatment. 
Despite the recent progress in the treatment of HCC since the approval of sorafenib as the 
unique drug for HCC systemic treatment, the results in terms of surveillance are still low 
and need to be improved. Therapeutical options considered for HCC depends on the stage 
of the disease and are the following: 
a) Resection and transplantation 
Resection is usually the first considered option for patients with less than three 
localized tumor without surrounding cirrhosis (Bruix et al., 2015; Yu, 2016). It implicates 
the removal of the tumoral tissue and the non-tumoral surrounding tissue. Resection rises  
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Figure 2.9 TKR signalling in hepatocellular carcinoma. Tyrosine kinase receptors (TKRs) are 
frequently overactivated in HCC, activitating oncogenic signalling cascades related to different 
properties of HCC. Ras/raf/MEK/ERK and PI3K signalling pathways are frequently overactivated in 
HCC by different TKRs, conferring proliferation and survival advantages to hepatocellular carcinoma. 
 
several major problems as it is a highly aggressive intervention and recurrence is 
frequently observed after 5 years (70%). Complications in HCC patients with cirrhosis 
are greater, including possibility of liver failure (Bruix et al., 2015). 
Liver transplantation is more frequently performed in patients with 
decompensated cirrhosis, included in the Milan criteria (single nodule <5 cm or <3 
nodules, without vascular invasion). The overall survival of patients undergoing liver 
transplantation is higher than those with resection, and recurrence is significantly lower 
(Liver and Cancer, 2012; Llovet et al., 1999). The major problem concerning liver 
transplantation is the low availability of liver donors. 
 b) Locoregional therapy 
These non-surgical therapies are frequently used in combination with surgery or 
when surgery is not an option in patients presenting intermediate HCC. They include 
tumor radiofrequency ablation and TACE (transcatheter arterial chemoembolization). 
Tumor ablation induces tumor necrosis by heat (generated by radiofrequency, laser 
cryoablation, etc.). TACE is more frequently used in patients with large multifocal HCC 
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and it is based in the injection of chemotherapy through the arteries followed by ischemia-
embolization (Llovet et al., 2002). 
c) Systemic therapies 
Systemic therapy is normally directed to patients with advanced HCC that are not 
eligible for other mentioned therapies or to those patients with low response to previous 
treatments. Nowadays, sorafenib is the only drug approved for the systemic therapy of 
HCC. Sorafenib is a multikinase inhibitor that acts mainly upon Ras/Raf/MEK/ERK, 
VEGF and PDGF pathways (Wilhelm et al., 2006). Sorafenib treatment has shown 
improved survival in advanced HCC patients in initial studies (Llovet et al., 2008), 
however, loss of efficacy, development of resistances and side effects have evidenced the 
need of improvements in HCC-sorafenib based therapies (Berasain, 2013). The following 
section will present the importance of sorafenib in HCC treatment, regarding its 
molecular mechanism, efficacy and resistances. 
2.1.3.3.1 Sorafenib 
The advances produced during the last decades in understanding cancer biology 
and molecular mechanism implicated in oncogenesis and tumor development have led to 
the increased development of rationally-designed drugs instead of non-specific cytotoxic 
chemotherapeutic agents for the treatment of cancer. The most important drug recently 
approved for the treatment of HCC is sorafenib, a multikinase inhibitor that has also 
shown benefit in other cancer types. 
 
Figure 2.10 Chemical structure of Sorafenib (from Wilhelm et al 2006). 
 
Sorafenib (Nexavar, BAY 43-9006, Bayern Pharmaceuticals) is a multikinase 
inhibitor with proved antitumoral activity in HCC and other cancer types (Liu et al., 2006; 
Llovet et al., 2008; Wilhelm et al., 2006, 2004) (Figure 2.10). This multikinase has been 
shown to inhibit both proliferation and angiogenesis acting through different targets: it 
inhibits the serine/threonine kinases c-RAF and BRAF, as well as the angiogenic receptor 
tyrosine kinases VEGFR2/3, PDGFR, ret and c-Kit. As mentioned in section 2.1.3.2.2, 
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HCC tumors show overactivation of tyrosine/kinases pathways and are highly dependent 
on blood supply and vascularization, thus the rationale use of sorafenib in HCC emerges 
as an interesting therapeutical option. As mentioned, sorafenib directly inhibits 
Ras/Raf/MEK/ERK in HCC through the direct inhibition of Raf kinases, with the 
consequent ablation of MEK/ERK signalling pathway and cyclin D1 dependent 
proliferation (Liu et al., 2006). Parallel, sorafenib also inhibits the phosphorylation and 
autophosphorylation of angiogenic tyrosine/kinase receptors VEGFR and PDGFR, 
contributing to its antitumoral effect (Liu et al., 2006; Wilhelm et al., 2006). Finally, in 
HCC, an important role of sorafenib in the inhibition of transcription and proliferation 
through STAT3 inhibition has been described (Blechacz et al., 2009; Chen et al., 2010; 
Tai et al., 2011) (Figure 2.11). 
Besides antiproliferative and antiangiogenic properties, sorafenib has also been 
demonstrated to exert proapoptotic effects in HCC (Figure 2.11). Regarding induction of 
apoptosis, different mechanisms have been proposed to underlie sorafenib induced 
apoptosis. First, sorafenib was proposed to inhibit MCL-1, an anti-apoptotic Bcl-2 protein 
member, through the inhibition of phosphorylation of eIF4E in HCC cell lines (Liu et al., 
2006). Sorafenib inhibition of MCL-1 has been shown in other cancers such as leukemia 
(Rahmani et al., 2005; Yu et al., 2005). Second, a role of the p53-upregulated modulator 
of apoptosis (PUMA) has been proposed to be essential for apoptosis initiation mediated 
by sorafenib in HCC (Dudgeon et al., 2012). PUMA is a BH3-only Bcl-2 family member 
that functions as a critical initiator of apoptosis in cancer cells through the inhibition of 
anti-apoptotic Bcl-2 protein members and activation of pro-apoptotic members, resulting 
in mitochondrial dysfunction and caspase cascade activation (Yu and Zhang, 2008). 
PUMA is classically induced by P53 upon DNA damage, however it has been 
demonstrated that can be induced through p53-independent mechanism (TNF, P73, NF-
κB or c-JUN) (Cazanave et al., 2010; Ming et al., 2008; Wang et al., 2009). Regarding 
PUMA induction by sorafenib, it has been described to occur in a P53-independent 
manner, through the activation of the NF-κB transcription factor (Dudgeon et al., 2012). 
Other studies have describe other mechanisms as transcription factors (GADD45β) (Ou 
et al., 2010) and physiological apoptotic stimulation (e.g. TGFβ and TNF) (Fernando et 
al., 2012), implicating in some cases activation of JNK/c-JUN signalling pathways as 
essential for the response to sorafenib (Fernando et al., 2012; Lin et al., 2017; Ou et al., 
2010; Wei et al., 2010; Yu et al., 2006). Interestingly, despite the well characterized role 
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of P53 in induction of apoptosis in HCC and many other cancer cell, sorafenib induced 
apoptosis have been proved to be P53-independent in several of these studies, affecting 
sorafenib in the same extent to P53-wild-type/mutant cells.  
Recent progress above mentioned in understanding sorafenib mechanism will help 
to improve sorafenib treatment in HCC patients, especially regarding the loss of 
effectiveness and appearance of resistance upon the continued treatment with sorafenib. 
In this context, there have been only one effective pharmacological combined therapy 
improving survival in HCC patients showing no benefit from sorafenib treatment. 
Regorafenib, a multikinase inhibitor that blocks the activity of kinases involved in 
angiogenesis, oncogenesis, metastasis and tumor immunity is approved for the treatment 
of metastatic colorectal cancer and gastrointestinal tumors, and have been shown 
beneficial effects in a phase 3 study in HCC patients treated with sorafenib (Bruix et al., 
2017). 
 
Figure 2.11 Sorafenib mechanisms in HCC. Sorafenib have been proposed to inhibit HCC 
proliferation by different mechanism. Sorafenib blocks proliferation and survival by inhibiting Raf/ERK 
signalling. Sorafenib also blocks angiogenesis acting over the TKRs VGFR and PDGFR and inhibits 
transcription and survival signaling governed by STAT3. Sorafenib directly induces apoptosis inhibiting 
MCL-1 antiapoptotic protein and activating PUMA effector of apoptosis.   
 
2.1.3.3.2 Drug resistances in HCC 
One of the major clinical challenge in the treatment of HCC relies behind 
overcoming drug resistances frequently presented in HCC patients. It has been shown that 
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HCC presents several different mechanisms implicated in non-acquired (primary) and 
acquired resistance to different therapies. This is in part due to the heterogeneity 
underlying HCC development, related also to the high genetic instability characteristic of 
HCC and the tumoral response to the therapy. In this sense, different mechanisms of 
chemoresistance (MOCs) can be divided in five principal groups affecting: changes in the 
intracellular drug concentration by decrease drug uptake (MOC-1a) or export (MOC-1b), 
enhanced drug inactivation or decreased prodrug activation (MOC-2), changes in the 
molecular targets of the drugs (MOC-3), increased repair response to drug-induced DNA 
damage (MOC-4) and misbalance between signalling mechanisms implicated in survival 
and apoptosis (Marin and Briz, 2010; Marin et al., 2017). In this thesis, we have studied 
sorafenib resistances regarding intracellular levels of sorafenib and mechanisms of 
apoptosis (i.e. MOC-1a-b and MOC-5). 
a) Sorafenib uptake/export pumps 
MOC-1a-b involves mechanisms implicated in reducing the intracellular levels of 
the therapeutic drugs, including drug transporters responsible for the drug uptake (MOC-
1a, solute carrier family, SLCs) and drug export (MOC1-bexporting pups belonging to 
the ATP-binding cassette ABC superfamily, MRPs/MDRs) implicated in the 
development of the multi drug resistant (MDR) phenotype (Marin et al., 2014, 2010). 
Different transporters included in the MOC-1a have been found downregulated in HCC 
and other liver cancers, being the most important SLC22A1, implicated in the 
intracellular uptake of sorafenib as well as other drugs (e.g. platinum based drugs and 
doxorubicin) (Herraez et al., 2013; Martinez-Becerra et al., 2012; Zollner et al., 2005). 
On the contrary, some export pumps (e.g. MDR1, MRP2 and MRP4) are frequently 
overexpressed (in basal levels or response to treatment) or related to poor prognosis in 
HCC  (Marin and Briz, 2010; Ng et al., 2000; Wakamatsu et al., 2007). 
a) Mechanism evading sorafenib-reduced viability and apoptosis  
There are different mechanisms implicated in loss of drug efficacy. In the case of 
sorafenib, there are different pathways that have been described to play a role in HCC 
resistance, such as activation of proliferation compensatory pathways (PI3K/AKT), 
induction of EMT, activation of hypoxia-related signalling, dysregulation of pro/anti-
apoptotic proteins and genetic/epigenetic characteristics of the tumor than can contribute 
to the  different response (Berasain, 2013; Zhai and Sun, 2013). Importantly, regarding 
 Introduction 
 
73 
 
epigenetic characteristics of the tumor, microRNA signature and response to different 
drugs have emerged in the recent years as important contributors to the development of 
drug resistance (Fornari et al., 2009, 2017; Xia et al., 2006; Xu et al., 2016).  
In summary, different mechanisms are implicated in primary/acquired resistance 
to sorafenib in HCC. Since sorafenib represents the unique drug for systemic treatment 
of HCC but has shown only relevant improvement regarding overall survival in patients, 
uncovering these resistance mechanisms will be highly relevant for the treatment of HCC. 
In the next two sections the importance of methionine metabolism in the liver and 
the role of epigenetics as important drivers of chronic liver disease progression (NAFLD, 
fibrosis and HCC) will be presented. 
2.2 METHIONINE METABOLISM IN LIVER DISEASE 
Several studies have linked alterations in methionine metabolism with 
development of liver disease. First insight into the role of methionine metabolism was in 
1932, Best demonstrated that rats fed with a diet deficient in methyl groups (methionine, 
choline and folates) developed liver steatosis, which progressed to steatohepatitis, fibrosis 
and HCC when prolonged in time (Best et al., 1932). Later, in human patients suffering 
cirrhosis, Kinsell demonstrated the deficient methionine clearance from the plasma in 
those cirrhotic patients, linking liver disease and hypermethionemia (Kinsell et al., 1947, 
1948). Since then, the link between methionine metabolism and liver disease have been 
largely studied, providing important evidence into its regulation by different enzymes and 
its implication in several pathways differently implicated in the development of liver 
disease. 
2.2.1 METHIONINE, S-ADENOSYLMETHIONINE AND 
METHIONINE CYCLE 
Methionine is an essential amino acid that is converted into S-adenosylmethionine 
(SAMe, SAM or AdoMet) in a reaction catalyzed by the enzyme methionine 
adenosyltransferase I and III (MATI/III), using ATP as co-substrate (Cantoni, 1953; 
Cantoni and Durell, 1957). SAMe is the most important biological methyl donor and it 
can be produced in all the cells, although the liver is the responsible of approximately the 
50% of methionine metabolism and the 85% SAMe methylation reactions (Finkelstein, 
1990; Mato et al., 2002; Mudd and Poole, 1975). SAMe is involved in transmethylation 
reactions, it can donate the methyl group to DNA, RNA, proteins, amino acids, sugars 
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and phospholipids in reactions catalyzed by specific methyltransferases (Mato et al., 
2008, 2013; Petrossian and Clarke, 2011). Moreover, SAMe not only participates in 
transmethylation reactions but it is also involved in polyamines synthesis and in the 
transulfuration pathway to generate glutathione, the main antioxidant in the cell (Lieber 
and Packer, 2002; Lu, 2000; Mato et al., 1997). 
Methionine and SAMe levels are controlled by a set of enzymes that participates 
in the named “Methionine cycle” (Figure 2.12). In this cycle, SAMe is synthetized from 
L-methionine in an ATP-dependent reaction by MATI/III. Then, SAMe can be 
demethylated by different methyltransferases, being the most important glycine N-
methyltransferase (GNMT, section 2.2.4), generating S-adenosylhomocysteine (SAH), 
an inhibitor of many methyltransferases. In this sense, GNMT is the responsible of the 
maintenance of SAMe/SAH ratio, considered as the indicator of the methylation capacity 
of the cell (Finkelstein, 2007). SAH is hydrolyzed by SAH hydrolase (SAHH), to prevent 
SAH accumulation, in a reversible reaction that generates homocysteine (HCY) and 
adenine. Homocysteine can enter two pathways then: the remethylation and the 
transulfuration pathways. The transulfuration pathway is of particular importance in liver 
because of its high activity. In this transulfuration pathway, homocysteine is used as a 
substrate of cystathionine-6-synthase (CBS), generating cysteine and glutathione (Lu, 
1999, 2009). 
Alternatively, methionine can be regenerated from homocysteine through the 
remethylation pathway, which can be directed by two different enzymes: betaine 
homocysteine methyltransferase (BHMT) and methionine synthase (MS). BHMT is a 
liver and renal specific enzyme, which converts homocysteine into methionine using 
betaine as co-substrate. MS-mediated remethylation requires normal levels of vitamin B12 
and folates and it is coupled to the folate cycle. MS uses 5-methyltetrahydrofolate (5-
MTHF) as methyl donor for HCY, generating methionine and tetrahydrofolate (THF). 
THF is then converted to 5,10-MTHF by the enzyme 5,10-MTHF synthetase (MTHFS) 
and finally regenerated to 5-MTHF by the last enzyme of the cycle, MTHF reductase 
(MTHFR) (FIG 2.12). 
The fate of HCY to enter transulfuration or transmethylation pathways is 
determined by the hepatic levels of SAMe, which is an activator of CBS and an inhibitor 
of MS and MTHFR activities. Thus, when SAMe levels are high, HCY enter the 
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transulfuration pathway, while low SAMe levels directs HCY to the remethylation 
pathway to regenerate methionine and SAMe (Mato et al., 1997; Prudova et al., 2006). 
An alternative pathway of the methionine pathway is the use of SAMe for 
polyamine synthesis. In these pathways, SAMe is not metabolized by any 
methyltransferase but is decarboxylated by a specific SAMe decarboxylase in a reaction 
that generates two molecules of 5’-methylthioadenosine (MTA). MTA is an inhibitor of 
polyamine synthesis (Pegg and Williams-Ashman, 1969), methylation reactions (Dante 
et al., 1983) and SAHH activity (Della Ragione and Pegg, 1983) and can affect gene 
expression, proliferation, differentiation and apoptosis (Avila et al., 2004). MTA is 
removed to restore methionine levels in a process known as the methionine salvage 
pathways (Avila et al., 2004) (Figure 2.12). 
Methionine and SAMe levels and metabolism are frequently found altered in liver 
disease. The regulation of the methionine cycle is controlled, as we have mention 
previously, by enzymes and by the products generated during different reactions over the 
cycle. For example, SAH is a potent inhibitor of SAMe-mediated methylation reactions 
and high levels of SAMe activate CBS and transulfuration pathway while inhibiting 
MTHFR and regeneration pathway. The alteration in the expression of the enzymes 
implicated in methionine and SAMe metabolism leads to whole dysregulation of the 
methionine cycle. Low levels of SAMe are frequently found in liver disease, as a 
consequence of low expression of MAT1A gene and MATI/III enzymes (Avila et al., 
2000; Duce et al., 1988). However, on the contrary, the gene codifying for the enzyme 
implicated in SAMe catabolism, GNMT, is also found downregulated in liver disease, 
contributing to abnormally elevated SAMe levels and directly to liver disease (Avila et 
al., 2000; Luka et al., 2002; Mudd et al., 2001). All these data indicate that the liver needs 
to tightly regulate the amount of SAMe, since the impairment in its metabolism leads to 
liver injury. In the next sections, the main enzymes implicated in the regulation of SAMe, 
MATI/III (anabolism) and GNMT (catabolism), and the study of hypermethioninemia 
based in this two enzymes knock-out mouse models, will be described in detail. 
MicroRNAs in liver disease 
76 
 
 
Figure 2.12 The methionine cycle. Brief overview of the methionine and SAMe metabolism in the liver 
and the pathways implicated in their use and regeneration. 
 
2.2.2 METHIONINE ADENOSYLTRANSFERASE 
MAT enzymes are the responsible of SAMe generation, activating methionine and 
using ATP. MAT gene is very well conserved from bacteria to humans and it is considered 
essential in order to sustain life (Kotb et al., 1997). 
In mammals, MAT catalytic subunit is codified by two genes located in different 
chromosomes, MAT1A and MAT2A, encoding for the two homologous MAT catalytic 
subunits α1 and α2 (sharing 84% of amino acid homology), respectively (Kotb et al., 
1997). A third MAT gene exists, MAT2B, only expressed in fetal and regenerating liver 
and extrahepatic tissues, which encodes for the β regulatory subunit (Halim et al., 1999). 
MAT1A is expressed in adult and differentiated liver (Gil et al., 1996). The encoded α1 
subunit can be organized forming dimers (MATIII) or tetramers (MATI) (Kotb et al., 
1997; Mato et al., 1997). MAT2A is expressed in fetal and proliferating liver and 
extrahepatic tissues (Gil et al., 1996). The encoded α2 subunit is organized as a tetramer 
(MAT II) that associates with the β regulatory subunit (LeGros et al., 2000; YANG et al., 
2008). MAT enzymes are tightly regulated regarding expression and enzymatic activity. 
a) Regulation of MAT expression 
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MAT1A and MAT2A are differentially expressed in several liver scenario. During 
fetal rat development, MAT1A expression increases very rapidly, being highly expressed 
in adult rat. Conversely, MAT2A, decreases during development and after birth, being 
minimally expressed in adult rat liver (Gil et al., 1996).  
In HCC and different liver diseases, MAT1A is downregulated, while MAT2A is 
found overexpressed. In murine and rat liver, loss of MAT1A and increase MAT2A 
expression have been also found in situation of rapid growth, such as hepatocyte de-
differentiation to fibroblast in culture (García-Trevijano et al., 2000) and liver 
regeneration after partial hepatectomy (Huang et al., 1998).  
Different mechanisms implicated in the regulation of MAT genes in these 
situations have been described. The implication of DNA methylation has been described 
in different cases. MAT1A promoter is hypermethylated in two CpG sites in fetal liver and 
extrahepatic tissues, and have been found hypermethylated in cirrhosis, HCC and 
hepatoma cell lines (Avila et al., 2000; Mato et al., 2002). On the contrary, MAT2A 
promoter is hypomethylated in HCC (Yang et al., 2001). Other mechanisms such as 
histone acetylation (Latasa et al., 2001; Torres et al., 2000) and microRNA (Yang et al., 
2013a) mediated repression have been described concerning MAT regulation in liver 
disease.  
b) Regulation of MAT enzymatic activity  
The three different MAT enzymes have different kinetic properties implicated in 
the regulation of its activity. MATII has the lowest Km for he methionine (4-10 µM), 
MATI has intermediate (23 µM-1 mM) and MATIII possesses the highest Km for the 
methionine (215 µM-7 mM) (Mato et al., 2013). The rate of inhibition by its product 
SAMe, shows an opposite trend: MATII is strongly inhibited by SAMe (IC50= 60 µM); 
MATI (IC50= 400 µM) is slightly inhibited and MATIII, on the contrary is strongly 
activated by SAMe (Sullivan and Hoffman, 1983). Other mechanisms implicated in the 
regulation of enzymatic activity are the production of nitric oxide (NO) and ROS, which 
can switch MATI and III to inactive conformational forms (Mato et al., 2002). 
2.2.2.1 Mat1a-knock-out mouse model 
Mat1a-/-mice are characterized by the absence of MAT1A gene and the consequent 
lack of MATI/III enzymes (Lu et al., 2001). These mice have reduced SAMe levels (74% 
compared to WT mice) and GSH levels (40%) and increased blood levels of methionine 
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(Lu et al., 2001). The lack of Mat1a results in the spontaneous development of NAFLD 
and HCC at 8 and 18 months, respectively. Mat1a-/- mice present hyperglycemia and high 
levels of hepatic triglycerides (Lu et al., 2001) together with deficient VLDLs formation, 
which are smaller and with less TG content (Cano et al., 2011), contributing to the 
development of steatosis. Moreover, these mice show overexpression of CYP2E1 and 
UCP2, both related with ROS production, which together with the decreased GSH levels 
predispose these mice to the development of liver injury (Martínez-Chantar et al., 2002). 
Finally, these mice are characterized by increased expression of proliferating markers, 
such as PCNA, AFP and MATII, corresponding with increased proliferation. All these 
features predispose Mat1a-/- mice to the spontaneous development of HCC at 18 months. 
2.2.3  GLYCINE N-METHYLTRANSFERASE 
Glycine N-methyltransferase (GNMT) is the most important enzyme implicated 
in SAMe catabolism. GNMT is a tetrameric protein composed of four identical subunits 
that is mainly localized in the cytoplasm of the cell (Ogawa et al., 1998; Yeo and Wagner, 
1994). In the liver, it represents about 1-3% of the total cytosolic protein content, and it 
is also expressed in the pancreas, prostate and peripheral nervous system (Luka et al., 
2009; Varela-Rey et al., 2014). Similarly to MAT1A, GNMT, is not expressed during 
development and its expression rapidly increases after birth, representing an marker of 
adult and differentiated liver (Luka et al., 2009). 
GNMT catalyzes the conversion of SAMe to SAH, using glycine as substrate and 
generating sarcosine, being considered to intracellular regulator of SAMe levels, 
maintaining the ratio SAMe/SAH (transmethylation capacity of the cell) constant.  Under 
situations of high methionine levels in the cell, SAMe levels will be increased, and 
GNMT activation will metabolize SAMe. The resulting SAH is known to inhibit most 
methyltransferase, however, GNMT activity is not inhibited by high levels of SAH 
(Wagner et al., 1985), allowing a continued activity of GNMT in order to catabolize 
SAMe (Martinov et al., 2010; Rowling et al., 2002). On the other hand, the second product 
generated by GNMT is sarcosine, a molecule with unknown metabolic functions that can 
be used to regenerate glycine and 5,10-MTHF, linking GNMT with the folate cycle. In 
fact, GNMT was first described as a folate-binding protein, GNMT activity is inhibited 
by 5-MTHF under low methionine conditions, allowing the use of SAMe-methyl group 
to be used for the desired biological fate (Luka et al., 2009; Rowling et al., 2002; Wagner 
et al., 1985).  
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GNMT expression is frequently found downregulated in liver disease (Avila et 
al., 2000; Heady and Kerr, 1975; Liao et al., 2012; Luka et al., 2002; Mudd et al., 2001; 
Tseng et al., 2003). However, the mechanisms mediating GNMT downregulation are not 
profoundly described. Mechanism implicating GNMT promoter hypermethylation in 
hepatocellular carcinoma have been proposed (Huidobro et al., 2013), however, aberrant 
GNMT hypermethylation was only found in 20% of human HCC lacking GNMT 
expression, thus, explaining only partially GNMT downregulation. GNMT promoter 
acetylation has been proposed but not profoundly studied in HCC (Kant et al., 2016). 
Finally, GNMT activity has been proposed to be induced by Vitamin A, glucocorticoids 
and glucagon (Nieman et al., 2004; Williams and Schalinske, 2007). Thus, better 
characterization of GNMT expression in liver disease is necessary to overcome GNMT-
deficient related liver injury.  
2.2.3.1 Gnmt-knock-out mouse model 
As previously mentioned, GNMT is frequently absent or low expressed in HCC 
and other liver diseases (NAFLD and cirrhosis), supporting an essential role of GNMT in 
liver homeostasis. Aiming to understand the functions of GNMT, the Gnmt-/- mouse has 
been generated (Luka et al., 2006). Gnmt-/- mice are characterized by 35-fold increased 
hepatic SAMe levels and 100-fold increase in SAMe/SAH ratio, as well as elevated serum 
levels of methionine an transaminases (Martínez-Chantar et al., 2008). Gnmt-/- mice 
develop steatosis and steatohepatitis and fibrosis at 3 months and hepatocellular 
carcinoma at 8 months (Martínez-Chantar et al., 2008) (Figure 2.13). This Gnmt-/-  murine 
model has been extremely useful for the study of GNMT-deficiency associated diseases 
and SAMe excess in the liver. Different mechanisms contributing to liver injury in the 
absence of GNMT have been described (Figure 2.14):  
 
 
Figure 2.13 Gnmt-/- mice present DNA hypermethylation and develop HCC. GNMT deficiency leads 
to chronic accumulation of SAMe in the liver and hepatocellular carcinoma. SAMe excess is associated 
with a DNA hypermethylation signature. Gene promoter methylation of inhibitors of Ras/ERK and 
JAK/STAT pathways is produced in the absence of GNMT, and, as a consequence, these oncogenic 
pathways are overactivated in these mice contributing to HCC development. 
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a) DNA hypermethylation 
The first characterization of Gnmt-/- mice identified a role of GNMT in the 
maintenance of normal DNA methylation. The absence of GNMT leads to chronic SAMe 
accumulation in the liver and the 100-fold SAMe/SAH. SAMe/SAH ratio is related to the 
methylation capacity of the cell, and its increase promotes aberrant methylation reactions. 
SAMe is able to methylate DNA at gene promoter. In these mice, the chronic excess of 
SAMe has been related to hypermethylation of Ras-association domain family (RASFF) 
and suppressor of cytokine signalling (SOCS) promoters. RASFF and SOCS are 
inhibitors of Ras and JAK/STAT signalling pathways. This inhibition results in 
Ras/MEK/ERK and JAK/STAT/CyclinD1/D2 signalling hyperactivation, increasing the 
proliferative and survival capacity of the cells, driving HCC development (Martínez-
Chantar et al., 2008) (Figure 2.13).  
b) Alterations in the PEMT flux 
SAMe participates in the synthesis of around 30% of liver phosphatidylcholine 
(PC), in a reaction in which phosphatidylethanolamine (PE) is converted into PC through 
the action of the phosphatidylethanolamine N-methyltransferase (PEMT) enzyme. The 
flux from PE to PC is known as PEMT flux. PC is catabolised into diglycerides, a 
precursor for TG synthesis. Thus, the increase in SAMe in Gnmt-/- livers leads to increased 
PEMT flux and PC formation, contributing to increase TGs and steatosis in these mice 
(Martínez-Uña et al., 2013). Moreover, PEMT flux has been described to be essential for 
VLDL secretion from the liver (Noga et al., 2002). In this regard, the increased PEMT 
flux in Gnmt-/- mice due to excess of SAMe increases VLDL assembly and secretion but 
also VLDL uptake, mainly due to the VLDL specific features. Altogether, these 
alterations contribute to steatosis and some of the extrahepatic complications of NAFLD 
(Martinez-Una et al., 2015). 
c) Alterations in autophagy 
Excess of SAMe in Gnmt-/- mice has been related to the development of steatosis 
through disruption of lipophagy (Zubiete-Franco et al., 2016).  Lipophagy is a type of 
autophagy implicated in the degradation of lipids. It has been proposed that autophagy 
can protect the liver from steatosis by eliminating the accumulation of lipids within the 
hepatocytes (Singh et al., 2009). High levels of methionine and SAMe inhibit autophagy 
through the methylation of PP2A, a protein implicated in inhibition of mTOR-mediated 
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autophagy. The inhibition of autophagy through this mechanisms leads to liver steatosis 
in Gnmt-/- mice (Sutter et al., 2013; Zubiete-Franco et al., 2016). 
d) Hypercholesterolemia 
Recently, the deficiency of GNMT has been shown to impact cholesterol 
metabolism, in this case, independently of SAMe metabolism. GNMT interacts with and 
stabilizes Niemann-Pick type C2 (NPC2), a protein implicated in cholesterol trafficking 
and metabolism through the binding with free cholesterol. Low GNMT hepatic levels 
decreases the stability of NPC2, contributing to cholesterol accumulation within the 
hepatocytes (Liao et al., 2012). 
e) GNMT deficiency associated inflammation in steatohepatitis.  
The role of GNMT and SAMe in the regulation of inflammatory processes and 
immune system have been described in two studies using Gnmt-/- mice. In a first study it 
was shown that GNMT deficiency and SAMe excess in the liver leads to overactivation 
of immune system, increasing the number and cytotoxic activity of TRAIL-producing 
NK/NKT cells in the liver, contributing to the chronic proinflammatory environment 
characteristic during NASH progression in the Gnmt-/- mice (Gomez-Santos et al., 2012). 
Finally, the role of TRAIL-producing NK cells in GNMT deficient mice was also 
described in the progression of chronic liver injury and fibrogenesis (Fernández-Álvarez 
et al., 2015).  
f) Other signalling pathways contributing to HCC. 
Despite the highlighted role of GNMT in the regulation of SAMe/SAH ratio and 
the methylation capacity of the cell, other mechanisms have been shown to be implicated 
in GNMT-deficient derived hepatocellular carcinoma, besides DNA promoter 
hypermethylation above described. In one study, Gnmt-/- mice showed hyperactivation of 
canonical Wnt pathways (Liao et al., 2009). Another study implicates GNMT as an 
interacting protein of DEPDC6/DEPTOR protein, regulating mTOR signalling and HCC 
(Yen et al., 2012). Finally, recently published data discovered PREX2 (an inhibitor of 
PTEN) as a novel interacting protein of GNMT. GNMT-PREX2 interaction enhances 
PREX2 proteasome degradation. Thus, lack of GNMT correlates with increased PREX2 
levels, PTEN inhibition and hyperactivation of Akt signalling and HCC development (Li 
et al., 2017). 
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Figure 2.14 GNMT-deficiency associated alterations. Deficiency in GNMT have been associated with 
different liver dysfunctions such as alterations in VLDL secretion, lipophagy, cholesterol trafficking and 
deregulation of NK cell toxicity in the liver. 
 
2.3 EPIGENETICS IN LIVER DISEASE 
Alterations in SAMe metabolism caused by any possible disruption in the 
expression or function of the enzymes implicated in the methionine cycle are strongly 
associated to epigenetic modifications. Specifically, in the context of GNMT deficiency 
and excessive SAMe, epigenetic changes can involve DNA methylation and histone 
methylation. The term epigenetics involves a variety of regulatory processes implicated 
in the control of gene expression by operating “above” (“epi”) the DNA sequence. The 
consensus definition of an epigenetic trait is “a stably inherited phenotype resulting from 
changes in a chromosome without alterations in the DNA sequence.” Most important 
mechanisms of epigenetics include: DNA methylation, histone modifications, 
microRNAs and long noncoding RNAs, transcription factors and chromatin remodeling 
complexes. In the next sections, most important epigenetic mechanisms and their 
implications in liver disease will be described. 
2.3.1 DNA METHYLATION 
DNA methylation occurs in the cytosine, at the 5th carbon ring, mainly found 
within CpG islands, which are long stretches of DNA with dense sequences CpG (55%), 
frequently located in the 5’ promoter regions. CpG methylation is associated with 
transcriptional repression, which is mediated by the union of methyl binding domain 
proteins (MBDs: MBD1, MBD2, MeCP2, KAISO and MBD4) that recognizes methyl-
CpG regions in the DNA. Besides MBD union, methylation of CpG islands also inhibit 
DNA transcription promoting high chromatin condensation (Bird, 2002; Bird and Wolffe, 
1999; Cedar and Bergman, 2012; Suzuki and Bird, 2008). Of note, DNA methylation out 
of the CpG islands is related to increased transcriptional activity, by mechanisms still not 
fully understood (Jones, 2012). DNA methylation is known to be established during 
embryonic development, becoming stable through the adult life, and it is maintained 
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through cell division (Smith and Meissner, 2013). Methylation of DNA is mediated by 
the enzymes called DNA methyltransferases (DNMTs), which transfer the methyl group 
of SAMe to DNA. DNMTs can be classified as de novo DNMTs (DNMT3a and 3b) or 
maintenance DNMT (DNMT1), regarding its DNA substrate. On one hand, DNMT1 is 
the responsible of the maintenance of the DNA methylation status during DNA 
replication and cell division. On the other hand, DNMT3a and DNMT3b methylate new 
CpG islands stablishing new epigenetic marks (Goyal et al., 2006; Jones and Liang, 2009; 
Klose and Bird, 2006; Okano et al., 1999). Recently, it has been described the role of 
cytosine oxidation in DNA methylation, 5-hyroxymethylcytosine. Hydroxymethyl CpG 
is an intermediate step in DNA demethylation and is associated to increased 
transcriptional activity. Oxidation of methyl-CpGs is produced by the activity of the Ten 
Eleven Translocation (TET) enzymes (TET1, TET2 y TET3) (Delatte et al., 2014; 
Tahiliani et al., 2009). 
The role of DNA methylation in liver disease is one of the best characterized 
epigenetic mechanisms, especially in fibrosis and hepatocellular carcinoma (Figure 2.15-
16). 
a) DNA methylation in NAFLD 
The study of DNA methylation in NAFLD is increasing in the recent years and it 
is mainly focused in the progression to fibrosis. One of the most important firsts studies 
in this field, identified differential DNA methylation in about 70000 CpG islands in liver 
biopsies from mild versus severe NAFLD, linking DNA methylation with the progression 
of NAFLD to fibrosis (Murphy et al., 2013). A similar study, using DNA methylation and 
transcriptomics analysis, has identified differentially methylated genes in healthy, obese 
and NASH patients (Ahrens et al., 2013). Some studies have identified aberrant 
methylation of important genes involved in NAFLD progression, such as PNPLA3 
(Kitamoto et al., 2015), MT-ND6 (a mitochondrial NADH dehydrogenase) (Pirola et al., 
2013), or PGC1α (Sookoian et al., 2010), and, more importantly, global mitochondrial 
DNA hypermethylation (Carabelli et al., 2011; Lee et al., 2017; Sun et al., 2015a), linking 
it with the progression and the severity of the disease. Moreover, in the context of NAFLD 
progression to fibrosis, genes involved in bile acid metabolism and detoxification (FXR, 
BSEP, CYPs, etc.) have been found aberrantly methylated, contributing to fibrosis 
development (Schiöth et al., 2016). 
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In another study, it was shown that DNA methylation status of key genes involved 
in fibrosis progression could stratify NASH patients according to the severity of the 
disease (Zeybel et al., 2015). Although these studies have been useful for identifying a 
role of DNA methylation in NAFLD progression, they present some major limitation: 
they reveal low mechanistic implications; presents impossibility of identifying DNA 
methylation as a cause of the disease and they were carried out in liver biopsies, which 
implicates that the changes observed in the whole liver can be due to cellular changes 
related to the fibrogenic process. In this regard, most recent study in the field has 
identified PPARγ promoter methylation in serum as an important predictor of fibrosis 
progression in NAFLD and a biomarker for disease severity (Hardy et al., 2017). 
b) DNA methylation in fibrosis  
Liver fibrosis (section 2.1.2) is driven by different mechanism and cell types 
among which, hepatic stellate cells (HSC) are the main contributors to extracellular 
matrix deposition and scar formation in the liver. During fibrosis, HSCs are activated 
through transdifferentiation acquiring a myofibroblast-like phenotype. This HSC 
activation may be orchestrated by different epigenetic mechanisms, such as transcription 
factors, DNA methylation, histone remodeling and miRNAs, allowing fast phenotypic 
changes in the cell. Changes in the DNA methylation landscape of HSCs during 
transdifferentiation have been study by different authors. Upon activation, HSCs express 
higher MeCP2 levels, associated to increased methylation of CpG islands (Mann et al., 
2006, 2010; Meehan et al., 1992). MeCP2 is related to transcriptional repression. It has 
been show that MeCP2 together with the histone methyltransferase EZH2 (section 
2.4.2.2) mediates the repression of PPARγ in HSCs, a master regulator of the maintenance 
of the quiescent phenotype in the HSCs (Mann et al., 2006, 2010). Moreover, MeCP2 
binding to DNA in association to CBF1 mediates transcriptional repression of IκB (Mann 
et al., 2006; Oakley et al., 2005). Finally, MeCP2 has been also implicated in repression 
of PTCH1 in HSCs (Yang et al., 2013c) However, MeCP2 is not only implicated in 
transcriptional repression but also in activation. In this sense, MeCP2 induces the 
expression of ASH1, an histone methyltransferase expressed during HSCs 
transdifferentiation that induces profibrogenic gene expression (section 2.4.2.2) 
(Perugorria et al., 2012). Overall, these functions of MeCP2 together with the fact that 
MeCP2 deficient mice do not develop liver fibrosis, indicates MeCP2 is a master 
regulator of liver fibrosis. 
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A recently published study has further implicated DNA methylation in the control 
of liver fibrogenesis. In this study, it is demonstrated, in different experimental animal 
models of liver fibrosis, that DNA methyltransferases (DNMTs), DNMT1 and, specially, 
de novo DNMT3a and DNMT3b, are upregulated in the liver and HSCs during 
fibrogenesis initiation. On the contrary, TET enzymes are downregulated during this 
process. These observations are in accordance with the global changes in the DNA 
methylome produced during HSC activation, showing a tendency towards increased 
levels of 5-methylcytosine (5-mC) and a clear decrease of 5-hydroxymethylcytosine (5-
hmC). Importantly, the results described in the experimental animal models were similar 
to epigenetic marks observed in fibrotic human patients in the same study (Page et al., 
2016). 
Despite HSCs are the main contributors to liver fibrosis and are the best 
characterized cell regarding its control by epigenetic mechanisms, not only HSC 
methylome is changed during fibrogenesis. Methylation have been described to affect the 
expression of important genes in hepatocytes, such as PPARγ (Hardy et al., 2017). The 
hypermethylation of different bile acid transporters and metabolism regulators above 
mentioned have been also described, affecting bile acid induced cholestasis and fibrosis 
(FXR, HNF4α, ABCG5, BSEP, etc.) (Schiöth et al., 2016). 
c) DNA methylation in HCC 
DNA methylation changes in HCC and other cancers has specially attracted the 
attention of researchers in the last years. Regarding cancer development, DNA 
methylation can play two opposite roles: hypomethylation of oncogenes leads to 
increased expression of oncogenic drivers, while hypermethylation of tumor suppressor 
genes contributes to cancer development through the downregulation of genes implicated 
in cancer progression blockage. Several studies of HCC have identified different 
signatures of DNA methylation in HCC at genome-wide levels, showing global 
alterations of variable number of hypo/hypermethylation of gene promoters (Nishida et 
al., 2012; Revill et al., 2013; Shen et al., 2012; Song et al., 2013; Stefanska et al., 2011; 
Villanueva et al., 2015). Some of these studies were able to stablish a correlation between 
some methylation signatures and prognosis and recurrence of HCC (Nishida et al., 2012; 
Villanueva et al., 2015). Nevertheless, the major limitation concerning genome-wide 
methylation studies is the fact that HCC is a very heterogenic cancer with a high number 
of cells implicated, and thus, detected changes in methylation could be only the 
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consequence of different cell population relative presence (Hardy and Mann, 2016). 
Moreover, some other studies more focused on the analysis of concrete gene promoter 
methylation have identified specific promoter hypermethylation of tumor suppressor 
genes frequently downregulated in HCC, such as CDKN2A, APC, DKK, SOCS, RASSF, 
p16 (INK4A), CASP8, ASC and GSTP1 among others, implicated in the inhibition of 
different pathways known to contribute to HCC development (Ras, JAK/STAT, Wnt, 
section 2.1.3.2.2), regulation of apoptosis and DNA repair (Calvisi et al., 2006, 2007; 
Kaneto et al., 2001; Kubo et al., 2004; Nishida et al., 2012; Niwa et al., 2005; Tischoff 
and Tannapfel, 2008; Yu et al., 2002). As previously mentioned, the promoters of 
MAT1A and GNMT have been described to be hypermethylated in HCC. Thus, both 
tumor suppressor genes highly implicated in the regulation of SAMe metabolism are 
susceptible of SAMe-mediated hypermethylation. Finally, as for the case of DNA 
methylation analysis mentioned in NAFLD and fibrosis, recent advances are providing 
increasing evidence suggesting the use of DNA methylation in serum as a marker of 
detection and prognosis in HCC (Hardy and Mann, 2016; Shen et al., 2012; Snyder et al., 
2016; Xu et al., 2017) 
According to increased promoter methylation, DNMT (DNMT1, DNMT3a and 
DNMT3b) overexpression in HCC have been described by different authors. However, a 
clear correlation between promoter methylation and the DNMT expression levels has not 
been stablished (Lim et al., 2008; Nagai et al., 2003; Park et al., 2006; Saito et al., 2001, 
2003; Tischoff and Tannapfel, 2008). Conversely, some studies have described TET 
enzymes downregulation in HCC, contributing to the mentioned changes in DNA 
methylation (Chen et al., 2017; Chuang et al., 2015; Liu et al., 2013; Yang et al., 2013b). 
2.3.2 HISTONE MODIFICATIONS 
DNA must be packed in the nucleus to form chromatin in two different states, 
heterocromatin (highly packed) and euchromatin (lightly packed). This package is 
mediated by the histone proteins and must be differentially regulated depending on the 
transcriptional necessity of the cell. The most basic structure of chromatin is the 
nucleosome, consisting on 147 base pair of double stranded DNA wrapped around a core 
of eight histones (H2A, H2B, H3 and H4, each of them twice). The core of histones has 
an N-terminal amino acid tail that can be the target of different covalent post-translational 
modification (methylation, acetylation, phosphorylation, ubiquitination, sumoylation and 
ADP-rybosilation), which in turn will control the grade of package of the chromatin, 
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promoting or suppressing the transcription (Clapier and Cairns, 2009). Moreover, histone 
modifications are highly related to chromatin spacing and packaging remodeling, 
processes carried out by different protein complexes (SWI/SNF and the polycomb group, 
PcG, respectively) that determine the grade of accessibly of transcription factors to the 
nucleosome, i.e. the transcription of DNA (Clapier and Cairns, 2009; Margueron and 
Reinberg, 2011; Mohrmann and Verrijzer, 2005).  
 Histone methylation and acetylation are one of the best characterized 
modification in liver disease. Histone acetylation promotes a chromatin relaxed state, 
correlating with increased transcriptional activity, and it is controlled by the balance 
between histone acetyltransferases (HAT) and histone deacteylases (HDAC). 
Dysregulation of HDACs and histone acetylation have been proved in several studies in 
NAFLD, fibrosis and HCC. Moreover, the benefit of HDAC inhibitors has been 
demonstrated in different models of liver disease (Armeanu et al., 2005; Barbier-Torres 
et al., 2015; Elsharkawy et al., 2010; Kirpich et al., 2013; Lee et al., 2017; Mannaerts et 
al., 2010; Niki et al., 1999; Pathil et al., 2006; Van Beneden et al., 2013). 
As mentioned before, proteins are one of the known substrates of SAMe for 
methylation (Section 2.2.1). Histones are among the group of proteins that can be 
methylated by SAMe (Ara et al., 2008; Shyh-Chang et al., 2013), thus, influencing 
chromatin accessibility and DNA transcription. Histones can be methylated in different 
lysines, exerting opposite effects depending on the lysine residue methylated. H3 
trimethylation in lysine 4 (H3K4me3) and lysine 6 (H3K6me2/3) are associated with light 
packed chromatin and gene expression, while H3 trimethylation in lysine 9 (H3K9me3) 
and 27 (H3K27me3) are associated with gene silencing (Black et al., 2012; Martin and 
Zhang, 2005). Histone methylation at different residues is mediated by histone 
methyltransferases, whose contribution to liver disease have been specially characterized 
in liver fibrosis and HSCs transdifferentiation. During HSCs activation, DNA 
methylation changes are frequently accompanied by changes in histone methylation and 
histone methyltransferases expression. As previously mentioned, the histone 
methyltransferase EZH2 is known to play an important role in the repression of PPARγ 
together with MeCP2, mediating H3K27me3, which is crucial for HSC activation (Mann 
et al., 2010). Another important histone methyltransferase in liver fibrosis is ASH1 
(methylates H3 at lysine 4 and 36), which accumulates at the promoter region of COL1A1, 
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αSMA, TIMP1 and TGFβ1 genes, enhancing its transcription and the consequent 
development of liver fibrosis (Perugorria et al., 2012). 
2.3.3 MicroRNAs IN LIVER DISEASE 
The last epigenetic modification that can control gene expression is governed by 
microRNAs (miRNA, miR). MicroRNAs are small non-coding RNAs (21-25 
nucleotides) that regulate gene expression at the posttranscriptional level by mRNA 
repression or degradation. Gene regulation by microRNAs takes places through 
complementarity base pairing with the mRNA, being that one microRNA can target 
thousands of mRNAs, as well as one mRNA can be targeted by thousands of microRNAs. 
In the recent years, microRNAs have been implicated in the control of many biological 
process such as proliferation, cell cycle control, metabolism, apoptosis and tumorigenesis. 
Importantly, alterations in microRNA levels have been described in many human diseases 
and cancer (as for the case of liver disease). The discovery and characterization of 
microRNAs have improved the understanding of the pathogenesis of diseases, emerging 
as useful targets for intervention and also as powerful disease-associated markers in tissue 
and serum. In the liver, dysregulation of microRNAs has been related with NAFLD 
development, fibrosis and liver cancer.  
The next sections will summarize the basic aspects of microRNA-mediated gene 
repression and the role of microRNAs in liver disease. 
2.3.3.1 MicroRNA regulation and gene repression 
MicroRNA synthesis is a well characterized process in which 6 sequential steps 
take place to produce the mature microRNA. MiRNAs are transcribed from the host gene 
to large RNA precursors (pri-miRNAs) by RNA polymerase II. Pri-miRNAs are then 
processed by the canonical microprocessor complex (formed by the RNase III, Drosha 
and the double-stranded-RNA-binding protein, Phasa/DGCR8, DroshaDGCR8), 
resulting in a ⁓70 nucleotide hairpin-like sequence called pre-miRNA. Pre-miRNAs are 
exported from the nucleus to the cytoplasm by the exportin 5 and Ran-GTP complex, 
where they are additionally processed by the RNase III, DICER, generating a double-
stranded RNA (⁓22 nucleotides) composed by the mature miRNA and complementary 
sequence. DICER also induces the formation of the RNA-induced silencing complex, the 
RISC complex, where only the mature miRNA (single-stranded) coming from the double-
stranded miRNA is finally loaded and directed to the target mRNA. Once in the RISC 
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complex, mature single-stranded miRNA targets the mRNA at complementary sequences 
within the 3’ untranslated regions (UTRs), interacting with Argonaute members, forming 
the miRISC, where the target mRNA is repressed through different mechanism, such as 
deadenylation, degradation or translational repression. The selection of the mature 
miRNA strand is controlled by the Argonaute proteins and it is mainly based on the 
stability of the sequence. The complementary strand of the miRNA is degraded by the 
RISC complex (Ambros, 2001; Filipowicz et al., 2005; Ha and Kim, 2014; Jonas and 
Izaurralde, 2015; Shukla et al., 2011; Wang et al., 2012) (Figure 2.16). 
MicroRNAs and the above described regulatory mechanism of microRNA 
synthesis and mRNA targeting it is known to be a highly evolutionary conserved 
mechanism (Krol et al., 2010). The importance of microRNAs in the regulation of many 
biological process and its link to diseases and cancer development indicates microRNAs 
levels must be tightly regulated by strictly controlled processes. The regulation of 
microRNAs can be controlled by transcriptional activation or repression (Calin et al., 
2004; Dews et al., 2006; Marson et al., 2008; O’Donnell et al., 2005; Woods et al., 2007) 
and by its own promoter hypermethylation (Lujambio et al., 2008; Shen et al., 2012; 
Toffanin et al., 2011). 
 
Figure 2.16 Overview of microRNA biogenesis and mRNA targeting. 
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2.3.3.2 MicroRNAs in liver disease 
Since the publication of the first study describing a link between a microRNA and 
cancer (Calin et al., 2002), the number of studies aiming to identify new microRNAs and 
target genes implicated in the regulation of different diseases, and specially cancer, has 
increased exponentially in the last decade. As for other disease, microRNAs have been 
largely studied in liver cancer progression as well as NAFLD and fibrosis. Several 
microRNAs have been described to orchestrate liver development, directing the fate of 
embryonic progenitor cells through the regulation of gene expression. For example, miR-
122, the most abundant (70%) miRNA in liver is not expressed in embryonic liver, while 
its expression is switched on during liver development, regulating the expression of 
different transcription factors implicated in proliferation and cell differentiation (Chang 
et al., 2004; Deng et al., 2014; Lagos-Quintana et al., 2002). 
In the case of NAFLD, microRNAs are emerging as important regulators of 
disease progression, regulating different pathways contributing to this disease, as lipid 
metabolism, lipogenesis, insulin resistance, lipoapoptosis and inflammation (Finch et al., 
2014). Several microRNAs have been identified up-downregulated in human NAFLD 
patients and in animal NAFLD models. Moreover, microRNA detection in serum of 
NAFLD patients is starting to be extremely useful as non-invasive biomarkers of the 
disease (Ceccarelli et al., 2013).  
MicroRNAs are also involved in the development of liver fibrosis and cirrhosis. 
Changes in the expression of different microRNAs and target genes have been identified 
in liver and in the different cells implicated in this disease. For example, downregulation 
of miR-29 family members results in HSCs activation and liver fibrosis (Roderburg et al., 
2011). In parallel, miR-122 downregulation contributes to cytokine-mediated activation 
of HSCs (Hsu et al., 2012). Thus, the regulation of microRNAs in different cells is highly 
involved in the development of liver fibrosis. The contribution of microRNAs has been 
more profoundly studied in HSCs, as they are the major cells contributing to fibrosis. In 
HSCs, up-downregulated microRNAs have been proposed for different roles, including 
their activation, transdifferentiation, proliferation, migration and apoptosis (Kitano and 
Bloomston, 2016). 
The implication of microRNAs in liver cancer and in concrete in hepatocellular 
carcinoma, has been the most studied field in the recent years. Different studies have 
identified important numbers of microRNAs downregulated (tumor suppressor miRNAs) 
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and upregulated (oncomiRs) in HCC. Important microRNAs frequently downregulated 
in HCC are the miR-122 (highly implicated in all manifestations of liver disease), miR-
26, let-7 and miR-199. On the other hand, frequently microRNAs overexpressed in HCC 
(oncomiRs) are miR-151, miR-221, miR-21, miR-17-92 family and C19MC microRNA 
family members (miR-516-520), which are specifically characteristic of a subclass of 
HCC (Finch et al., 2014; Pineau et al., 2010; Toffanin et al., 2011; Wang et al., 2012). 
Moreover, the levels of some of these microRNAs are related to tumor recurrence, 
malignancy, invasion and metastasis, clinical outcome of patients or resistance to 
apoptosis and HCC treatment. Concerning the latter, microRNA profiling is being studied 
in the recent years aiming to identify microRNAs involved in drug resistance and in 
particular, sorafenib drug resistance. Some examples highlighting the potential of miRNA 
management in overcoming drug resistance involve the miR-122, miR-221 and miR-21 
(Bai et al., 2009; Fornari et al., 2009, 2017; Xia et al., 2013; Xu et al., 2016), but the 
number of studies identifying new microRNAs and target genes involved in drug 
resistance in HCC is increasing in the last years. 
Finally, the use of microRNAs as non-invasive biomarkers of liver disease is an 
important field of research. MicroRNAs are highly stable in cells and in circulation and 
can be isolated from serum, plasma and other body fluids. Thus, the detection of 
microRNAs in circulation is of special interest diagnosis. Despite the expectative 
concerning microRNAs as diagnostic tools for liver disease, there are some concerns 
limiting their use, as the relative difficulty of isolation and purification and the 
discrepancy regarding quantification methods.  
2.3.3.3 Targeting microRNAs in liver disease 
The broad regulatory roles of microRNAs in different liver processes and disease 
has positioned them in the spotlight of targeting therapy development. There are two 
different ways of targeting microRNAs, inhibiting or mimicking them, each one with their 
respective limitations and advantages. MicroRNA-mimics are based on short RNA 
duplex that mimics a microRNA, restoring to normal values the levels of the target 
mRNA. However, mimic-microRNAs present the major limitation of potentially 
targeting other mRNAs besides the desired target. On the other hand, microRNA-
inhibitors are chemically modified single-stranded oligonucleotides that antagonize a 
microRNA by base complementarity, sequestering or degrading the microRNA. Major 
advantages of microRNA inhibitors are the low concentration required for their effect and 
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low toxicity, while major limitations concern the possibility of off-target effects over 
microRNAs belonging to the same family (Wang et al., 2012). 
Despite the mentioned inconveniences of targeting microRNAs for therapeutic 
intervention, the interest in microRNA research have increased during the last years. 
Some studies, especially in complex diseases, as they are NAFLD, fibrosis and liver 
cancer, have demonstrated that targeting one microRNA can be highly beneficial in order 
to regulate at the same time the expression of different genes, sometimes associated to a 
complex regulatory network. In these situations, the possibility of targeting different 
mRNAs with one microRNA becomes an advantage instead of a problem, resulting easier 
than the conventional silencing or overexpression of a single gene.  
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3 HYPOTHESIS AND OBJECTIVES 
 
The work presented in this thesis deals with the study of the regulation of GNMT 
by different microRNAs in the liver and its role in liver pathology in different 
manifestations of hepatic disease. In concrete, we have studied the impact of miR-873-5p 
and miR-518d-5p in Non-Alcoholic Fatty Liver Disease, in cholestasis induced fibrosis 
and in hepatocellular carcinoma. 
Over the last years, several studies have highlighted the importance of methionine 
and SAMe metabolism in the liver. Dysregulation of SAMe metabolism and enzymes 
implicated in the methionine cycle have been reported in different liver diseases, as for 
the case of GNMT, the most important enzyme responsible for SAMe catabolism. GNMT 
is frequently found downregulated in liver disease, including NAFLD, cholestasis, 
fibrosis, cirrhosis and HCC, being considered a tumor suppressor in the liver and an 
interesting target for the study and design of liver disease therapies. 
Despite the importance of GNTM in maintaining liver function and its frequent 
downregulation in liver disease, few mechanisms implicated in GNMT downregulation 
have been described. Moreover, these described mechanisms can only be considered in 
some specific liver diseases or have not even been described to occur in human pathology. 
Thus, we believe that the identification of general mechanisms mediating GNMT 
downregulation in different disease scenarios would be of high interest for the 
development of new liver disease targeted therapies.  
During the last decade, microRNAs have emerged as important epigenetic 
regulators that mediate posttranscriptional gene repression and whose expression is 
altered in different diseases, such as cancer and in the liver in NAFLD, cirrhosis and HCC. 
The targeting of microRNAs in several preclinical studies has been shown as a promising 
strategy for the development of therapies. The main advantage of microRNA targeting, 
particularly in liver disease, relies in the fact that targeting a single microRNA can result 
in the regulation of different target genes, sometimes controlling or implicated in the 
control of the same pathway.  
On this basis, we hypothesize that diverse microRNAs can be targeting GNMT in 
different liver diseases and that the regulation of these microRNAs could represent a 
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potential interesting therapeutic approach. Thus, the principal aims of this thesis are as 
follows, 
Aim 1. To identify microRNAs targeting GNMT in human and murine liver, 
studying the expression levels of these microRNAs in association with liver diseases 
where GNMT is downregulated. 
Aim 2. To study microRNAs implication in NAFLD through the repression of 
GNMT and its role in liver lipid metabolism. 
Aim 3. To identify and characterize the implication of microRNAs targeting 
GNMT in cholestasis induced fibrosis. 
Aim 4. To investigate the role of microRNAs and GNMT in HCC progression and 
study their link with HCC response to sorafenib treatment. 
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7 CONCLUSIONS 
1. GNMT expression is essential for liver health and its downregulation is frequently 
found in different chronic liver disease manifestations, including NAFLD, 
cholestasis, fibrosis, cirrhosis and hepatocellular carcinoma, acting as an important 
driver of the disease. 
2. GNMT is regulated by the microRNAs miR-873-5p and miR-518d-5p in NAFLD and 
fibrosis and in liver cancer, respectively. 
a) MiR-873-5p inhibition recovers GNMT levels in the mitochondria, regulating 
Complex II activity in the ETC potentially through sarcosine metabolism. This 
regulation results in decreased mitochondrial dysfunction and enhanced fatty acid 
β-oxidation protecting from NAFLD progression.  
b) In cholestasis, there is a broadly effect of miR-873-5p in the different cell 
populations implicated in hepatocytes apoptosis, ductular reactions, 
inflammation and HSC activation mediated by epigenetic mechanism.  
c) MiR-518d-5p levels in liver and serum correlate with the prognosis of HCC and 
mediates GNMT downregulation. 
d) MiR-518d-5 levels can predict HCC response to sorafenib and its inhibition 
overcomes sorafenib resistance.  
e) MiR-518d-5p targeting sorafenib induced apoptosis is mediated by increased 
ROS and mitochondrial dysfunction through the direct regulation of GNMT as 
well as c-Jun and its downstream target PUMA. 
3. Targeting microRNAs regulates GNMT expression alongside other genes and 
pathways implicated in liver injury, underscoring the benefit of microRNA-based 
therapy versus conventional gene-specific-targeted therapies. 
 
 
 
  
 
  
 
 
 
 
 
 
 
 
 
 
 
8 BIBLIOGRAPHY 
 
  
  
  
 Bibliography 
215 
 
 8 BIBLIOGRAPHY 
Abeni, E., Salvi, A., Marchina, E., Traversa, M., Arici, B., and De Petro, G. (2017). Sorafenib induces variations of the 
DNA methylome in HA22T/VGH human hepatocellular carcinoma-derived cells. Int. J. Oncol. 51, 128–144. 
Adams, L.A., and Lindor, K.D. (2007). Nonalcoholic fatty liver disease. Ann. Epidemiol. 17, 863–869. 
Adams, L.A., Angulo, P., and Lindor, K.D. (2005). Nonalcoholic fatty liver disease. CMAJ Can. Med. Assoc. J. 172, 
899–905. 
Aharoni-Simon, M., Hann-Obercyger, M., Pen, S., Madar, Z., and Tirosh, O. (2011). Fatty liver is associated with 
impaired activity of PPARγ-coactivator 1α (PGC1α) and mitochondrial biogenesis in mice. Lab. Investig. J. Tech. 
Methods Pathol. 91, 1018–1028. 
Ahrens, M., Ammerpohl, O., von Schönfels, W., Kolarova, J., Bens, S., Itzel, T., Teufel, A., Herrmann, A., Brosch, M., 
Hinrichsen, H., et al. (2013). DNA methylation analysis in nonalcoholic fatty liver disease suggests distinct disease-
specific and remodeling signatures after bariatric surgery. Cell Metab. 18, 296–302. 
Alexander, J., Torbenson, M., Wu, T.-T., and Yeh, M.M. (2013). Non-alcoholic fatty liver disease contributes to 
hepatocarcinogenesis in non-cirrhotic liver: a clinical and pathological study. J. Gastroenterol. Hepatol. 28, 848–854. 
Alkhouri, N., Dixon, L.J., and Feldstein, A.E. (2009). Lipotoxicity in Nonalcoholic Fatty Liver Disease: Not All Lipids 
Are Created Equal. Expert Rev. Gastroenterol. Hepatol. 3, 445–451. 
Alpini, G., Lenzi, R., Sarkozi, L., and Tavoloni, N. (1988). Biliary physiology in rats with bile ductular cell hyperplasia. 
Evidence for a secretory function of proliferated bile ductules. J. Clin. Invest. 81, 569–578. 
Alpini, G., Lenzi, R., Zhai, W.R., Slott, P.A., Liu, M.H., Sarkozi, L., and Tavoloni, N. (1989). Bile secretory function of 
intrahepatic biliary epithelium in the rat. Am. J. Physiol. - Gastrointest. Liver Physiol. 257, G124–G133. 
Alpini, G., Roberts, S., Kuntz, S.M., Ueno, Y., Gubba, S., Podila, P.V., LeSage, G., and LaRusso, N.F. (1996). 
Morphological, molecular, and functional heterogeneity of cholangiocytes from normal rat liver. Gastroenterology 110, 
1636–1643. 
Alpini, G., Glaser, S.S., Ueno, Y., Rodgers, R., Phinizy, J.L., Francis, H., Baiocchi, L., Holcomb, L.A., Caligiuri, A., and 
LeSage, G.D. (1999). Bile acid feeding induces cholangiocyte proliferation and secretion: evidence for bile acid-regulated 
ductal secretion. Gastroenterology 116, 179–186. 
Ambros, V. (2001). microRNAs. Cell 107, 823–826. 
Anstee, Q.M., and Goldin, R.D. (2006). Mouse models in non-alcoholic fatty liver disease and steatohepatitis research. 
Int. J. Exp. Pathol. 87, 1–16. 
Ara, A.I., Xia, M., Ramani, K., Mato, J.M., and Lu, S.C. (2008). S-adenosylmethionine inhibits lipopolysaccharide-
induced gene expression via modulation of histone methylation. Hepatology 47, 1655–1666. 
Armeanu, S., Pathil, A., Venturelli, S., Mascagni, P., Weiss, T.S., Göttlicher, M., Gregor, M., Lauer, U.M., and Bitzer, 
M. (2005). Apoptosis on hepatoma cells but not on primary hepatocytes by histone deacetylase inhibitors valproate and 
ITF2357. J. Hepatol. 42, 210–217. 
Arthur, M.J., Stanley, A., Iredale, J.P., Rafferty, J.A., Hembry, R.M., and Friedman, S.L. (1992). Secretion of 72 kDa 
type IV collagenase/gelatinase by cultured human lipocytes. Analysis of gene expression, protein synthesis and proteinase 
activity. Biochem. J. 287, 701–707. 
Attili, A.F., Angelico, M., Cantafora, A., Alvaro, D., and Capocaccia, L. (1986). Bile acid-induced liver toxicity: relation 
to the hydrophobic-hydrophilic balance of bile acids. Med. Hypotheses 19, 57–69. 
Attwa, M.H., and El-Etreby, S.A. (2015). Guide for diagnosis and treatment of hepatocellular carcinoma. World J. 
Hepatol. 7, 1632–1651. 
Augello, C., Vaira, V., Caruso, L., Destro, A., Maggioni, M., Park, Y.N., Montorsi, M., Santambrogio, R., Roncalli, M., 
and Bosari, S. (2012). MicroRNA profiling of hepatocarcinogenesis identifies C19MC cluster as a novel prognostic 
biomarker in hepatocellular carcinoma. Liver Int. Off. J. Int. Assoc. Study Liver 32, 772–782. 
Avila, M.A., Berasain, C., Torres, L., Martín-Duce, A., Corrales, F.J., Yang, H., Prieto, J., Lu, S.C., Caballería, J., Rodés, 
J., et al. (2000). Reduced mRNA abundance of the main enzymes involved in methionine metabolism in human liver 
cirrhosis and hepatocellular carcinoma. J. Hepatol. 33, 907–914. 
MicroRNAs in liver disease 
216 
 
Avila, M.A. (Matías A., Garcia-Trevijano, E.R. (Elena R.), Lu, S.C. (Shelly C.), Corrales, F.J. (Fernando J., and Mato, 
J.M. (José M. (2004). Methylthioadenosine. 
Baffy, G., Brunt, E.M., and Caldwell, S.H. (2012). Hepatocellular carcinoma in non-alcoholic fatty liver disease: an 
emerging menace. J. Hepatol. 56, 1384–1391. 
Bai, S., Nasser, M.W., Wang, B., Hsu, S.-H., Datta, J., Kutay, H., Yadav, A., Nuovo, G., Kumar, P., and Ghoshal, K. 
(2009). MicroRNA-122 inhibits tumorigenic properties of hepatocellular carcinoma cells and sensitizes these cells to 
sorafenib. J. Biol. Chem. 284, 32015–32027. 
Barbier-Torres, L., Beraza, N., Fernández-Tussy, P., Lopitz-Otsoa, F., Fernández-Ramos, D., Zubiete-Franco, I., Varela-
Rey, M., Delgado, T.C., Gutiérrez, V., Anguita, J., et al. (2015). Histone Deacetylase 4 promotes cholestatic liver injury 
in the absence of Prohibitin-1. Hepatol. Baltim. Md 62, 1237–1248. 
Bassett, M.D., and Murray, K.F. (2008). Biliary atresia: recent progress. J. Clin. Gastroenterol. 42, 720–729. 
Bataller, R., and Brenner, D.A. (2005). Liver fibrosis. J. Clin. Invest. 115, 209–218. 
Beaussier, M., Wendum, D., Schiffer, E., Dumont, S., Rey, C., Lienhart, A., and Housset, C. (2007). Prominent 
contribution of portal mesenchymal cells to liver fibrosis in ischemic and obstructive cholestatic injuries. Lab. Investig. 
J. Tech. Methods Pathol. 87, 292–303. 
Begriche, K., Igoudjil, A., Pessayre, D., and Fromenty, B. (2006). Mitochondrial dysfunction in NASH: causes, 
consequences and possible means to prevent it. Mitochondrion 6, 1–28. 
Begriche, K., Massart, J., Robin, M.-A., Bonnet, F., and Fromenty, B. (2013). Mitochondrial adaptations and dysfunctions 
in nonalcoholic fatty liver disease. Hepatology 58, 1497–1507. 
Bellentani, S., Scaglioni, F., Marino, M., and Bedogni, G. (2010). Epidemiology of Non-Alcoholic Fatty Liver Disease. 
Dig. Dis. 28, 155–161. 
Benyon, R.C., and Iredale, J.P. (2000). Is liver fibrosis reversible? Gut 46, 443–446. 
Benyon, R.C., Iredale, J.P., Goddard, S., Winwood, P.J., and Arthur, M.J. (1996). Expression of tissue inhibitor of 
metalloproteinases 1 and 2 is increased in fibrotic human liver. Gastroenterology 110, 821–831. 
Berasain, C. (2013). Hepatocellular carcinoma and sorafenib: too many resistance mechanisms? Gut 62, 1674–1675. 
Beraza, N., Lüdde, T., Assmus, U., Roskams, T., Vander Borght, S., and Trautwein, C. (2007). Hepatocyte-specific IKK 
gamma/NEMO expression determines the degree of liver injury. Gastroenterology 132, 2504–2517. 
Berg, J.M., Tymoczko, J.L., and Stryer, L. (2002). The Respiratory Chain Consists of Four Complexes: Three Proton 
Pumps and a Physical Link to the Citric Acid Cycle. 
Berson, A., De Beco, V., Lettéron, P., Robin, M.A., Moreau, C., El Kahwaji, J., Verthier, N., Feldmann, G., Fromenty, 
B., and Pessayre, D. (1998). Steatohepatitis-inducing drugs cause mitochondrial dysfunction and lipid peroxidation in rat 
hepatocytes. Gastroenterology 114, 764–774. 
Best, C.H., Hershey, J.M., and Huntsman, M.E. (1932). The effect of lecithine on fat deposition in the liver of the normal 
rat. J. Physiol. 75, 56–66. 
Bhat, M., Sonenberg, N., and Gores, G.J. (2013). The mTOR pathway in hepatic malignancies. Hepatol. Baltim. Md 58, 
810–818. 
Bird, A. (2002). DNA methylation patterns and epigenetic memory. Genes Dev. 16, 6–21. 
Bird, A.P., and Wolffe, A.P. (1999). Methylation-induced repression--belts, braces, and chromatin. Cell 99, 451–454. 
Black, J.C., Van Rechem, C., and Whetstine, J.R. (2012). Histone Lysine Methylation Dynamics: Establishment, 
Regulation, and Biological Impact. Mol. Cell 48. 
Blechacz, B.R.A., Smoot, R.L., Bronk, S.F., Werneburg, N.W., Sirica, A.E., and Gores, G.J. (2009). Sorafenib inhibits 
signal transducer and activator of transcription-3 signaling in cholangiocarcinoma cells by activating the phosphatase 
shatterproof 2. Hepatol. Baltim. Md 50, 1861–1870. 
Bomble, M., Tacke, F., Rink, L., Kovalenko, E., and Weiskirchen, R. (2010). Analysis of antigen-presenting functionality 
of cultured rat hepatic stellate cells and transdifferentiated myofibroblasts. Biochem. Biophys. Res. Commun. 396, 342–
347. 
Bonacchi, A., Romagnani, P., Romanelli, R.G., Efsen, E., Annunziato, F., Lasagni, L., Francalanci, M., Serio, M., Laffi, 
G., Pinzani, M., et al. (2001). Signal transduction by the chemokine receptor CXCR3: activation of Ras/ERK, Src, and 
 Bibliography 
217 
 
phosphatidylinositol 3-kinase/Akt controls cell migration and proliferation in human vascular pericytes. J. Biol. Chem. 
276, 9945–9954. 
Bonis, P.A.L., Friedman, S.L., and Kaplan, M.M. (2001). Is Liver Fibrosis Reversible? N. Engl. J. Med. 344, 452–454. 
Boonstra, K., Beuers, U., and Ponsioen, C.Y. (2012). Epidemiology of primary sclerosing cholangitis and primary biliary 
cirrhosis: A systematic review. J. Hepatol. 56, 1181–1188. 
Botla, R., Spivey, J.R., Aguilar, H., Bronk, S.F., and Gores, G.J. (1995). Ursodeoxycholate (UDCA) inhibits the 
mitochondrial membrane permeability transition induced by glycochenodeoxycholate: a mechanism of UDCA 
cytoprotection. J. Pharmacol. Exp. Ther. 272, 930–938. 
Boveris, A., and Chance, B. (1973). The mitochondrial generation of hydrogen peroxide. General properties and effect of 
hyperbaric oxygen. Biochem. J. 134, 707–716. 
Braconi, C., Huang, N., and Patel, T. (2010). MicroRNA-dependent regulation of DNA methyltransferase-1 and tumor 
suppressor gene expression by interleukin-6 in human malignant cholangiocytes. Hepatology 51, 881–890. 
Breitkopf, K., Godoy, P., Ciuclan, L., Singer, M.V., and Dooley, S. (2006). TGF-beta/Smad signaling in the injured liver. 
Z. Gastroenterol. 44, 57–66. 
Bruce, K.D., Cagampang, F.R., Argenton, M., Zhang, J., Ethirajan, P.L., Burdge, G.C., Bateman, A.C., Clough, G.F., 
Poston, L., Hanson, M.A., et al. (2009). Maternal high-fat feeding primes steatohepatitis in adult mice offspring, involving 
mitochondrial dysfunction and altered lipogenesis gene expression. Hepatol. Baltim. Md 50, 1796–1808. 
Bruix, J., Han, K.-H., Gores, G., Llovet, J.M., and Mazzaferro, V. (2015). Liver cancer: Approaching a personalized care. 
J. Hepatol. 62, S144-156. 
Bruix, J., Qin, S., Merle, P., Granito, A., Huang, Y.-H., Bodoky, G., Pracht, M., Yokosuka, O., Rosmorduc, O., Breder, 
V., et al. (2017). Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment 
(RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet 389, 56–66. 
Caldwell, S.H., Swerdlow, R.H., Khan, E.M., Iezzoni, J.C., Hespenheide, E.E., Parks, J.K., and Parker, W.D. (1999). 
Mitochondrial abnormalities in non-alcoholic steatohepatitis. J. Hepatol. 31, 430–434. 
Calin, G.A., Dumitru, C.D., Shimizu, M., Bichi, R., Zupo, S., Noch, E., Aldler, H., Rattan, S., Keating, M., Rai, K., et al. 
(2002). Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic 
leukemia. Proc. Natl. Acad. Sci. U. S. A. 99, 15524–15529. 
Calin, G.A., Sevignani, C., Dumitru, C.D., Hyslop, T., Noch, E., Yendamuri, S., Shimizu, M., Rattan, S., Bullrich, F., 
Negrini, M., et al. (2004). Human microRNA genes are frequently located at fragile sites and genomic regions involved 
in cancers. Proc. Natl. Acad. Sci. U. S. A. 101, 2999–3004. 
Calvisi, D.F., Ladu, S., Gorden, A., Farina, M., Conner, E.A., Lee, J.-S., Factor, V.M., and Thorgeirsson, S.S. (2006). 
Ubiquitous Activation of Ras and Jak/Stat Pathways in Human HCC. Gastroenterology 130, 1117–1128. 
Calvisi, D.F., Ladu, S., Gorden, A., Farina, M., Lee, J.-S., Conner, E.A., Schroeder, I., Factor, V.M., and Thorgeirsson, 
S.S. (2007). Mechanistic and prognostic significance of aberrant methylation in the molecular pathogenesis of human 
hepatocellular carcinoma. J. Clin. Invest. 117, 2713–2722. 
Calzadilla Bertot, L., and Adams, L.A. (2016). The Natural Course of Non-Alcoholic Fatty Liver Disease. Int. J. Mol. 
Sci. 17. 
Canbay, A., Feldstein, A.E., Higuchi, H., Werneburg, N., Grambihler, A., Bronk, S.F., and Gores, G.J. (2003a). Kupffer 
cell engulfment of apoptotic bodies stimulates death ligand and cytokine expression. Hepatol. Baltim. Md 38, 1188–1198. 
Canbay, A., Taimr, P., Torok, N., Higuchi, H., Friedman, S., and Gores, G.J. (2003b). Apoptotic body engulfment by a 
human stellate cell line is profibrogenic. Lab. Investig. J. Tech. Methods Pathol. 83, 655–663. 
Canbay, A., Friedman, S., and Gores, G.J. (2004). Apoptosis: the nexus of liver injury and fibrosis. Hepatol. Baltim. Md 
39, 273–278. 
Cano, A., Buqué, X., Martínez-Uña, M., Aurrekoetxea, I., Menor, A., García-Rodriguez, J.L., Lu, S.C., Martínez-Chantar, 
M.L., Mato, J.M., Ochoa, B., et al. (2011). Methionine adenosyltransferase 1A gene deletion disrupts hepatic VLDL 
assembly in mice. Hepatol. Baltim. Md 54, 1975–1986. 
Cantoni, G.L. (1953). S-ADENOSYLMETHIONINE; A NEW INTERMEDIATE FORMED ENZYMATICALLY 
FROM l-METHIONINE AND ADENOSINETRIPHOSPHATE. J. Biol. Chem. 204, 403–416. 
MicroRNAs in liver disease 
218 
 
Cantoni, G.L., and Durell, J. (1957). Activation of methionine for transmethylation. II. The methionine-activating 
enzyme; studies on the mechanism of the reaction. J. Biol. Chem. 225, 1033–1048. 
Carabelli, J., Burgueño, A.L., Rosselli, M.S., Gianotti, T.F., Lago, N.R., Pirola, C.J., and Sookoian, S. (2011). High fat 
diet-induced liver steatosis promotes an increase in liver mitochondrial biogenesis in response to hypoxia. J. Cell. Mol. 
Med. 15, 1329–1338. 
Carey, E.J., Ali, A.H., and Lindor, K.D. (2015). Primary biliary cirrhosis. The Lancet 386, 1565–1575. 
Cariou, B., Hanf, R., Lambert-Porcheron, S., Zaïr, Y., Sauvinet, V., Noël, B., Flet, L., Vidal, H., Staels, B., and Laville, 
M. (2013). Dual peroxisome proliferator-activated receptor α/δ agonist GFT505 improves hepatic and peripheral insulin 
sensitivity in abdominally obese subjects. Diabetes Care 36, 2923–2930. 
Castéra, L., Vergniol, J., Foucher, J., Le Bail, B., Chanteloup, E., Haaser, M., Darriet, M., Couzigou, P., and De 
Lédinghen, V. (2005). Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the 
assessment of fibrosis in chronic hepatitis C. Gastroenterology 128, 343–350. 
Cazanave, S.C., Mott, J.L., Elmi, N.A., Bronk, S.F., Werneburg, N.W., Akazawa, Y., Kahraman, A., Garrison, S.P., 
Zambetti, G.P., Charlton, M.R., et al. (2009). JNK1-dependent PUMA Expression Contributes to Hepatocyte 
Lipoapoptosis. J. Biol. Chem. 284, 26591–26602. 
Cazanave, S.C., Elmi, N.A., Akazawa, Y., Bronk, S.F., Mott, J.L., and Gores, G.J. (2010). CHOP and AP-1 cooperatively 
mediate PUMA expression during lipoapoptosis. Am. J. Physiol. Gastrointest. Liver Physiol. 299, G236-243. 
Ceccarelli, S., Panera, N., Gnani, D., and Nobili, V. (2013). Dual Role of MicroRNAs in NAFLD. Int. J. Mol. Sci. 14, 
8437–8455. 
Cedar, H., and Bergman, Y. (2012). Programming of DNA methylation patterns. Annu. Rev. Biochem. 81, 97–117. 
Chackelevicius, C.M., Gambaro, S.E., Tiribelli, C., and Rosso, N. (2016). Th17 involvement in nonalcoholic fatty liver 
disease progression to non-alcoholic steatohepatitis. World J. Gastroenterol. 22, 9096–9103. 
Chalasani, N., Younossi, Z., Lavine, J.E., Diehl, A.M., Brunt, E.M., Cusi, K., Charlton, M., and Sanyal, A.J. (2012). The 
diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the 
Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. 
Hepatol. Baltim. Md 55, 2005–2023. 
Chang, J., Nicolas, E., Marks, D., Sander, C., Lerro, A., Buendia, M.A., Xu, C., Mason, W.S., Moloshok, T., Bort, R., et 
al. (2004). miR-122, a Mammalian Liver-Specific microRNA, is Processed from hcr mRNA and MayDownregulate the 
High Affinity Cationic Amino Acid Transporter CAT-1. RNA Biol. 1, 106–113. 
Chen, C.-Y., Ching, L.-C., Liao, Y.-J., Yu, Y.-B., Tsou, C.-Y., Shyue, S.-K., Chen, Y.-M.A., and Lee, T.-S. (2012). 
Deficiency of Glycine N-Methyltransferase Aggravates Atherosclerosis in Apolipoprotein E–Null Mice. Mol. Med. 18, 
744–752. 
Chen, K.-F., Tai, W.-T., Liu, T.-H., Huang, H.-P., Lin, Y.-C., Shiau, C.-W., Li, P.-K., Chen, P.-J., and Cheng, A.-L. 
(2010). Sorafenib overcomes TRAIL resistance of hepatocellular carcinoma cells through the inhibition of STAT3. Clin. 
Cancer Res. Off. J. Am. Assoc. Cancer Res. 16, 5189–5199. 
Chen, Q., Yin, D., Zhang, Y., Yu, L., Li, X.-D., Zhou, Z.-J., Zhou, S.-L., Gao, D.-M., Hu, J., Jin, C., et al. (2017). 
MicroRNA-29a induces loss of 5-hydroxymethylcytosine and promotes metastasis of hepatocellular carcinoma through 
a TET-SOCS1-MMP9 signaling axis. Cell Death Dis. 8, e2906. 
Chiang, J.Y.L. (2013). Bile acid metabolism and signaling. Compr. Physiol. 3, 1191–1212. 
Chiou, J.-F., Tai, C.-J., Wang, Y.-H., Liu, T.-Z., Jen, Y.-M., and Shiau, C.-Y. (2009). Sorafenib induces preferential 
apoptotic killing of a drug- and radio-resistant hep G2 cells through a mitochondria-dependent oxidative stress 
mechanism. Cancer Biol. Ther. 8, 1904–1913. 
Choi, S.S., Sicklick, J.K., Ma, Q., Yang, L., Huang, J., Qi, Y., Chen, W., Li, Y.-X., Goldschmidt-Clermont, P.J., and 
Diehl, A.M. (2006). Sustained activation of Rac1 in hepatic stellate cells promotes liver injury and fibrosis in mice. 
Hepatol. Baltim. Md 44, 1267–1277. 
Chu, A.S., Diaz, R., Hui, J.-J., Yanger, K., Zong, Y., Alpini, G., Stanger, B.Z., and Wells, R.G. (2011). Lineage tracing 
demonstrates no evidence of cholangiocyte epithelial-to-mesenchymal transition in murine models of hepatic fibrosis. 
Hepatol. Baltim. Md 53, 1685–1695. 
 Bibliography 
219 
 
Chuang, K.-H., Whitney-Miller, C.L., Chu, C.-Y., Zhou, Z., Dokus, M.K., Schmit, S., and Barry, C.T. (2015). 
MicroRNA-494 is a master epigenetic regulator of multiple invasion-suppressor microRNAs by targeting ten eleven 
translocation 1 in invasive human hepatocellular carcinoma tumors. Hepatol. Baltim. Md 62, 466–480. 
Clapier, C.R., and Cairns, B.R. (2009). The biology of chromatin remodeling complexes. Annu. Rev. Biochem. 78, 273–
304. 
Cortez-Pinto, H., Chatham, J., Chacko, V.P., Arnold, C., Rashid, A., and Diehl, A.M. (1999). Alterations in liver ATP 
homeostasis in human nonalcoholic steatohepatitis: a pilot study. JAMA 282, 1659–1664. 
Cui, J., Yang, Y., Li, H., Leng, Y., Qian, K., Huang, Q., Zhang, C., Lu, Z., Chen, J., Sun, T., et al. (2015). MiR-873 
regulates ERα transcriptional activity and tamoxifen resistance via targeting CDK3 in breast cancer cells. Oncogene 34, 
3895–3907. 
Cusi, K. (2012). Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and 
clinical implications. Gastroenterology 142, 711–725.e6. 
Dante, R., Arnaud, M., and Niveleau, A. (1983). Effects of 5’deoxy-5’-methylthioadenosine on the metabolism of S-
adenosyl methionine. Biochem. Biophys. Res. Commun. 114, 214–221. 
Dara, L., Ji, C., and Kaplowitz, N. (2011). THE CONTRIBUTION OF ER STRESS TO LIVER DISEASES. Hepatol. 
Baltim. Md 53, 1752–1763. 
Day, C.P. (2006). From Fat to Inflammation. Gastroenterology 130, 207–210. 
Day, C.P., and James, O.F.W. (1998). Steatohepatitis: A tale of two “hits”? Gastroenterology 114, 842–845. 
DebRoy, S., Kramarenko, I.I., Ghose, S., Oleinik, N.V., Krupenko, S.A., and Krupenko, N.I. (2013). A Novel Tumor 
Suppressor Function of Glycine N-Methyltransferase Is Independent of Its Catalytic Activity but Requires Nuclear 
Localization. PLoS ONE 8. 
Delatte, B., Deplus, R., and Fuks, F. (2014). Playing TETris with DNA modifications. EMBO J. 33, 1198–1211. 
Della Ragione, F., and Pegg, A.E. (1983). Effect of analogues of 5’-methylthioadenosine on cellular metabolism. 
Inactivation of S-adenosylhomocysteine hydrolase by 5’-isobutylthioadenosine. Biochem. J. 210, 429–435. 
Delzenne, N.M., Calderon, P.B., Taper, H.S., and Roberfroid, M.B. (1992). Comparative hepatotoxicity of cholic acid, 
deoxycholic acid and lithocholic acid in the rat: in vivo and in vitro studies. Toxicol. Lett. 61, 291–304. 
Deng, X.-G., Qiu, R.-L., Wu, Y.-H., Li, Z.-X., Xie, P., Zhang, J., Zhou, J.-J., Zeng, L.-X., Tang, J., Maharjan, A., et al. 
(2014). Overexpression of miR-122 promotes the hepatic differentiation and maturation of mouse ESCs through a miR-
122/FoxA1/HNF4a-positive feedback loop. Liver Int. 34, 281–295. 
Desmoulière, A., Darby, I., Costa, A.M., Raccurt, M., Tuchweber, B., Sommer, P., and Gabbiani, G. (1997). Extracellular 
matrix deposition, lysyl oxidase expression, and myofibroblastic differentiation during the initial stages of cholestatic 
fibrosis in the rat. Lab. Investig. J. Tech. Methods Pathol. 76, 765–778. 
Dews, M., Homayouni, A., Yu, D., Murphy, D., Sevignani, C., Wentzel, E., Furth, E.E., Lee, W.M., Enders, G.H., 
Mendell, J.T., et al. (2006). Augmentation of tumor angiogenesis by a Myc-activated microRNA cluster. Nat. Genet. 38, 
1060–1065. 
Diraison, F., Moulin, P., and Beylot, M. (2003). Contribution of hepatic de novo lipogenesis and reesterification of plasma 
non esterified fatty acids to plasma triglyceride synthesis during non-alcoholic fatty liver disease. Diabetes Metab. 29, 
478–485. 
Donnelly, K.L., Smith, C.I., Schwarzenberg, S.J., Jessurun, J., Boldt, M.D., and Parks, E.J. (2005). Sources of fatty acids 
stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J. Clin. Invest. 115, 1343–
1351. 
Dranoff, J.A., and Wells, R.G. (2010). Portal fibroblasts: Underappreciated mediators of biliary fibrosis. Hepatol. Baltim. 
Md 51, 1438–1444. 
Duce, A.M., Ortíz, P., Cabrero, C., and Mato, J.M. (1988). S-adenosyl-L-methionine synthetase and phospholipid 
methyltransferase are inhibited in human cirrhosis. Hepatol. Baltim. Md 8, 65–68. 
Dudgeon, C., Peng, R., Wang, P., Sebastiani, A., Yu, J., and Zhang, L. (2012). Inhibiting oncogenic signaling by sorafenib 
activates PUMA via GSK3β and NF-κB to suppress tumor cell growth. Oncogene 31, 4848–4858. 
Eloranta, J.J., and Kullak-Ublick, G.A. (2008). The role of FXR in disorders of bile acid homeostasis. Physiol. Bethesda 
Md 23, 286–295. 
MicroRNAs in liver disease 
220 
 
El-Serag, H.B., Marrero, J.A., Rudolph, L., and Reddy, K.R. (2008). Diagnosis and Treatment of Hepatocellular 
Carcinoma. Gastroenterology 134, 1752–1763. 
Elsharkawy, A.M., Oakley, F., Lin, F., Packham, G., Mann, D.A., and Mann, J. (2010). The NF-κB p50:p50:HDAC-1 
repressor complex orchestrates transcriptional inhibition of multiple pro-inflammatory genes. J. Hepatol. 53, 519–527. 
Ertle, J., Dechêne, A., Sowa, J.-P., Penndorf, V., Herzer, K., Kaiser, G., Schlaak, J.F., Gerken, G., Syn, W.-K., and 
Canbay, A. (2011). Non-alcoholic fatty liver disease progresses to hepatocellular carcinoma in the absence of apparent 
cirrhosis. Int. J. Cancer 128, 2436–2443. 
Fabbrini, E., Sullivan, S., and Klein, S. (2010). Obesity and Nonalcoholic Fatty Liver Disease: Biochemical, Metabolic 
and Clinical Implications. Hepatol. Baltim. Md 51, 679–689. 
Farrell, G.C., and Larter, C.Z. (2006). Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatol. Baltim. Md 
43, S99–S112. 
Fasbender, F., Widera, A., Hengstler, J.G., and Watzl, C. (2016). Natural Killer Cells and Liver Fibrosis. Front. Immunol. 
7. 
Faubion, W.A., Guicciardi, M.E., Miyoshi, H., Bronk, S.F., Roberts, P.J., Svingen, P.A., Kaufmann, S.H., and Gores, 
G.J. (1999). Toxic bile salts induce rodent hepatocyte apoptosis via direct activation of Fas. J. Clin. Invest. 103, 137–145. 
Feldstein, A.E., Canbay, A., Guicciardi, M.E., Higuchi, H., Bronk, S.F., and Gores, G.J. (2003a). Diet associated hepatic 
steatosis sensitizes to Fas mediated liver injury in mice. J. Hepatol. 39, 978–983. 
Feldstein, A.E., Canbay, A., Angulo, P., Taniai, M., Burgart, L.J., Lindor, K.D., and Gores, G.J. (2003b). Hepatocyte 
apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis. Gastroenterology 125, 437–
443. 
Feldstein, A.E., Charatcharoenwitthaya, P., Treeprasertsuk, S., Benson, J.T., Enders, F.B., and Angulo, P. (2009). THE 
NATURAL HISTORY OF NONALCOHOLIC FATTY LIVER DISEASE IN CHILDREN: A FOLLOW-UP STUDY 
FOR UP TO 20-YEARS. Gut 58, 1538–1544. 
Fernández-Álvarez, S., Juan, V.G., Zubiete-Franco, I., Barbier-Torres, L., Lahoz, A., Parés, A., Luka, Z., Wagner, C., 
Lu, S.C., Mato, J.M., et al. (2015). TRAIL-producing NK cells contribute to liver injury and related fibrogenesis in the 
context of GNMT deficiency. Lab. Investig. J. Tech. Methods Pathol. 95, 223–236. 
Fernando, J., Sancho, P., Fernández-Rodriguez, C.M., Lledó, J.L., Caja, L., Campbell, J.S., Fausto, N., and Fabregat, I. 
(2012). Sorafenib sensitizes hepatocellular carcinoma cells to physiological apoptotic stimuli. J. Cell. Physiol. 227, 1319–
1325. 
Filipowicz, W., Jaskiewicz, L., Kolb, F.A., and Pillai, R.S. (2005). Post-transcriptional gene silencing by siRNAs and 
miRNAs. Curr. Opin. Struct. Biol. 15, 331–341. 
Finch, M.L., Marquardt, J.U., Yeoh, G.C., and Callus, B.A. (2014). Regulation of microRNAs and their role in liver 
development, regeneration and disease. Int. J. Biochem. Cell Biol. 54, 288–303. 
Finkelstein, J.D. (1990). Methionine metabolism in mammals. J. Nutr. Biochem. 1, 228–237. 
Finkelstein, J.D. (2007). Metabolic regulatory properties of S-adenosylmethionine and S-adenosylhomocysteine. Clin. 
Chem. Lab. Med. 45, 1694–1699. 
Floreani, A., and Mangini, C. (2018). Primary biliary cholangitis: Old and novel therapy. Eur. J. Intern. Med. 47, 1–5. 
Folch, J., Lees, M., and Sloane Stanley, G.H. (1957). A simple method for the isolation and purification of total lipides 
from animal tissues. J. Biol. Chem. 226, 497–509. 
Forbes, S.J., Russo, F.P., Rey, V., Burra, P., Rugge, M., Wright, N.A., and Alison, M.R. (2004). A significant proportion 
of myofibroblasts are of bone marrow origin in human liver fibrosis. Gastroenterology 126, 955–963. 
Fornari, F., Gramantieri, L., Giovannini, C., Veronese, A., Ferracin, M., Sabbioni, S., Calin, G.A., Grazi, G.L., Croce, 
C.M., Tavolari, S., et al. (2009). MiR-122/cyclin G1 interaction modulates p53 activity and affects doxorubicin sensitivity 
of human hepatocarcinoma cells. Cancer Res. 69, 5761–5767. 
Fornari, F., Milazzo, M., Chieco, P., Negrini, M., Marasco, E., Capranico, G., Mantovani, V., Marinello, J., Sabbioni, S., 
Callegari, E., et al. (2012). In hepatocellular carcinoma miR-519d is up-regulated by p53 and DNA hypomethylation and 
targets CDKN1A/p21, PTEN, AKT3 and TIMP2. J. Pathol. 227, 275–285. 
 Bibliography 
221 
 
Fornari, F., Ferracin, M., Trerè, D., Milazzo, M., Marinelli, S., Galassi, M., Venerandi, L., Pollutri, D., Patrizi, C., Borghi, 
A., et al. (2015). Circulating microRNAs, miR-939, miR-595, miR-519d and miR-494, Identify Cirrhotic Patients with 
HCC. PLOS ONE 10, e0141448. 
Fornari, F., Pollutri, D., Patrizi, C., La Bella, T., Marinelli, S., Casadei Gardini, A., Marisi, G., Baron Toaldo, M., 
Baglioni, M., Salvatore, V., et al. (2017). In Hepatocellular Carcinoma miR-221 Modulates Sorafenib Resistance through 
Inhibition of Caspase-3-Mediated Apoptosis. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 23, 3953–3965. 
Forner, A., Llovet, J.M., and Bruix, J. (2012). Hepatocellular carcinoma. The Lancet 379, 1245–1255. 
Freeman, B.A., and Crapo, J.D. (1982). Biology of disease: free radicals and tissue injury. Lab. Investig. J. Tech. Methods 
Pathol. 47, 412–426. 
Friedman, S.L. (2003). Liver fibrosis -- from bench to bedside. J. Hepatol. 38 Suppl 1, S38-53. 
Friedman, S.L. (2007). Reversibility of hepatic fibrosis and cirrhosis—is it all hype? Nat. Rev. Gastroenterol. Hepatol. 4, 
236–237. 
Friedman, S.L. (2008a). Mechanisms of hepatic fibrogenesis. Gastroenterology 134, 1655–1669. 
Friedman, S.L. (2008b). Hepatic Stellate Cells: Protean, Multifunctional, and Enigmatic Cells of the Liver. Physiol. Rev. 
88, 125–172. 
Gao, B., Radaeva, S., and Jeong, W.-I. (2007). Activation of natural killer cells inhibits liver fibrosis: a novel strategy to 
treat liver fibrosis. Expert Rev. Gastroenterol. Hepatol. 1, 173–180. 
Gao, X., van der Veen, J.N., Hermansson, M., Ordoñez, M., Gomez-Muñoz, A., Vance, D.E., and Jacobs, R.L. (2015a). 
Decreased lipogenesis in white adipose tissue contributes to the resistance to high fat diet-induced obesity in 
phosphatidylethanolamine N-methyltransferase-deficient mice. Biochim. Biophys. Acta 1851, 152–162. 
Gao, Y., Xue, Q., Wang, D., Du, M., Zhang, Y., and Gao, S. (2015b). miR-873 induces lung adenocarcinoma cell 
proliferation and migration by targeting SRCIN1. Am. J. Transl. Res. 7, 2519–2526. 
García-Ruiz, C., Baulies, A., Mari, M., García-Rovés, P.M., and Fernandez-Checa, J.C. (2013). Mitochondrial 
dysfunction in non-alcoholic fatty liver disease and insulin resistance: cause or consequence? Free Radic. Res. 47, 854–
868. 
García-Ruiz, I., Rodríguez-Juan, C., Díaz-Sanjuan, T., del Hoyo, P., Colina, F., Muñoz-Yagüe, T., and Solís-Herruzo, 
J.A. (2006). Uric acid and anti-TNF antibody improve mitochondrial dysfunction in ob/ob mice. Hepatol. Baltim. Md 44, 
581–591. 
García-Ruiz, I., Solís-Muñoz, P., Fernández-Moreira, D., Grau, M., Colina, F., Muñoz-Yagüe, T., and Solís-Herruzo, J.A. 
(2014). High-fat diet decreases activity of the oxidative phosphorylation complexes and causes nonalcoholic 
steatohepatitis in mice. Dis. Model. Mech. 7, 1287–1296. 
García-Trevijano, E.R., Latasa, M.U., Carretero, M.V., Berasain, C., Mato, J.M., and Avila, M.A. (2000). S-
adenosylmethionine regulates MAT1A and MAT2A gene expression in cultured rat hepatocytes: a new role for S-
adenosylmethionine in the maintenance of the differentiated status of the liver. FASEB J. Off. Publ. Fed. Am. Soc. Exp. 
Biol. 14, 2511–2518. 
Garibaldi, F., Falcone, E., Trisciuoglio, D., Colombo, T., Lisek, K., Walerych, D., Del Sal, G., Paci, P., Bossi, G., Piaggio, 
G., et al. (2016). Mutant p53 inhibits miRNA biogenesis by interfering with the microprocessor complex. Oncogene 35, 
3760–3770. 
Gil, B., Casado, M., Pajares, M.A., Boscá, L., Mato, J.M., Martín-Sanz, P., and Alvarez, L. (1996). Differential expression 
pattern of S-adenosylmethionine synthetase isoenzymes during rat liver development. Hepatol. Baltim. Md 24, 876–881. 
Gomes, A.L., Teijeiro, A., Burén, S., Tummala, K.S., Yilmaz, M., Waisman, A., Theurillat, J.-P., Perna, C., and Djouder, 
N. (2016). Metabolic Inflammation-Associated IL-17A Causes Non-alcoholic Steatohepatitis and Hepatocellular 
Carcinoma. Cancer Cell 30, 161–175. 
Gomez-Santos, L., Luka, Z., Wagner, C., Fernandez-Alvarez, S., Lu, S.C., Mato, J.M., Martinez-Chantar, M.L., and 
Beraza, N. (2012). INHIBITION OF NK CELLS PROTECTS THE LIVER AGAINST ACUTE INJURY IN THE 
ABSENCE OF GNMT. Hepatol. Baltim. Md 56, 747–759. 
Gonzalez-Sanchez, E., Marin, J.J.G., and Perez, M.J. (2014). The Expression of Genes Involved in Hepatocellular 
Carcinoma Chemoresistance Is Affected by Mitochondrial Genome Depletion. Mol. Pharm. 11, 1856–1868. 
Govaere, O., and Roskams, T. (2015). Pathogenesis and prognosis of hepatocellular carcinoma at the cellular and 
molecular levels. Clin. Liver Dis. 19, 261–276. 
MicroRNAs in liver disease 
222 
 
Goyal, R., Reinhardt, R., and Jeltsch, A. (2006). Accuracy of DNA methylation pattern preservation by the Dnmt1 
methyltransferase. Nucleic Acids Res. 34, 1182–1188. 
Grappone, C., Pinzani, M., Parola, M., Pellegrini, G., Caligiuri, A., DeFranco, R., Marra, F., Herbst, H., Alpini, G., and 
Milani, S. (1999). Expression of platelet-derived growth factor in newly formed cholangiocytes during experimental 
biliary fibrosis in rats. J. Hepatol. 31, 100–109. 
Gregor, M.F., Yang, L., Fabbrini, E., Mohammed, B.S., Eagon, J.C., Hotamisligil, G.S., and Klein, S. (2009). 
Endoplasmic reticulum stress is reduced in tissues of obese subjects after weight loss. Diabetes 58, 693–700. 
Gressner, A.M., Lotfi, S., Gressner, G., Haltner, E., and Kropf, J. (1993). Synergism between hepatocytes and Kupffer 
cells in the activation of fat storing cells (perisinusoidal lipocytes). J. Hepatol. 19, 117–132. 
Guo, H., Ahmed, M., Zhang, F., Yao, C.Q., Li, S., Liang, Y., Hua, J., Soares, F., Sun, Y., Langstein, J., et al. (2016). 
Modulation of long noncoding RNAs by risk SNPs underlying genetic predispositions to prostate cancer. Nat. Genet. 48, 
1142. 
Gutiérrez-de-Juan, V., López de Davalillo, S., Fernández-Ramos, D., Barbier-Torres, L., Zubiete-Franco, I., Fernández-
Tussy, P., Simon, J., Lopitz-Otsoa, F., de Las Heras, J., Iruzubieta, P., et al. (2017). A morphological method for ammonia 
detection in liver. PloS One 12, e0173914. 
Guzman, G., Brunt, E.M., Petrovic, L.M., Chejfec, G., Layden, T.J., and Cotler, S.J. (2008). Does Nonalcoholic Fatty 
Liver Disease Predispose Patients to Hepatocellular Carcinoma in the Absence of Cirrhosis? Arch. Pathol. Lab. Med. 
132, 1761–1766. 
Ha, M., and Kim, V.N. (2014). Regulation of microRNA biogenesis. Nat. Rev. Mol. Cell Biol. 15, nrm3838. 
Halim, A.B., LeGros, L., Geller, A., and Kotb, M. (1999). Expression and functional interaction of the catalytic and 
regulatory subunits of human methionine adenosyltransferase in mammalian cells. J. Biol. Chem. 274, 29720–29725. 
Hammerich, L., Heymann, F., and Tacke, F. (2011). Role of IL-17 and Th17 Cells in Liver Diseases. Clin. Dev. Immunol. 
2011. 
Han, Y.-P., Yan, C., Zhou, L., Qin, L., and Tsukamoto, H. (2007). A matrix metalloproteinase-9 activation cascade by 
hepatic stellate cells in trans-differentiation in the three-dimensional extracellular matrix. J. Biol. Chem. 282, 12928–
12939. 
Hanahan, D., and Weinberg, R.A. (2000). The hallmarks of cancer. Cell 100, 57–70. 
Hardy, T., and Mann, D.A. (2016). Epigenetics in liver disease: from biology to therapeutics. Gut 65, 1895–1905. 
Hardy, T., Zeybel, M., Day, C.P., Dipper, C., Masson, S., McPherson, S., Henderson, E., Tiniakos, D., White, S., French, 
J., et al. (2017). Plasma DNA methylation: a potential biomarker for stratification of liver fibrosis in non-alcoholic fatty 
liver disease. Gut 66, 1321–1328. 
Harley, I.T.W., Stankiewicz, T.E., Giles, D.A., Softic, S., Flick, L.M., Cappelletti, M., Sheridan, R., Xanthakos, S.A., 
Steinbrecher, K.A., Sartor, R.B., et al. (2014). IL-17 signaling accelerates the progression of nonalcoholic fatty liver 
disease in mice. Hepatol. Baltim. Md 59, 1830–1839. 
Harrison, S.A., Torgerson, S., and Hayashi, P.H. (2003). The natural history of nonalcoholic fatty liver disease: a clinical 
histopathological study. Am. J. Gastroenterol. 98, 2042–2047. 
Hashmi, A.Z., Hakim, W., Kruglov, E.A., Watanabe, A., Watkins, W., Dranoff, J.A., and Mehal, W.Z. (2007). Adenosine 
inhibits cytosolic calcium signals and chemotaxis in hepatic stellate cells. Am. J. Physiol. Gastrointest. Liver Physiol. 
292, G395-401. 
He, C., Dong, X., Zhai, B., Jiang, X., Dong, D., Li, B., Jiang, H., Xu, S., and Sun, X. (2015). MiR-21 mediates sorafenib 
resistance of hepatocellular carcinoma cells by inhibiting autophagy via the PTEN/Akt pathway. Oncotarget 6, 28867–
28881. 
Heady, J.E., and Kerr, S.J. (1975). Alteration of glycine N-methyltransferase activity in fetal, adult, and tumor tissues. 
Cancer Res. 35, 640–643. 
Hebbard, L., and George, J. (2011). Animal models of nonalcoholic fatty liver disease. Nat. Rev. Gastroenterol. Hepatol. 
8, 35–44. 
Hellerbrand,  null, Wang, S.C., Tsukamoto, H., Brenner, D.A., and Rippe, R.A. (1996). Expression of intracellular 
adhesion molecule 1 by activated hepatic stellate cells. Hepatol. Baltim. Md 24, 670–676. 
 Bibliography 
223 
 
Henderson, N.C., and Iredale, J.P. (2007). Liver fibrosis: cellular mechanisms of progression and resolution. Clin. Sci. 
Lond. Engl. 1979 112, 265–280. 
Herraez, E., Lozano, E., Macias, R.I.R., Vaquero, J., Bujanda, L., Banales, J.M., Marin, J.J.G., and Briz, O. (2013). 
Expression of SLC22A1 variants may affect the response of hepatocellular carcinoma and cholangiocarcinoma to 
sorafenib. Hepatology 58, 1065–1073. 
Higuchi, H., and Gores, G.J. (2003). Mechanisms of Liver Injury: An Overview. Curr. Mol. Med. 3, 483–490. 
Higuchi, H., Bronk, S.F., Takikawa, Y., Werneburg, N., Takimoto, R., El-Deiry, W., and Gores, G.J. (2001). The bile 
acid glycochenodeoxycholate induces trail-receptor 2/DR5 expression and apoptosis. J. Biol. Chem. 276, 38610–38618. 
Higuchi, H., Grambihler, A., Canbay, A., Bronk, S.F., and Gores, G.J. (2004). Bile Acids Up-regulate Death Receptor 
5/TRAIL-receptor 2 Expression via a c-Jun N-terminal Kinase-dependent Pathway Involving Sp1. J. Biol. Chem. 279, 
51–60. 
Hinz, B., Phan, S.H., Thannickal, V.J., Galli, A., Bochaton-Piallat, M.-L., and Gabbiani, G. (2007). The Myofibroblast. 
Am. J. Pathol. 170, 1807–1816. 
Hirschey, M.D., Shimazu, T., Goetzman, E., Jing, E., Schwer, B., Lombard, D.B., Grueter, C.A., Harris, C., Biddinger, 
S., Ilkayeva, O.R., et al. (2010). SIRT3 regulates mitochondrial fatty-acid oxidation by reversible enzyme deacetylation. 
Nature 464, 121–125. 
Hoofnagle, J.H., Van Natta, M.L., Kleiner, D.E., Clark, J.M., Kowdley, K.V., Loomba, R., Neuschwander-Tetri, B.A., 
Sanyal, A.J., Tonascia, J., and Non-alcoholic Steatohepatitis Clinical Research Network (NASH CRN) (2013). Vitamin 
E and changes in serum alanine aminotransferase levels in patients with non-alcoholic steatohepatitis. Aliment. 
Pharmacol. Ther. 38, 134–143. 
Hoskins, D.D., and Mackenzie, C.G. (1961). Solubilization and electron transfer flavoprtein requirement of mitochondrial 
sarcosine dehydrogenase and dimethylglycine dehydrogenase. J. Biol. Chem. 236, 177–183. 
Hsu, S.-H., Wang, B., Kota, J., Yu, J., Costinean, S., Kutay, H., Yu, L., Bai, S., La Perle, K., Chivukula, R.R., et al. 
(2012). Essential metabolic, anti-inflammatory, and anti-tumorigenic functions of miR-122 in liver. J. Clin. Invest. 122, 
2871–2883. 
Huang, Q., Gumireddy, K., Schrier, M., le Sage, C., Nagel, R., Nair, S., Egan, D.A., Li, A., Huang, G., Klein-Szanto, 
A.J., et al. (2008a). The microRNAs miR-373 and miR-520c promote tumour invasion and metastasis. Nat. Cell Biol. 10, 
202–210. 
Huang, Y.-C., Chen, M., Shyr, Y.-M., Su, C.-H., Chen, C.-K., Li, A.F.-Y., Ho, D.M.-T., and Chen, Y.-M.A. (2008b). 
Glycine N-methyltransferase is a favorable prognostic marker for human cholangiocarcinoma. J. Gastroenterol. Hepatol. 
23, 1384–1389. 
Huang, Z.Z., Mao, Z., Cai, J., and Lu, S.C. (1998). Changes in methionine adenosyltransferase during liver regeneration 
in the rat. Am. J. Physiol. 275, G14-21. 
Huidobro, C., Toraño, E.G., Fernández, A.F., Urdinguio, R.G., Rodríguez, R.M., Ferrero, C., Martínez-Camblor, P., Boix, 
L., Bruix, J., García-Rodríguez, J.L., et al. (2013). A DNA methylation signature associated with the epigenetic repression 
of glycine N-methyltransferase in human hepatocellular carcinoma. J. Mol. Med. Berl. Ger. 91, 939–950. 
Ikeda, K., Wakahara, T., Wang, Y.Q., Kadoya, H., Kawada, N., and Kaneda, K. (1999). In vitro migratory potential of 
rat quiescent hepatic stellate cells and its augmentation by cell activation. Hepatol. Baltim. Md 29, 1760–1767. 
Inagaki, Y., and Okazaki, I. (2007). Emerging insights into Transforming growth factor beta Smad signal in hepatic 
fibrogenesis. Gut 56, 284–292. 
Iredale, J.P., Murphy, G., Hembry, R.M., Friedman, S.L., and Arthur, M.J. (1992). Human hepatic lipocytes synthesize 
tissue inhibitor of metalloproteinases-1. Implications for regulation of matrix degradation in liver. J. Clin. Invest. 90, 282–
287. 
Iredale, J.P., Benyon, R.C., Pickering, J., McCullen, M., Northrop, M., Pawley, S., Hovell, C., and Arthur, M.J. (1998). 
Mechanisms of spontaneous resolution of rat liver fibrosis. Hepatic stellate cell apoptosis and reduced hepatic expression 
of metalloproteinase inhibitors. J. Clin. Invest. 102, 538–549. 
Iwaisako, K., Brenner, D.A., and Kisseleva, T. (2012). What’s new in liver fibrosis? The origin of myofibroblasts in liver 
fibrosis. J. Gastroenterol. Hepatol. 27, 65–68. 
Jemal, A., Bray, F., Center, M.M., Ferlay, J., Ward, E., and Forman, D. (2011). Global cancer statistics. CA. Cancer J. 
Clin. 61, 69–90. 
MicroRNAs in liver disease 
224 
 
Ji, Y., Nordgren, K.K.S., Chai, Y., Hebbring, S.J., Jenkins, G.D., Abo, R.P., Peng, Y., Pelleymounter, L.L., Moon, I., 
Eckloff, B.W., et al. (2012). Human Liver Methionine Cycle: MAT1A and GNMT Gene Resequencing, Functional 
Genomics, and Hepatic Genotype-Phenotype Correlation. Drug Metab. Dispos. 40, 1984–1992. 
Jiang, J.X., Mikami, K., Venugopal, S., Li, Y., and Török, N.J. (2009). Apoptotic body engulfment by hepatic stellate 
cells promotes their survival by the JAK/STAT and Akt/NF-κB-dependent pathways. J. Hepatol. 51, 139–148. 
Jonas, S., and Izaurralde, E. (2015). Towards a molecular understanding of microRNA-mediated gene silencing. Nat. 
Rev. Genet. 16, nrg3965. 
Jones, P.A. (2012). Functions of DNA methylation: islands, start sites, gene bodies and beyond. Nat. Rev. Genet. 13, 
484–492. 
Jones, P.A., and Liang, G. (2009). Rethinking how DNA methylation patterns are maintained. Nat. Rev. Genet. 10, 805–
811. 
Jueliger, S., Lyons, J., Cannito, S., Pata, I., Pata, P., Shkolnaya, M., Lo Re, O., Peyrou, M., Villarroya, F., Pazienza, V., 
et al. (2016). Efficacy and epigenetic interactions of novel DNA hypomethylating agent guadecitabine (SGI-110) in 
preclinical models of hepatocellular carcinoma. Epigenetics 11, 709–720. 
Kahraman, A., Barreyro, F.J., Bronk, S.F., Werneburg, N.W., Mott, J.L., Akazawa, Y., Masuoka, H.C., Howe, C.L., and 
Gores, G.J. (2008). TRAIL mediates liver injury by the innate immune system in the bile duct–ligated mouse. Hepatology 
47, 1317–1330. 
Kaneto, H., Sasaki, S., Yamamoto, H., Itoh, F., Toyota, M., Suzuki, H., Ozeki, I., Iwata, N., Ohmura, T., Satoh, T., et al. 
(2001). Detection of hypermethylation of the p16(INK4A) gene promoter in chronic hepatitis and cirrhosis associated 
with hepatitis B or C virus. Gut 48, 372–377. 
Kant, R., Yen, C.-H., Lu, C.-K., Lin, Y.-C., Li, J.-H., and Chen, Y.-M.A. (2016). Identification of 1,2,3,4,6-Penta-O-
galloyl-β-d-glucopyranoside as a Glycine N-Methyltransferase Enhancer by High-Throughput Screening of Natural 
Products Inhibits Hepatocellular Carcinoma. Int. J. Mol. Sci. 17. 
Katzenellenbogen, M., Mizrahi, L., Pappo, O., Klopstock, N., Olam, D., Jacob-Hirsch, J., Amariglio, N., Rechavi, G., 
Domany, E., Galun, E., et al. (2007). Molecular Mechanisms of Liver Carcinogenesis in the Mdr2-Knockout Mice. Mol. 
Cancer Res. 5, 1159–1170. 
Kawano, Y., and Cohen, D.E. (2013). Mechanisms of hepatic triglyceride accumulation in non-alcoholic fatty liver 
disease. J. Gastroenterol. 48, 434–441. 
Kershaw, E.E., and Flier, J.S. (2004). Adipose tissue as an endocrine organ. J. Clin. Endocrinol. Metab. 89, 2548–2556. 
Khan, F.Z., Perumpail, R.B., Wong, R.J., and Ahmed, A. (2015). Advances in hepatocellular carcinoma: Nonalcoholic 
steatohepatitis-related hepatocellular carcinoma. World J. Hepatol. 7, 2155–2161. 
Kim, K.W., Bae, S.K., Lee, O.H., Bae, M.H., Lee, M.J., and Park, B.C. (1998). Insulin-like growth factor II induced by 
hypoxia may contribute to angiogenesis of human hepatocellular carcinoma. Cancer Res. 58, 348–351. 
Kinnman, N., Hultcrantz, R., Barbu, V., Rey, C., Wendum, D., Poupon, R., and Housset, C. (2000). PDGF-mediated 
chemoattraction of hepatic stellate cells by bile duct segments in cholestatic liver injury. Lab. Investig. J. Tech. Methods 
Pathol. 80, 697–707. 
Kinnman, N., Francoz, C., Barbu, V., Wendum, D., Rey, C., Hultcrantz, R., Poupon, R., and Housset, C. (2003). The 
myofibroblastic conversion of peribiliary fibrogenic cells distinct from hepatic stellate cells is stimulated by platelet-
derived growth factor during liver fibrogenesis. Lab. Investig. J. Tech. Methods Pathol. 83, 163–173. 
Kinsell, L.W., Harper, H.A., Barton, H.C., Michaels, G.D., and Weiss, H.A. (1947). Rate of Disappearance From Plasma 
of Intravenously Administered Methionine in Patients With Liver Damage. Science 106, 589–590. 
Kinsell, L.W., Harper, H.A., Barton, H.C., Hutchin, M.E., and Hess, J.R. (1948). STUDIES IN METHIONINE AND 
SULFUR METABOLISM. I. THE FATE OF INTRAVENOUSLY ADMINISTERED METHIONINE, IN NORMAL 
INDIVIDUALS AND IN PATIENTS WITH LIVER DAMAGE 12. J. Clin. Invest. 27, 677–688. 
Kirpich, I., Zhang, J., Gobejishvili, L., Kharebava, G., Barker, D., Ghare, S., Joshi-Barve, S., McClain, C.J., and Barve, 
S. (2013). Binge ethanol-induced HDAC3 down-regulates Cpt1α expression leading to hepatic steatosis and injury. 
Alcohol. Clin. Exp. Res. 37, 1920–1929. 
Kitamoto, T., Kitamoto, A., Ogawa, Y., Honda, Y., Imajo, K., Saito, S., Yoneda, M., Nakamura, T., Nakajima, A., and 
Hotta, K. (2015). Targeted-bisulfite sequence analysis of the methylation of CpG islands in genes encoding PNPLA3, 
SAMM50, and PARVB of patients with non-alcoholic fatty liver disease. J. Hepatol. 63, 494–502. 
 Bibliography 
225 
 
Kitano, M., and Bloomston, P.M. (2016). Hepatic Stellate Cells and microRNAs in Pathogenesis of Liver Fibrosis. J. 
Clin. Med. 5. 
Kleinman, C.L., Gerges, N., Papillon-Cavanagh, S., Sin-Chan, P., Pramatarova, A., Quang, D.-A.K., Adoue, V., Busche, 
S., Caron, M., Djambazian, H., et al. (2014). Fusion of TTYH1 with the C19MC microRNA cluster drives expression of 
a brain-specific DNMT3B isoform in the embryonal brain tumor ETMR. Nat. Genet. 46, 39. 
Klose, R.J., and Bird, A.P. (2006). Genomic DNA methylation: the mark and its mediators. Trends Biochem. Sci. 31, 89–
97. 
Kogure, T., Lin, W.-L., Yan, I.K., Braconi, C., and Patel, T. (2011). Intercellular nanovesicle-mediated microRNA 
transfer: a mechanism of environmental modulation of hepatocellular cancer cell growth. Hepatol. Baltim. Md 54, 1237–
1248. 
Kotb, M., Mudd, S.H., Mato, J.M., Geller, A.M., Kredich, N.M., Chou, J.Y., and Cantoni, G.L. (1997). Consensus 
nomenclature for the mammalian methionine adenosyltransferase genes and gene products. Trends Genet. TIG 13, 51–
52. 
Kovacs, P., Kress, R., Rocha, J., Kurtz, U., Miquel, J.F., Nervi, F., Méndez-Sánchez, N., Uribe, M., Bock, H.H., Schirin-
Sokhan, R., et al. (2008). Variation of the gene encoding the nuclear bile salt receptor FXR and gallstone susceptibility 
in mice and humans. J. Hepatol. 48, 116–124. 
Krol, J., Loedige, I., and Filipowicz, W. (2010). The widespread regulation of microRNA biogenesis, function and decay. 
Nat. Rev. Genet. 11, 597–610. 
Kubo, T., Yamamoto, J., Shikauchi, Y., Niwa, Y., Matsubara, K., and Yoshikawa, H. (2004). Apoptotic speck protein-
like, a highly homologous protein to apoptotic speck protein in the pyrin domain, is silenced by DNA methylation and 
induces apoptosis in human hepatocellular carcinoma. Cancer Res. 64, 5172–5177. 
Lagos-Quintana, M., Rauhut, R., Yalcin, A., Meyer, J., Lendeckel, W., and Tuschl, T. (2002). Identification of Tissue-
Specific MicroRNAs from Mouse. Curr. Biol. 12, 735–739. 
Lai, M.-W., Liang, K.-H., Lin, W.-R., Huang, Y.-H., Huang, S.-F., Chen, T.-C., and Yeh, C.-T. (2016). 
Hepatocarcinogenesis in transgenic mice carrying hepatitis B virus pre-S/S gene with the sW172* mutation. Oncogenesis 
5, e273. 
Lambert, J.E., Ramos-Roman, M.A., Browning, J.D., and Parks, E.J. (2014). Increased de novo lipogenesis is a distinct 
characteristic of individuals with nonalcoholic fatty liver disease. Gastroenterology 146, 726–735. 
Lamireau, T., Le Bail, B., Boussarie, L., Fabre, M., Vergnes, P., Bernard, O., Gautier, F., Bioulac-Sage, P., and 
Rosenbaum, J. (1999). Expression of collagens type I and IV, osteonectin and transforming growth factor beta-1 
(TGFbeta1) in biliary atresia and paucity of intrahepatic bile ducts during infancy. J. Hepatol. 31, 248–255. 
Lamireau, T., Zoltowska, M., Levy, E., Yousef, I., Rosenbaum, J., Tuchweber, B., and Desmoulière, A. (2003). Effects 
of bile acids on biliary epithelial cells: proliferation, cytotoxicity, and cytokine secretion. Life Sci. 72, 1401–1411. 
Latasa, M.U., Boukaba, A., García-Trevijano, E.R., Torres, L., Rodríguez, J.L., Caballería, J., Lu, S.C., López-Rodas, G., 
Franco, L., Mato, J.M., et al. (2001). Hepatocyte growth factor induces MAT2A expression and histone acetylation in rat 
hepatocytes: role in liver regeneration. FASEB J. Off. Publ. Fed. Am. Soc. Exp. Biol. 15, 1248–1250. 
Lazaridis, K.N., Pham, L., Tietz, P., Marinelli, R.A., deGroen, P.C., Levine, S., Dawson, P.A., and LaRusso, N.F. (1997). 
Rat cholangiocytes absorb bile acids at their apical domain via the ileal sodium-dependent bile acid transporter. J. Clin. 
Invest. 100, 2714–2721. 
Le, T., Kim, K.-P., Fan, G., and Faull, K.F. (2011). A sensitive mass spectrometry method for simultaneous quantification 
of DNA methylation and hydroxymethylation levels in biological samples. Anal. Biochem. 412, 203–209. 
Leake, I. (2016). NAFLD: Severity of NAFLD in patients who are not obese. 
Lee, U.E., and Friedman, S.L. (2011). Mechanisms of Hepatic Fibrogenesis. Best Pract. Res. Clin. Gastroenterol. 25, 
195–206. 
Lee, C.-M., Shih, Y.-P., Wu, C.-H., and Chen, Y.-M.A. (2009). Characterization of the 5’ regulatory region of the human 
Glycine N-methyltransferase gene. Gene 443, 151–157. 
Lee, G.Y., Kim, N.H., Zhao, Z.-S., Cha, B.S., and Kim, Y.S. (2004). Peroxisomal-proliferator-activated receptor alpha 
activates transcription of the rat hepatic malonyl-CoA decarboxylase gene: a key regulation of malonyl-CoA level. 
Biochem. J. 378, 983–990. 
MicroRNAs in liver disease 
226 
 
Lee, J., Kim, Y., Friso, S., and Choi, S.-W. (2017). Epigenetics in non-alcoholic fatty liver disease. Mol. Aspects Med. 
54, 78–88. 
LeGros, H.L., Halim, A.B., Geller, A.M., and Kotb, M. (2000). Cloning, expression, and functional characterization of 
the beta regulatory subunit of human methionine adenosyltransferase (MAT II). J. Biol. Chem. 275, 2359–2366. 
LeSage, G., Glaser, S., and Alpini, G. (2001). Regulation of cholangiocyte proliferation. Liver 21, 73–80. 
LeSage, G.D., Benedetti, A., Glaser, S., Marucci, L., Tretjak, Z., Caligiuri, A., Rodgers, R., Phinizy, J.L., Baiocchi, L., 
Francis, H., et al. (1999). Acute carbon tetrachloride feeding selectively damages large, but not small, cholangiocytes 
from normal rat liver. Hepatol. Baltim. Md 29, 307–319. 
Leung, J.C.-F., Loong, T.C.-W., Wei, J.L., Wong, G.L.-H., Chan, A.W.-H., Choi, P.C.-L., Shu, S.S.-T., Chim, A.M.-L., 
Chan, H.L.-Y., and Wong, V.W.-S. (2017). Histological severity and clinical outcomes of nonalcoholic fatty liver disease 
in nonobese patients. Hepatol. Baltim. Md 65, 54–64. 
Li, C.-H., Yen, C.-H., Chen, Y.-F., Lee, K.-J., Fang, C.-C., Zhang, X., Lai, C.-C., Huang, S.-F., Lin, H.-K., and Arthur 
Chen, Y.-M. (2017). Characterization of the GNMT-HectH9-PREX2 tripartite relationship in the pathogenesis of 
hepatocellular carcinoma. Int. J. Cancer 140, 2284–2297. 
Li, M.-C., Yu, J.-H., Yu, S.-S., Chi, Y.-Y., and Xiang, Y.-B. (2015). MicroRNA-873 Inhibits Morphine-Induced 
Macrophage Apoptosis by Elevating A20 Expression. Pain Med. 16, 1993–1999. 
Liao, Y.-J., Liu, S.-P., Lee, C.-M., Yen, C.-H., Chuang, P.-C., Chen, C.-Y., Tsai, T.-F., Huang, S.-F., Lee, Y.-H.W., and 
Chen, Y.-M.A. (2009). Characterization of a glycine N-methyltransferase gene knockout mouse model for hepatocellular 
carcinoma: Implications of the gender disparity in liver cancer susceptibility. Int. J. Cancer 124, 816–826. 
Liao, Y.-J., Chen, T.-L., Lee, T.-S., Wang, H.-A., Wang, C.-K., Liao, L.-Y., Liu, R.-S., Huang, S.-F., and Chen, Y.-M.A. 
(2012). Glycine N-methyltransferase deficiency affects Niemann-Pick type C2 protein stability and regulates hepatic 
cholesterol homeostasis. Mol. Med. Camb. Mass 18, 412–422. 
Lieber, C.S., and Packer, L. (2002). S-Adenosylmethionine: molecular, biological, and clinical aspects--an introduction. 
Am. J. Clin. Nutr. 76, 1148S–50S. 
Lim, S.-O., Gu, J.-M., Kim, M.S., Kim, H.-S., Park, Y.N., Park, C.K., Cho, J.W., Park, Y.M., and Jung, G. (2008). 
Epigenetic Changes Induced by Reactive Oxygen Species in Hepatocellular Carcinoma: Methylation of the E-cadherin 
Promoter. Gastroenterology 135, 2128–2140.e8. 
Lin, S., Hoffmann, K., Gao, C., Petrulionis, M., Herr, I., and Schemmer, P. (2017). Melatonin promotes sorafenib-induced 
apoptosis through synergistic activation of JNK/c-jun pathway in human hepatocellular carcinoma. J. Pineal Res. 62. 
Listenberger, L.L., Han, X., Lewis, S.E., Cases, S., Farese, R.V., Ory, D.S., and Schaffer, J.E. (2003). Triglyceride 
accumulation protects against fatty acid-induced lipotoxicity. Proc. Natl. Acad. Sci. U. S. A. 100, 3077–3082. 
Liu, X., and Brenner, D.A. (2016). Liver: DNA methylation controls liver fibrogenesis. Nat. Rev. Gastroenterol. Hepatol. 
13, 126–128. 
Liu, C., Liu, L., Chen, X., Shen, J., Shan, J., Xu, Y., Yang, Z., Wu, L., Xia, F., Bie, P., et al. (2013). Decrease of 5-
hydroxymethylcytosine is associated with progression of hepatocellular carcinoma through downregulation of TET1. 
PloS One 8, e62828. 
Liu, L., Cao, Y., Chen, C., Zhang, X., McNabola, A., Wilkie, D., Wilhelm, S., Lynch, M., and Carter, C. (2006). Sorafenib 
blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular 
carcinoma model PLC/PRF/5. Cancer Res. 66, 11851–11858. 
Liu, X., He, F., Pang, R., Zhao, D., Qiu, W., Shan, K., Zhang, J., Lu, Y., Li, Y., and Wang, Y. (2014). Interleukin-17 (IL-
17)-induced microRNA 873 (miR-873) contributes to the pathogenesis of experimental autoimmune encephalomyelitis 
by targeting A20 ubiquitin-editing enzyme. J. Biol. Chem. 289, 28971–28986. 
Liver, E.A. for the S. of the, and Cancer, E.O. for R. and T. of (2012). EASL–EORTC Clinical Practice Guidelines: 
Management of hepatocellular carcinoma. J. Hepatol. 56, 908–943. 
Llovet, J.M., and Bruix, J. (2003). Systematic review of randomized trials for unresectable hepatocellular carcinoma: 
Chemoembolization improves survival. Hepatol. Baltim. Md 37, 429–442. 
Llovet, J.M., Fuster, J., and Bruix, J. (1999). Intention-to-treat analysis of surgical treatment for early hepatocellular 
carcinoma: resection versus transplantation. Hepatol. Baltim. Md 30, 1434–1440. 
 Bibliography 
227 
 
Llovet, J.M., Real, M.I., Montaña, X., Planas, R., Coll, S., Aponte, J., Ayuso, C., Sala, M., Muchart, J., Solà, R., et al. 
(2002). Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable 
hepatocellular carcinoma: a randomised controlled trial. Lancet Lond. Engl. 359, 1734–1739. 
Llovet, J.M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A.C., Santoro, A., Raoul, J.-L., 
Forner, A., et al. (2008). Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 359, 378–390. 
Lodish, H., Berk, A., Zipursky, S.L., Matsudaira, P., Baltimore, D., and Darnell, J. (2000). Electron Transport and 
Oxidative Phosphorylation. 
Loomba, R., and Sanyal, A.J. (2013). The global NAFLD epidemic. Nat. Rev. Gastroenterol. Hepatol. 10, 686–690. 
Love, M.I., Huber, W., and Anders, S. (2014). Moderated estimation of fold change and dispersion for RNA-seq data 
with DESeq2. Genome Biol. 15, 550. 
Lu, S.C. (1999). Regulation of hepatic glutathione synthesis: current concepts and controversies. FASEB J. Off. Publ. 
Fed. Am. Soc. Exp. Biol. 13, 1169–1183. 
Lu, S.C. (2000). S-Adenosylmethionine. Int. J. Biochem. Cell Biol. 32, 391–395. 
Lu, S.C. (2009). REGULATION OF GLUTATHIONE SYNTHESIS. Mol. Aspects Med. 30, 42–59. 
Lu, S.C., Alvarez, L., Huang, Z.Z., Chen, L., An, W., Corrales, F.J., Avila, M.A., Kanel, G., and Mato, J.M. (2001). 
Methionine adenosyltransferase 1A knockout mice are predisposed to liver injury and exhibit increased expression of 
genes involved in proliferation. Proc. Natl. Acad. Sci. U. S. A. 98, 5560–5565. 
Lujambio, A., Calin, G.A., Villanueva, A., Ropero, S., Sánchez-Céspedes, M., Blanco, D., Montuenga, L.M., Rossi, S., 
Nicoloso, M.S., Faller, W.J., et al. (2008). A microRNA DNA methylation signature for human cancer metastasis. Proc. 
Natl. Acad. Sci. U. S. A. 105, 13556–13561. 
Luka, Z., Cerone, R., Phillips, J.A., Mudd, H.S., and Wagner, C. (2002). Mutations in human glycine N-methyltransferase 
give insights into its role in methionine metabolism. Hum. Genet. 110, 68–74. 
Luka, Z., Capdevila, A., Mato, J.M., and Wagner, C. (2006). A Glycine N-methyltransferase knockout mouse model for 
humans with deficiency of this enzyme. Transgenic Res. 15, 393–397. 
Luka, Z., Mudd, S.H., and Wagner, C. (2009). Glycine N-Methyltransferase and Regulation of S-Adenosylmethionine 
Levels. J. Biol. Chem. 284, 22507–22511. 
Lutchman, G., Modi, A., Kleiner, D.E., Promrat, K., Heller, T., Ghany, M., Borg, B., Loomba, R., Liang, T.J., Premkumar, 
A., et al. (2007). The effects of discontinuing pioglitazone in patients with nonalcoholic steatohepatitis. Hepatol. Baltim. 
Md 46, 424–429. 
Ma, L., Chua, M.-S., Andrisani, O., and So, S. (2014). Epigenetics in hepatocellular carcinoma: An update and future 
therapy perspectives. World J. Gastroenterol. WJG 20, 333–345. 
Maher, J.J. (2001). Interactions between Hepatic Stellate Cells and the Immune System. Semin. Liver Dis. 21, 417–426. 
Makishima, M., Okamoto, A.Y., Repa, J.J., Tu, H., Learned, R.M., Luk, A., Hull, M.V., Lustig, K.D., Mangelsdorf, D.J., 
and Shan, B. (1999). Identification of a nuclear receptor for bile acids. Science 284, 1362–1365. 
Malhi, H., and Kaufman, R.J. (2011). Endoplasmic reticulum stress in liver disease. J. Hepatol. 54, 795–809. 
Malhi, H., Barreyro, F.J., Isomoto, H., Bronk, S.F., and Gores, G.J. (2007). Free fatty acids sensitise hepatocytes to 
TRAIL mediated cytotoxicity. Gut 56, 1124–1131. 
Mandard, S., Müller, M., and Kersten, S. (2004). Peroxisome proliferator-activated receptor alpha target genes. Cell. Mol. 
Life Sci. CMLS 61, 393–416. 
Mann, J., Oakley, F., Akiboye, F., Elsharkawy, A., Thorne, A.W., and Mann, D.A. (2006). Regulation of myofibroblast 
transdifferentiation by DNA methylation and MeCP2: implications for wound healing and fibrogenesis. Cell Death Differ. 
14, 275–285. 
Mann, J., Chu, D.C., Maxwell, A., Oakley, F., Zhu, N.-L., Tsukamoto, H., and Mann, D.A. (2010). MeCP2 controls an 
epigenetic pathway that promotes myofibroblast transdifferentiation and fibrosis. Gastroenterology 138, 705. 
Mannaerts, I., Nuytten, N.R., Rogiers, V., Vanderkerken, K., van Grunsven, L.A., and Geerts, A. (2010). Chronic 
administration of valproic acid inhibits activation of mouse hepatic stellate cells in vitro and in vivo. Hepatol. Baltim. Md 
51, 603–614. 
Margueron, R., and Reinberg, D. (2011). The Polycomb complex PRC2 and its mark in life. Nature 469, 343–349. 
MicroRNAs in liver disease 
228 
 
Marin, J.J.G., and Briz, M.R.R. and O. (2010). Molecular Bases of Liver Cancer Refractoriness to Pharmacological 
Treatment. 
Marin, J.J., Monte, M.J., Blazquez, A.G., Macias, R.I., Serrano, M.A., and Briz, O. (2014). The role of reduced 
intracellular concentrations of active drugs in the lack of response to anticancer chemotherapy. Acta Pharmacol. Sin. 35, 
1–10. 
Marin, J.J.G., Castaño, B., Blazquez, A.G., Rosales, R., Efferth, T., and Monte, M.J. (2010). Strategies for overcoming 
chemotherapy resistance in enterohepatic tumours. Curr. Mol. Med. 10, 467–485. 
Marin, J.J.G., Lozano, E., Briz, O., Al-Abdulla, R., Serrano, M.A., and Macias, R.I.R. (2017). Molecular Bases of 
Chemoresistance in Cholangiocarcinoma. Curr. Drug Targets 18, 889–900. 
Marra, F., DeFranco, R., Grappone, C., Milani, S., Pastacaldi, S., Pinzani, M., Romanelli, R.G., Laffi, G., and Gentilini, 
P. (1998). Increased expression of monocyte chemotactic protein-1 during active hepatic fibrogenesis: correlation with 
monocyte infiltration. Am. J. Pathol. 152, 423–430. 
Marra, F., Romanelli, R.G., Giannini, C., Failli, P., Pastacaldi, S., Arrighi, M.C., Pinzani, M., Laffi, G., Montalto, P., and 
Gentilini, P. (1999). Monocyte chemotactic protein-1 as a chemoattractant for human hepatic stellate cells. Hepatol. 
Baltim. Md 29, 140–148. 
Marrero, J.A., Fontana, R.J., Su, G.L., Conjeevaram, H.S., Emick, D.M., and Lok, A.S. (2002). NAFLD may be a 
common underlying liver disease in patients with hepatocellular carcinoma in the United States. Hepatol. Baltim. Md 36, 
1349–1354. 
Marson, A., Levine, S.S., Cole, M.F., Frampton, G.M., Brambrink, T., Johnstone, S., Guenther, M.G., Johnston, W.K., 
Wernig, M., Newman, J., et al. (2008). Connecting microRNA genes to the core transcriptional regulatory circuitry of 
embryonic stem cells. Cell 134, 521–533. 
Martin, C., and Zhang, Y. (2005). The diverse functions of histone lysine methylation. Nat. Rev. Mol. Cell Biol. 6, 838–
849. 
Martinez-Becerra, P., Vaquero, J., Romero, M.R., Lozano, E., Anadon, C., Macias, R.I.R., Serrano, M.A., Grañé-
Boladeras, N., Muñoz-Bellvis, L., Alvarez, L., et al. (2012). No Correlation between the Expression of FXR and Genes 
Involved in Multidrug Resistance Phenotype of Primary Liver Tumors. Mol. Pharm. 9, 1693–1704. 
Martínez-Chantar, M.L., Corrales, F.J., Martínez-Cruz, L.A., García-Trevijano, E.R., Huang, Z.-Z., Chen, L., Kanel, G., 
Avila, M.A., Mato, J.M., and Lu, S.C. (2002). Spontaneous oxidative stress and liver tumors in mice lacking methionine 
adenosyltransferase 1A. FASEB J. Off. Publ. Fed. Am. Soc. Exp. Biol. 16, 1292–1294. 
Martínez-Chantar, M.L., Vázquez-Chantada, M., Ariz, U., Martínez, N., Varela, M., Luka, Z., Capdevila, A., Rodríguez, 
J., Aransay, A.M., Matthiesen, R., et al. (2008). Loss of the glycine N-methyltransferase gene leads to steatosis and 
hepatocellular carcinoma in mice. Hepatol. Baltim. Md 47, 1191–1199. 
Martínez-López, N., García-Rodríguez, J.L., Varela-Rey, M., Gutiérrez, V., Fernández-Ramos, D., Beraza, N., Aransay, 
A.M., Schlangen, K., Lozano, J.J., Aspichueta, P., et al. (2012). Hepatoma cells from mice deficient in glycine N-
methyltransferase have increased RAS signaling and activation of liver kinase B1. Gastroenterology 143, 787–798.e13. 
Martínez-Uña, M., Varela-Rey, M., Cano, A., Fernández-Ares, L., Beraza, N., Aurrekoetxea, I., Martínez-Arranz, I., 
García-Rodríguez, J.L., Buqué, X., Mestre, D., et al. (2013). Excess S-adenosylmethionine reroutes 
phosphatidylethanolamine towards phosphatidylcholine and triglyceride synthesis. Hepatol. Baltim. Md 58, 1296–1305. 
Martinez-Una, M., Varela-Rey, M., Mestre, D., Fernandez-Ares, L., Fresnedo, O., Fernandez-Ramos, D., Juan, V.G., 
Martin-Guerrero, I., Garcia-Orad, A., Luka, Z., et al. (2015). S-adenosylmethionine increases circulating very-low density 
lipoprotein clearance in nonalcoholic fatty liver disease. J. Hepatol. 62, 673–681. 
Martinov, M.V., Vitvitsky, V.M., Banerjee, R., and Ataullakhanov, F.I. (2010). The logic of the hepatic methionine 
metabolic cycle. Biochim. Biophys. Acta 1804, 89–96. 
Marucci, L., Svegliati Baroni, G., Mancini, R., Benedetti, A., Jezequel, A.M., and Orlandi, F. (1993). Cell proliferation 
following extrahepatic biliary obstruction: Evaluation by immunohistochemical methods. J. Hepatol. 17, 163–169. 
Mato, J.M., Alvarez, L., Ortiz, P., and Pajares, M.A. (1997). S-adenosylmethionine synthesis: molecular mechanisms and 
clinical implications. Pharmacol. Ther. 73, 265–280. 
Mato, J.M., Corrales, F.J., Lu, S.C., and Avila, M.A. (2002). S-Adenosylmethionine: a control switch that regulates liver 
function. FASEB J. Off. Publ. Fed. Am. Soc. Exp. Biol. 16, 15–26. 
 Bibliography 
229 
 
Mato, J.M., Martínez-Chantar, M.L., and Lu, S.C. (2008). Methionine Metabolism and Liver Disease. Annu. Rev. Nutr. 
28, 273–293. 
Mato, J.M., Martínez-Chantar, M.L., and Lu, S.C. (2013). S-adenosylmethionine metabolism and liver disease. Ann. 
Hepatol. 12, 183–189. 
McClain, C.J., Barve, S., and Deaciuc, I. (2007). Good fat/bad fat. Hepatol. Baltim. Md 45, 1343–1346. 
McGlynn, K.A., and London, W.T. (2011). The global epidemiology of hepatocellular carcinoma: present and future. 
Clin. Liver Dis. 15, 223–243, vii–x. 
McMullen, M.H., Rowling, M.J., Ozias, M.K., and Schalinske, K.L. (2002). Activation and induction of glycine N-
methyltransferase by retinoids are tissue- and gender-specific. Arch. Biochem. Biophys. 401, 73–80. 
Mederacke, I., Hsu, C.C., Troeger, J.S., Huebener, P., Mu, X., Dapito, D.H., Pradere, J.-P., and Schwabe, R.F. (2013). 
Fate-tracing reveals hepatic stellate cells as dominant contributors to liver fibrosis independent of its etiology. Nat. 
Commun. 4, 2823. 
Meehan, R.R., Lewis, J.D., and Bird, A.P. (1992). Characterization of MeCP2, a vertebrate DNA binding protein with 
affinity for methylated DNA. Nucleic Acids Res. 20, 5085–5092. 
Mello, T., Materozzi, M., and Galli, A. (2016). PPARs and Mitochondrial Metabolism: From NAFLD to HCC. PPAR 
Res. 2016. 
Meng, F., Wang, K., Aoyama, T., Grivennikov, S.I., Paik, Y., Scholten, D., Cong, M., Iwaisako, K., Liu, X., Zhang, M., 
et al. (2012). Interleukin-17 signaling in inflammatory, Kupffer cells, and hepatic stellate cells exacerbates liver fibrosis 
in mice. Gastroenterology 143, 765–776.e3. 
Merino-Azpitarte, M., Lozano, E., Perugorria, M.J., Esparza-Baquer, A., Erice, O., Santos-Laso, Á., O’Rourke, C.J., 
Andersen, J.B., Jiménez-Agüero, R., Lacasta, A., et al. (2017). SOX17 regulates cholangiocyte differentiation and acts as 
a tumor suppressor in cholangiocarcinoma. J. Hepatol. 67, 72–83. 
Michelotti, G.A., Machado, M.V., and Diehl, A.M. (2013). NAFLD, NASH and liver cancer. Nat. Rev. Gastroenterol. 
Hepatol. 10, 656–665. 
Milani, S., Herbst, H., Schuppan, D., Stein, H., and Surrenti, C. (1991). Transforming growth factors beta 1 and beta 2 
are differentially expressed in fibrotic liver disease. Am. J. Pathol. 139, 1221–1229. 
Ming, L., Sakaida, T., Yue, W., Jha, A., Zhang, L., and Yu, J. (2008). Sp1 and p73 activate PUMA following serum 
starvation. Carcinogenesis 29, 1878–1884. 
Mishra, A., and Younossi, Z.M. (2012). Epidemiology and Natural History of Non-alcoholic Fatty Liver Disease. J. Clin. 
Exp. Hepatol. 2, 135–144. 
Mittal, S., and El-Serag, H.B. (2013). Epidemiology of HCC: Consider the Population. J. Clin. Gastroenterol. 47, S2–S6. 
Mohrmann, L., and Verrijzer, C.P. (2005). Composition and functional specificity of SWI2/SNF2 class chromatin 
remodeling complexes. Biochim. Biophys. Acta BBA - Gene Struct. Expr. 1681, 59–73. 
Moylan, C.A., Pang, H., Dellinger, A., Suzuki, A., Garrett, M.E., Guy, C.D., Murphy, S.K., Ashley-Koch, A.E., Choi, 
S.S., Michelotti, G.A., et al. (2014). Hepatic Gene Expression Profiles Differentiate Pre-symptomatic Patients with Mild 
versus Severe Nonalcoholic Fatty Liver Disease. Hepatol. Baltim. Md 59, 471–482. 
Mudd, S.H., and Poole, J.R. (1975). Labile methyl balances for normal humans on various dietary regimens. Metabolism. 
24, 721–735. 
Mudd, S.H., Cerone, R., Schiaffino, M.C., Fantasia, A.R., Minniti, G., Caruso, U., Lorini, R., Watkins, D., Matiaszuk, 
N., Rosenblatt, D.S., et al. (2001). Glycine N-methyltransferase deficiency: a novel inborn error causing persistent isolated 
hypermethioninaemia. J. Inherit. Metab. Dis. 24, 448–464. 
Murphy, F.R., Issa, R., Zhou, X., Ratnarajah, S., Nagase, H., Arthur, M.J.P., Benyon, C., and Iredale, J.P. (2002). 
Inhibition of apoptosis of activated hepatic stellate cells by tissue inhibitor of metalloproteinase-1 is mediated via effects 
on matrix metalloproteinase inhibition: implications for reversibility of liver fibrosis. J. Biol. Chem. 277, 11069–11076. 
Murphy, S.K., Yang, H., Moylan, C.A., Pang, H., Dellinger, A., Abdelmalek, M.F., Garrett, M.E., Ashley-Koch, A., 
Suzuki, A., Tillmann, H.L., et al. (2013). Relationship between methylome and transcriptome in patients with 
nonalcoholic fatty liver disease. Gastroenterology 145, 1076–1087. 
Muto, J., Shirabe, K., Sugimachi, K., and Maehara, Y. (2015). Review of angiogenesis in hepatocellular carcinoma. 
Hepatol. Res. Off. J. Jpn. Soc. Hepatol. 45, 1–9. 
MicroRNAs in liver disease 
230 
 
Nagai, M., Nakamura, A., Makino, R., and Mitamura, K. (2003). Expression of DNA (5-cytosin)-methyltransferases 
(DNMTs) in hepatocellular carcinomas. Hepatol. Res. 26, 186–191. 
Nassir, F., and Ibdah, J.A. (2014). Role of mitochondria in nonalcoholic fatty liver disease. Int. J. Mol. Sci. 15, 8713–
8742. 
Nassir, F., Adewole, O.L., Brunt, E.M., and Abumrad, N.A. (2013). CD36 deletion reduces VLDL secretion, modulates 
liver prostaglandins, and exacerbates hepatic steatosis in ob/ob mice. J. Lipid Res. 54, 2988–2997. 
Neuschwander-Tetri, B.A. (2010). Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: the central 
role of nontriglyceride fatty acid metabolites. Hepatol. Baltim. Md 52, 774–788. 
Neuschwander-Tetri, B.A., Loomba, R., Sanyal, A.J., Lavine, J.E., Van Natta, M.L., Abdelmalek, M.F., Chalasani, N., 
Dasarathy, S., Diehl, A.M., Hameed, B., et al. (2015). Farnesoid X nuclear receptor ligand obeticholic acid for non-
cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet Lond. Engl. 
385, 956–965. 
Ng, I.O.L., Liu, C.L., Fan, S.T., and Ng, M. (2000). Expression of P-Glycoprotein in Hepatocellular CarcinomaA 
Determinant of Chemotherapy Response. Am. J. Clin. Pathol. 113, 355–363. 
Nieman, K.M., Rowling, M.J., Garrow, T.A., and Schalinske, K.L. (2004). Modulation of Methyl Group Metabolism by 
Streptozotocin-induced Diabetes and All-trans-retinoic Acid. J. Biol. Chem. 279, 45708–45712. 
Niki, T., Rombouts, K., De Bleser, P., De Smet, K., Rogiers, V., Schuppan, D., Yoshida, M., Gabbiani, G., and Geerts, 
A. (1999). A histone deacetylase inhibitor, trichostatin A, suppresses myofibroblastic differentiation of rat hepatic stellate 
cells in primary culture. Hepatology 29, 858–867. 
Nishida, N., Kudo, M., Nagasaka, T., Ikai, I., and Goel, A. (2012). Characteristic patterns of altered DNA methylation 
predict emergence of human hepatocellular carcinoma. Hepatol. Baltim. Md 56, 994–1003. 
Niwa, Y., Kanda, H., Shikauchi, Y., Saiura, A., Matsubara, K., Kitagawa, T., Yamamoto, J., Kubo, T., and Yoshikawa, 
H. (2005). Methylation silencing of SOCS-3 promotes cell growth and migration by enhancing JAK/STAT and FAK 
signalings in human hepatocellular carcinoma. Oncogene 24, 6406–6417. 
Noga, A.A., Zhao, Y., and Vance, D.E. (2002). An unexpected requirement for phosphatidylethanolamine N-
methyltransferase in the secretion of very low density lipoproteins. J. Biol. Chem. 277, 42358–42365. 
Noguer-Dance, M., Abu-Amero, S., Al-Khtib, M., Lefèvre, A., Coullin, P., Moore, G.E., and Cavaillé, J. (2010). The 
primate-specific microRNA gene cluster (C19MC) is imprinted in the placenta. Hum. Mol. Genet. 19, 3566–3582. 
Noureddin, M., and Rinella, M.E. (2015). Nonalcoholic Fatty liver disease, diabetes, obesity, and hepatocellular 
carcinoma. Clin. Liver Dis. 19, 361–379. 
Oakley, F., Meso, M., Iredale, J.P., Green, K., Marek, C.J., Zhou, X., May, M.J., Millward-Sadler, H., Wright, M.C., and 
Mann, D.A. (2005). Inhibition of inhibitor of kappaB kinases stimulates hepatic stellate cell apoptosis and accelerated 
recovery from rat liver fibrosis. Gastroenterology 128, 108–120. 
O’Brien, K.M., Allen, K.M., Rockwell, C.E., Towery, K., Luyendyk, J.P., and Copple, B.L. (2013). IL-17A 
Synergistically Enhances Bile Acid–Induced Inflammation during Obstructive Cholestasis. Am. J. Pathol. 183, 1498–
1507. 
O’Donnell, K.A., Wentzel, E.A., Zeller, K.I., Dang, C.V., and Mendell, J.T. (2005). c-Myc-regulated microRNAs 
modulate E2F1 expression. Nature 435, 839–843. 
Ogawa, H., Gomi, T., Takusagawa, F., and Fujioka, M. (1998). Structure, function and physiological role of glycine N-
methyltransferase. Int. J. Biochem. Cell Biol. 30, 13–26. 
Ohanian, M., Garcia-Manero, G., Jabbour, E.J., Daver, N., Borthakur, G., Kadia, T.M., Brandt, M., Pierce, S., Burger, J., 
Richie, M.A., et al. (2016). Combination of Sorafenib and 5-Azacytidine in Older Patients with Untreated Acute Myeloid 
Leukemia with FLT3-ITDmutation. Blood 128, 1611–1611. 
Okano, M., Bell, D.W., Haber, D.A., and Li, E. (1999). DNA Methyltransferases Dnmt3a and Dnmt3b Are Essential for 
De Novo Methylation and Mammalian Development. Cell 99, 247–257. 
Ota, T., Gayet, C., and Ginsberg, H.N. (2008). Inhibition of apolipoprotein B100 secretion by lipid-induced hepatic 
endoplasmic reticulum stress in rodents. J. Clin. Invest. 118, 316–332. 
Ou, D.-L., Shen, Y.-C., Yu, S.-L., Chen, K.-F., Yeh, P.-Y., Fan, H.-H., Feng, W.-C., Wang, C.-T., Lin, L.-I., Hsu, C., et 
al. (2010). Induction of DNA damage-inducible gene GADD45beta contributes to sorafenib-induced apoptosis in 
hepatocellular carcinoma cells. Cancer Res. 70, 9309–9318. 
 Bibliography 
231 
 
Ozcan, U., Cao, Q., Yilmaz, E., Lee, A.-H., Iwakoshi, N.N., Ozdelen, E., Tuncman, G., Görgün, C., Glimcher, L.H., and 
Hotamisligil, G.S. (2004). Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes. Science 306, 
457–461. 
Pagadala, M.R., and McCullough, A.J. (2012). Non-alcoholic fatty liver disease and obesity: not all about body mass 
index. Am. J. Gastroenterol. 107, 1859–1861. 
Page, A., Paoli, P., Salvador, E.M., White, S., French, J., and Mann, J. (2016). Hepatic stellate cell transdifferentiation 
involves genome-wide remodeling of the DNA methylation landscape. J. Hepatol. 64, 661–673. 
Palmer, M., and Schaffner, F. (1990). Effect of weight reduction on hepatic abnormalities in overweight patients. 
Gastroenterology 99, 1408–1413. 
Pan, M., Cederbaum, A.I., Zhang, Y.-L., Ginsberg, H.N., Williams, K.J., and Fisher, E.A. (2004). Lipid peroxidation and 
oxidant stress regulate hepatic apolipoprotein B degradation and VLDL production. J. Clin. Invest. 113, 1277–1287. 
Park, H.-J., Yu, E., and Shim, Y.-H. (2006). DNA methyltransferase expression and DNA hypermethylation in human 
hepatocellular carcinoma. Cancer Lett. 233, 271–278. 
Parks, D.J., Blanchard, S.G., Bledsoe, R.K., Chandra, G., Consler, T.G., Kliewer, S.A., Stimmel, J.B., Willson, T.M., 
Zavacki, A.M., Moore, D.D., et al. (1999). Bile acids: natural ligands for an orphan nuclear receptor. Science 284, 1365–
1368. 
Patel, T., Bronk, S.F., and Gores, G.J. (1994). Increases of intracellular magnesium promote glycodeoxycholate-induced 
apoptosis in rat hepatocytes. J. Clin. Invest. 94, 2183–2192. 
Pathil, A., Armeanu, S., Venturelli, S., Mascagni, P., Weiss, T.S., Gregor, M., Lauer, U.M., and Bitzer, M. (2006). HDAC 
inhibitor treatment of hepatoma cells induces both TRAIL-independent apoptosis and restoration of sensitivity to TRAIL. 
Hepatol. Baltim. Md 43, 425–434. 
Pegg, A.E., and Williams-Ashman, H.G. (1969). Phosphate-stimulated breakdown of 5’-methylthioadenosine by rat 
ventral prostate. Biochem. J. 115, 241–247. 
Pérez-Carreras, M., Del Hoyo, P., Martín, M.A., Rubio, J.C., Martín, A., Castellano, G., Colina, F., Arenas, J., and Solis-
Herruzo, J.A. (2003). Defective hepatic mitochondrial respiratory chain in patients with nonalcoholic steatohepatitis. 
Hepatol. Baltim. Md 38, 999–1007. 
Perugorria, M.J., Wilson, C.L., Zeybel, M., Walsh, M., Amin, S., Robinson, S., White, S.A., Burt, A.D., Oakley, F., 
Tsukamoto, H., et al. (2012). Histone Methyltransferase ASH1 Orchestrates Fibrogenic Gene Transcription During 
Myofibroblast Transdifferentiation. Hepatol. Baltim. Md 56, 1129–1139. 
Pessayre, D., Mansouri, A., and Fromenty, B. (2002). Nonalcoholic steatosis and steatohepatitis. V. Mitochondrial 
dysfunction in steatohepatitis. Am. J. Physiol. Gastrointest. Liver Physiol. 282, G193-199. 
Petrossian, T.C., and Clarke, S.G. (2011). Uncovering the human methyltransferasome. Mol. Cell. Proteomics MCP 10, 
M110.000976. 
Pineau, P., Volinia, S., McJunkin, K., Marchio, A., Battiston, C., Terris, B., Mazzaferro, V., Lowe, S.W., Croce, C.M., 
and Dejean, A. (2010). miR-221 overexpression contributes to liver tumorigenesis. Proc. Natl. Acad. Sci. 107, 264–269. 
Pinzani, M. (2002). PDGF and signal transduction in hepatic stellate cells. Front. Biosci. J. Virtual Libr. 7, d1720-1726. 
Pinzani, M., Milani, S., Grappone, C., Weber, F.L., Gentilini, P., and Abboud, H.E. (1994). Expression of platelet-derived 
growth factor in a model of acute liver injury. Hepatol. Baltim. Md 19, 701–707. 
Pinzani, M., Rombouts, K., and Colagrande, S. (2005). Fibrosis in chronic liver diseases: diagnosis and management. J. 
Hepatol. 42 Suppl, S22-36. 
Pirola, C.J., Gianotti, T.F., Burgueño, A.L., Rey-Funes, M., Loidl, C.F., Mallardi, P., Martino, J.S., Castaño, G.O., and 
Sookoian, S. (2013). Epigenetic modification of liver mitochondrial DNA is associated with histological severity of 
nonalcoholic fatty liver disease. Gut 62, 1356–1363. 
Pollutri, D., Patrizi, C., Marinelli, S., Giovannini, C., Trombetta, E., Giannone, F.A., Baldassarre, M., Quarta, S., 
Vandewynckel, Y.P., Vandierendonck, A., et al. (2018). The epigenetically regulated miR-494 associates with stem-cell 
phenotype and induces sorafenib resistance in hepatocellular carcinoma. Cell Death Dis. 9, 4. 
Popov, Y., Patsenker, E., Fickert, P., Trauner, M., and Schuppan, D. (2005). Mdr2 (Abcb4)-/- mice spontaneously develop 
severe biliary fibrosis via massive dysregulation of pro- and antifibrogenic genes. J. Hepatol. 43, 1045–1054. 
Poupon, R., Chazouillères, O., and Poupon, R.E. (2000). Chronic cholestatic diseases. J. Hepatol. 32, 129–140. 
MicroRNAs in liver disease 
232 
 
Poupon, R.E., Balkau, B., Eschwège, E., Poupon, R., and Group*,  the U.-P.S. (1991). A Multicenter, Controlled Trial of 
Ursodiol for the Treatment of Primary Biliary Cirrhosis. N. Engl. J. Med. 324, 1548–1554. 
Prudova, A., Bauman, Z., Braun, A., Vitvitsky, V., Lu, S.C., and Banerjee, R. (2006). S-adenosylmethionine stabilizes 
cystathionine beta-synthase and modulates redox capacity. Proc. Natl. Acad. Sci. U. S. A. 103, 6489–6494. 
Puri, P., Mirshahi, F., Cheung, O., Natarajan, R., Maher, J.W., Kellum, J.M., and Sanyal, A.J. (2008). Activation and 
dysregulation of the unfolded protein response in nonalcoholic fatty liver disease. Gastroenterology 134, 568–576. 
Radaeva, S., Sun, R., Jaruga, B., Nguyen, V.T., Tian, Z., and Gao, B. (2006). Natural Killer Cells Ameliorate Liver 
Fibrosis by Killing Activated Stellate Cells in NKG2D-Dependent and Tumor Necrosis Factor–Related Apoptosis-
Inducing Ligand–Dependent Manners. Gastroenterology 130, 435–452. 
Rahman, S.M., Schroeder-Gloeckler, J.M., Janssen, R.C., Jiang, H., Qadri, I., Maclean, K.N., and Friedman, J.E. (2007). 
CCAAT/enhancing binding protein beta deletion in mice attenuates inflammation, endoplasmic reticulum stress, and lipid 
accumulation in diet-induced nonalcoholic steatohepatitis. Hepatol. Baltim. Md 45, 1108–1117. 
Rahmani, M., Davis, E.M., Bauer, C., Dent, P., and Grant, S. (2005). Apoptosis induced by the kinase inhibitor BAY 43-
9006 in human leukemia cells involves down-regulation of Mcl-1 through inhibition of translation. J. Biol. Chem. 280, 
35217–35227. 
Rakhshandehroo, M., Knoch, B., Müller, M., and Kersten, S. (2010). Peroxisome Proliferator-Activated Receptor Alpha 
Target Genes. PPAR Res. 2010. 
Ramirez-Tortosa, M.C., Ramirez-Tortosa, C.L., Mesa, M.D., Granados, S., Gil, Á., and Quiles, J.L. (2009). Curcumin 
ameliorates rabbits’s steatohepatitis via respiratory chain, oxidative stress, and TNF-α. Free Radic. Biol. Med. 47, 924–
931. 
Ratziu, V., Goodman, Z., and Sanyal, A. (2015). Current efforts and trends in the treatment of NASH. J. Hepatol. 62, 
S65–S75. 
Ravandi, F., Alattar, M.L., Grunwald, M.R., Rudek, M.A., Rajkhowa, T., Richie, M.A., Pierce, S., Daver, N., Garcia-
Manero, G., Faderl, S., et al. (2013). Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia 
and FLT-3 internal tandem duplication mutation. Blood 121, 4655–4662. 
Revill, K., Wang, T., Lachenmayer, A., Kojima, K., Harrington, A., Li, J., Hoshida, Y., Llovet, J.M., and Powers, S. 
(2013). Genome-wide methylation analysis and epigenetic unmasking identify tumor suppressor genes in hepatocellular 
carcinoma. Gastroenterology 145, 1424-1435-25. 
Riley, T., and Bhatti, A.M. (2001). Preventive Strategies in Chronic Liver Disease: Part I. Alcohol, Vaccines, Toxic 
Medications and Supplements, Diet and Exercise. Am. Fam. Physician 64, 1555. 
Roberts, A.B., and Wakefield, L.M. (2003). The two faces of transforming growth factor beta in carcinogenesis. Proc. 
Natl. Acad. Sci. U. S. A. 100, 8621–8623. 
Roberts, S.K., Ludwig, J., and Larusso, N.F. (1997). The pathobiology of biliary epithelia. Gastroenterology 112, 269–
279. 
Rockey, D.C., Boyles, J.K., Gabbiani, G., and Friedman, S.L. (1992). Rat hepatic lipocytes express smooth muscle actin 
upon activation in vivo and in culture. J. Submicrosc. Cytol. Pathol. 24, 193–203. 
Roderburg, C., Urban, G.-W., Bettermann, K., Vucur, M., Zimmermann, H., Schmidt, S., Janssen, J., Koppe, C., Knolle, 
P., Castoldi, M., et al. (2011). Micro-RNA profiling reveals a role for miR-29 in human and murine liver fibrosis. Hepatol. 
Baltim. Md 53, 209–218. 
Rowling, M.J., and Schalinske, K.L. (2001). Retinoid Compounds Activate and Induce Hepatic Glycine N-
Methyltransferase in Rats. J. Nutr. 131, 1914–1917. 
Rowling, M.J., and Schalinske, K.L. (2003). Retinoic Acid and Glucocorticoid Treatment Induce Hepatic Glycine N-
Methyltransferase and Lower Plasma Homocysteine Concentrations in Rats and Rat Hepatoma Cells. J. Nutr. 133, 3392–
3398. 
Rowling, M.J., McMullen, M.H., Chipman, D.C., and Schalinske, K.L. (2002). Hepatic glycine N-methyltransferase is 
up-regulated by excess dietary methionine in rats. J. Nutr. 132, 2545–2550. 
Ruiz, J.I., and Ochoa, B. (1997). Quantification in the subnanomolar range of phospholipids and neutral lipids by 
monodimensional thin-layer chromatography and image analysis. J. Lipid Res. 38, 1482–1489. 
Russell, D.W. (2003). The enzymes, regulation, and genetics of bile acid synthesis. Annu. Rev. Biochem. 72, 137–174. 
 Bibliography 
233 
 
Russo, F.P., Alison, M.R., Bigger, B.W., Amofah, E., Florou, A., Amin, F., Bou-Gharios, G., Jeffery, R., Iredale, J.P., 
and Forbes, S.J. (2006). The bone marrow functionally contributes to liver fibrosis. Gastroenterology 130, 1807–1821. 
Saab, S., Tam, S.P., Tran, B. inh N., Melton, A.C., Tangkijvanich, P., Wong, H., and Yee, H.F. (2002). Myosin mediates 
contractile force generation by hepatic stellate cells in response to endothelin-1. J. Biomed. Sci. 9, 607–612. 
Sahin, H., Trautwein, C., and Wasmuth, H.E. (2010). Functional role of chemokines in liver disease models. Nat. Rev. 
Gastroenterol. Hepatol. 7, 682–690. 
Saito, Y., Kanai, Y., Sakamoto, M., Saito, H., Ishii, H., and Hirohashi, S. (2001). Expression of mRNA for DNA 
methyltransferases and methyl-CpG-binding proteins and DNA methylation status on CpG islands and pericentromeric 
satellite regions during human hepatocarcinogenesis. Hepatol. Baltim. Md 33, 561–568. 
Saito, Y., Kanai, Y., Nakagawa, T., Sakamoto, M., Saito, H., Ishii, H., and Hirohashi, S. (2003). Increased protein 
expression of DNA methyltransferase (DNMT) 1 is significantly correlated with the malignant potential and poor 
prognosis of human hepatocellular carcinomas. Int. J. Cancer 105, 527–532. 
Sanyal, A.J. (2005). Mechanisms of Disease: pathogenesis of nonalcoholic fatty liver disease. Nat. Clin. Pract. 
Gastroenterol. Hepatol. 2, 46–53. 
Sanyal, A.J., Campbell-Sargent, C., Mirshahi, F., Rizzo, W.B., Contos, M.J., Sterling, R.K., Luketic, V.A., Shiffman, 
M.L., and Clore, J.N. (2001). Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial 
abnormalities. Gastroenterology 120, 1183–1192. 
Sanyal, A.J., Chalasani, N., Kowdley, K.V., McCullough, A., Diehl, A.M., Bass, N.M., Neuschwander-Tetri, B.A., 
Lavine, J.E., Tonascia, J., Unalp, A., et al. (2010). Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis. 
N. Engl. J. Med. 362, 1675–1685. 
Satapati, S., Sunny, N.E., Kucejova, B., Fu, X., He, T.T., Méndez-Lucas, A., Shelton, J.M., Perales, J.C., Browning, J.D., 
and Burgess, S.C. (2012). Elevated TCA cycle function in the pathology of diet-induced hepatic insulin resistance and 
fatty liver. J. Lipid Res. 53, 1080–1092. 
Savill, J., and Fadok, V. (2000). Corpse clearance defines the meaning of cell death. Nature 407, 784–788. 
Schaeffeler, E., Hellerbrand, C., Nies, A.T., Winter, S., Kruck, S., Hofmann, U., van der Kuip, H., Zanger, U.M., 
Koepsell, H., and Schwab, M. (2011). DNA methylation is associated with downregulation of the organic cation 
transporter OCT1 (SLC22A1) in human hepatocellular carcinoma. Genome Med. 3, 82. 
Schiöth, H.B., Boström, A., Murphy, S.K., Erhart, W., Hampe, J., Moylan, C., and Mwinyi, J. (2016). A targeted analysis 
reveals relevant shifts in the methylation and transcription of genes responsible for bile acid homeostasis and drug 
metabolism in non-alcoholic fatty liver disease. BMC Genomics 17, 462. 
Schmidt, C.M., McKillop, I.H., Cahill, P.A., and Sitzmann, J.V. (1997). Increased MAPK expression and activity in 
primary human hepatocellular carcinoma. Biochem. Biophys. Res. Commun. 236, 54–58. 
Scholten, D., Osterreicher, C.H., Scholten, A., Iwaisako, K., Gu, G., Brenner, D.A., and Kisseleva, T. (2010). Genetic 
labeling does not detect epithelial-to-mesenchymal transition of cholangiocytes in liver fibrosis in mice. Gastroenterology 
139, 987–998. 
Scholten, D., Trebicka, J., Liedtke, C., and Weiskirchen, R. (2015). The carbon tetrachloride model in mice. Lab. Anim. 
49, 4–11. 
Schuppan, D., and Afdhal, N.H. (2008). Liver Cirrhosis. Lancet 371, 838–851. 
Schuppan, D., Ruehl, M., Somasundaram, R., and Hahn, E.G. (2001). Matrix as a modulator of hepatic fibrogenesis. 
Semin. Liver Dis. 21, 351–372. 
Sedlaczek, N., Jia, J.-D., Bauer, M., Herbst, H., Ruehl, M., Hahn, E.G., and Schuppan, D. (2001). Proliferating Bile Duct 
Epithelial Cells Are a Major Source of Connective Tissue Growth Factor in Rat Biliary Fibrosis. Am. J. Pathol. 158, 
1239–1244. 
Serviddio, G., Bellanti, F., Tamborra, R., Rollo, T., Romano, A.D., Giudetti, A.M., Capitanio, N., Petrella, A., 
Vendemiale, G., and Altomare, E. (2008). Alterations of hepatic ATP homeostasis and respiratory chain during 
development of non-alcoholic steatohepatitis in a rodent model. Eur. J. Clin. Invest. 38, 245–252. 
Shafiei, M.S., and Rockey, D.C. (2006). The role of integrin-linked kinase in liver wound healing. J. Biol. Chem. 281, 
24863–24872. 
Shen, J., Wang, S., Zhang, Y.-J., Kappil, M., Wu, H.-C., Kibriya, M.G., Wang, Q., Jasmine, F., Ahsan, H., Lee, P.-H., et 
al. (2012). Genome-wide DNA methylation profiles in hepatocellular carcinoma. Hepatol. Baltim. Md 55, 1799–1808. 
MicroRNAs in liver disease 
234 
 
Shimano, H., Horton, J.D., Shimomura, I., Hammer, R.E., Brown, M.S., and Goldstein, J.L. (1997). Isoform 1c of sterol 
regulatory element binding protein is less active than isoform 1a in livers of transgenic mice and in cultured cells. J. Clin. 
Invest. 99, 846–854. 
Shimomura, I., Bashmakov, Y., Ikemoto, S., Horton, J.D., Brown, M.S., and Goldstein, J.L. (1999). Insulin selectively 
increases SREBP-1c mRNA in the livers of rats with streptozotocin-induced diabetes. Proc. Natl. Acad. Sci. U. S. A. 96, 
13656–13661. 
Shukla, G.C., Singh, J., and Barik, S. (2011). MicroRNAs: Processing, Maturation, Target Recognition and Regulatory 
Functions. Mol. Cell. Pharmacol. 3, 83–92. 
Shyh-Chang, N., Locasale, J.W., Lyssiotis, C.A., Zheng, Y., Teo, R.Y., Ratanasirintrawoot, S., Zhang, J., Onder, T., 
Unternaehrer, J.J., Zhu, H., et al. (2013). Influence of Threonine Metabolism on S-adenosyl-methionine and Histone 
Methylation. Science 339, 222–226. 
Siegel, A.B., and Zhu, A.X. (2009). Metabolic syndrome and hepatocellular carcinoma: two growing epidemics with a 
potential link. Cancer 115, 5651–5661. 
Singh, R., Kaushik, S., Wang, Y., Xiang, Y., Novak, I., Komatsu, M., Tanaka, K., Cuervo, A.M., and Czaja, M.J. (2009). 
Autophagy regulates lipid metabolism. Nature 458, 1131–1135. 
Smith, Z.D., and Meissner, A. (2013). DNA methylation: roles in mammalian development. Nat. Rev. Genet. 14, 204–
220. 
Snyder, M.W., Kircher, M., Hill, A.J., Daza, R.M., and Shendure, J. (2016). Cell-free DNA Comprises an In Vivo 
Nucleosome Footprint that Informs Its Tissues-Of-Origin. Cell 164, 57–68. 
Sodeman, T., Bronk, S.F., Roberts, P.J., Miyoshi, H., and Gores, G.J. (2000). Bile salts mediate hepatocyte apoptosis by 
increasing cell surface trafficking of Fas. Am. J. Physiol. - Gastrointest. Liver Physiol. 278, G992–G999. 
Soden, J.S., Devereaux, M.W., Haas, J.E., Gumpricht, E., Dahl, R., Gralla, J., Traber, M.G., and Sokol, R.J. (2007). 
Subcutaneous vitamin E ameliorates liver injury in an in vivo model of steatocholestasis. Hepatol. Baltim. Md 46, 485–
495. 
Sokol, R.J., Devereaux, M., Khandwala, R., and O’Brien, K. (1993). Evidence for involvement of oxygen free radicals in 
bile acid toxicity to isolated rat hepatocytes. Hepatol. Baltim. Md 17, 869–881. 
Sokol, R.J., Winklhofer-Roob, B.M., Devereaux, M.W., and McKim, J.M. (1995). Generation of hydroperoxides in 
isolated rat hepatocytes and hepatic mitochondria exposed to hydrophobic bile acids. Gastroenterology 109, 1249–1256. 
Sokol, R.J., McKim, J.M., Goff, M.C., Ruyle, S.Z., Devereaux, M.W., Han, D., Packer, L., and Everson, G. (1998). 
Vitamin E reduces oxidant injury to mitochondria and the hepatotoxicity of taurochenodeoxycholic acid in the rat. 
Gastroenterology 114, 164–174. 
Song, M.-A., Tiirikainen, M., Kwee, S., Okimoto, G., Yu, H., and Wong, L.L. (2013). Elucidating the landscape of 
aberrant DNA methylation in hepatocellular carcinoma. PloS One 8, e55761. 
Sookoian, S., Rosselli, M.S., Gemma, C., Burgueño, A.L., Fernández Gianotti, T., Castaño, G.O., and Pirola, C.J. (2010). 
Epigenetic regulation of insulin resistance in nonalcoholic fatty liver disease: Impact of liver methylation of the 
peroxisome proliferator–activated receptor γ coactivator 1α promoter. Hepatology 52, 1992–2000. 
Stachowicz, A., Suski, M., Olszanecki, R., Madej, J., Okoń, K., and Korbut, R. (2012). Proteomic analysis of liver 
mitochondria of apolipoprotein E knockout mice treated with metformin. J. Proteomics 77, 167–175. 
Staels, B., Rubenstrunk, A., Noel, B., Rigou, G., Delataille, P., Millatt, L.J., Baron, M., Lucas, A., Tailleux, A., Hum, 
D.W., et al. (2013). Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha/delta agonist, 
GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Hepatol. Baltim. Md 58, 1941–
1952. 
Starkel, P., and Leclercq, I.A. (2011). Animal models for the study of hepatic fibrosis. Best Pract. Res. Clin. Gastroenterol. 
25, 319–333. 
Stefanska, B., Huang, J., Bhattacharyya, B., Suderman, M., Hallett, M., Han, Z.-G., and Szyf, M. (2011). Definition of 
the landscape of promoter DNA hypomethylation in liver cancer. Cancer Res. 71, 5891–5903. 
Stoyanov, E., Ludwig, G., Mizrahi, L., Olam, D., Schnitzer-Perlman, T., Tasika, E., Sass, G., Tiegs, G., Jiang, Y., Nie, 
T., et al. (2015). Chronic liver inflammation modifies DNA methylation at the precancerous stage of murine 
hepatocarcinogenesis. Oncotarget 6, 11047–11060. 
 Bibliography 
235 
 
Strable, M.S., and Ntambi, J.M. (2010). Genetic control of de novo lipogenesis: role in diet-induced obesity. Crit. Rev. 
Biochem. Mol. Biol. 45, 199–214. 
Sullivan, D.M., and Hoffman, J.L. (1983). Fractionation and kinetic properties of rat liver and kidney methionine 
adenosyltransferase isozymes. Biochemistry (Mosc.) 22, 1636–1641. 
Sun, C., Fan, J.-G., and Qiao, L. (2015a). Potential Epigenetic Mechanism in Non-Alcoholic Fatty Liver Disease. Int. J. 
Mol. Sci. 16, 5161–5179. 
Sun, X., Liu, Y., Li, M., Wang, M., and Wang, Y. (2015b). Involvement of miR-485-5p in hepatocellular carcinoma 
progression targeting EMMPRIN. Biomed. Pharmacother. Biomedecine Pharmacother. 72, 58–65. 
Sutter, B.M., Wu, X., Laxman, S., and Tu, B.P. (2013). Methionine inhibits autophagy and promotes growth by inducing 
the SAM-responsive methylation of PP2A. Cell 154, 403–415. 
Suzuki, M.M., and Bird, A. (2008). DNA methylation landscapes: provocative insights from epigenomics. Nat. Rev. 
Genet. 9, 465–476. 
Szabo, G., and Bala, S. (2013). MicroRNAs in liver disease. Nat. Rev. Gastroenterol. Hepatol. 10, 542–552. 
Szendroedi, J., Chmelik, M., Schmid, A.I., Nowotny, P., Brehm, A., Krssak, M., Moser, E., and Roden, M. (2009). 
Abnormal hepatic energy homeostasis in type 2 diabetes. Hepatol. Baltim. Md 50, 1079–1086. 
Tacke, F., and Trautwein, C. (2015). Mechanisms of liver fibrosis resolution. J. Hepatol. 63, 1038–1039. 
Tag, C.G., Sauer-Lehnen, S., Weiskirchen, S., Borkham-Kamphorst, E., Tolba, R.H., Tacke, F., and Weiskirchen, R. 
(2015). Bile Duct Ligation in Mice: Induction of Inflammatory Liver Injury and Fibrosis by Obstructive Cholestasis. J. 
Vis. Exp. JoVE. 
Tahiliani, M., Koh, K.P., Shen, Y., Pastor, W.A., Bandukwala, H., Brudno, Y., Agarwal, S., Iyer, L.M., Liu, D.R., 
Aravind, L., et al. (2009). Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL 
partner TET1. Science 324, 930–935. 
Tai, W.-T., Cheng, A.-L., Shiau, C.-W., Huang, H.-P., Huang, J.-W., Chen, P.-J., and Chen, K.-F. (2011). Signal 
transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma. 
J. Hepatol. 55, 1041–1048. 
Takahashi, Y., Soejima, Y., and Fukusato, T. (2012). Animal models of nonalcoholic fatty liver disease/nonalcoholic 
steatohepatitis. World J. Gastroenterol. WJG 18, 2300–2308. 
Takuma, Y., and Nouso, K. (2010). Nonalcoholic steatohepatitis-associated hepatocellular carcinoma: Our case series 
and literature review. World J. Gastroenterol. WJG 16, 1436–1441. 
Tamaki, N., Hatano, E., Taura, K., Tada, M., Kodama, Y., Nitta, T., Iwaisako, K., Seo, S., Nakajima, A., Ikai, I., et al. 
(2008). CHOP deficiency attenuates cholestasis-induced liver fibrosis by reduction of hepatocyte injury. Am. J. Physiol. 
Gastrointest. Liver Physiol. 294, G498-505. 
Tang, Y., Bian, Z., Zhao, L., Liu, Y., Liang, S., Wang, Q., Han, X., Peng, Y., Chen, X., Shen, L., et al. (2011). Interleukin-
17 exacerbates hepatic steatosis and inflammation in non-alcoholic fatty liver disease. Clin. Exp. Immunol. 166, 281–
290. 
Taura, K., Miura, K., Iwaisako, K., Osterreicher, C.H., Kodama, Y., Penz-Osterreicher, M., and Brenner, D.A. (2010). 
Hepatocytes do not undergo epithelial-mesenchymal transition in liver fibrosis in mice. Hepatol. Baltim. Md 51, 1027–
1036. 
Teli, M.R., James, O.F., Burt, A.D., Bennett, M.K., and Day, C.P. (1995). The natural history of nonalcoholic fatty liver: 
a follow-up study. Hepatol. Baltim. Md 22, 1714–1719. 
Tesori, V., Piscaglia, A.C., Samengo, D., Barba, M., Bernardini, C., Scatena, R., Pontoglio, A., Castellini, L., Spelbrink, 
J.N., Maulucci, G., et al. (2015). The multikinase inhibitor Sorafenib enhances glycolysis and synergizes with glycolysis 
blockade for cancer cell killing. Sci. Rep. 5, srep09149. 
Thannickal, V.J., and Fanburg, B.L. (2000). Reactive oxygen species in cell signaling. Am. J. Physiol. - Lung Cell. Mol. 
Physiol. 279, L1005–L1028. 
Thomas, P.D., Campbell, M.J., Kejariwal, A., Mi, H., Karlak, B., Daverman, R., Diemer, K., Muruganujan, A., and 
Narechania, A. (2003). PANTHER: a library of protein families and subfamilies indexed by function. Genome Res. 13, 
2129–2141. 
MicroRNAs in liver disease 
236 
 
Thompson, M.D., and Monga, S.P.S. (2007). WNT/beta-catenin signaling in liver health and disease. Hepatol. Baltim. 
Md 45, 1298–1305. 
Tischoff, I., and Tannapfel, A. (2008). DNA methylation in hepatocellular carcinoma. World J. Gastroenterol. WJG 14, 
1741–1748. 
Toffanin, S., Hoshida, Y., Lachenmayer, A., Villanueva, A., Cabellos, L., Minguez, B., Savic, R., Ward, S.C., Thung, S., 
Chiang, D.Y., et al. (2011). MicroRNA-based classification of hepatocellular carcinoma and oncogenic role of miR-517a. 
Gastroenterology 140, 1618–1628.e16. 
Torres, L., Avila, M.A., Carretero, M.V., Latasa, M.U., Caballería, J., López-Rodas, G., Boukaba, A., Lu, S.C., Franco, 
L., and Mato, J.M. (2000). Liver-specific methionine adenosyltransferase MAT1A gene expression is associated with a 
specific pattern of promoter methylation and histone acetylation: implications for MAT1A silencing during 
transformation. FASEB J. Off. Publ. Fed. Am. Soc. Exp. Biol. 14, 95–102. 
Trapnell, C., Pachter, L., and Salzberg, S.L. (2009). TopHat: discovering splice junctions with RNA-Seq. Bioinforma. 
Oxf. Engl. 25, 1105–1111. 
Trauner, M., and Boyer, J.L. (2003). Bile salt transporters: molecular characterization, function, and regulation. Physiol. 
Rev. 83, 633–671. 
Trauner, M., Meier, P.J., and Boyer, J.L. (1998). Molecular Pathogenesis of Cholestasis. N. Engl. J. Med. 339, 1217–
1227. 
Trautwein, C., Friedman, S.L., Schuppan, D., and Pinzani, M. (2015). Hepatic fibrosis: Concept to treatment. J. Hepatol. 
62, S15-24. 
Tseng, T.-L., Shih, Y.-P., Huang, Y.-C., Wang, C.-K., Chen, P.-H., Chang, J.-G., Yeh, K.-T., Chen, Y.-M.A., and Buetow, 
K.H. (2003). Genotypic and phenotypic characterization of a putative tumor susceptibility gene, GNMT, in liver cancer. 
Cancer Res. 63, 647–654. 
Tuchweber, B., Desmoulière, A., Bochaton-Piallat, M.L., Rubbia-Brandt, L., and Gabbiani, G. (1996). Proliferation and 
phenotypic modulation of portal fibroblasts in the early stages of cholestatic fibrosis in the rat. Lab. Investig. J. Tech. 
Methods Pathol. 74, 265–278. 
Turnpenny, P.D., and Ellard, S. (2012). Alagille syndrome: pathogenesis, diagnosis and management. Eur. J. Hum. Genet. 
20, 251–257. 
Utzschneider, K.M., and Kahn, S.E. (2006). Review: The role of insulin resistance in nonalcoholic fatty liver disease. J. 
Clin. Endocrinol. Metab. 91, 4753–4761. 
Van Beers, B.E., Materne, R., Annet, L., Hermoye, L., Sempoux, C., Peeters, F., Smith, A.M., Jamart, J., and Horsmans, 
Y. (2003). Capillarization of the sinusoids in liver fibrosis: noninvasive assessment with contrast-enhanced MRI in the 
rabbit. Magn. Reson. Med. 49, 692–699. 
Van Beneden, K., Mannaerts, I., Pauwels, M., Van den Branden, C., and van Grunsven, L.A. (2013). HDAC inhibitors in 
experimental liver and kidney fibrosis. Fibrogenesis Tissue Repair 6, 1. 
Van Mil, S.W.C., Milona, A., Dixon, P.H., Mullenbach, R., Geenes, V.L., Chambers, J., Shevchuk, V., Moore, G.E., 
Lammert, F., Glantz, A.G., et al. (2007). Functional variants of the central bile acid sensor FXR identified in intrahepatic 
cholestasis of pregnancy. Gastroenterology 133, 507–516. 
Varela-Rey, M., Iruarrizaga-Lejarreta, M., Lozano, J.J., Aransay, A.M., Fernandez, A.F., Lavin, J.L., Mósen-Ansorena, 
D., Berdasco, M., Turmaine, M., Luka, Z., et al. (2014). S-adenosylmethionine levels regulate the Schwann cell DNA 
methylome. Neuron 81, 1024–1039. 
Vernon, G., Baranova, A., and Younossi, Z.M. (2011). Systematic review: the epidemiology and natural history of non-
alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment. Pharmacol. Ther. 34, 274–285. 
Villa, E., Critelli, R., Lei, B., Marzocchi, G., Cammà, C., Giannelli, G., Pontisso, P., Cabibbo, G., Enea, M., Colopi, S., 
et al. (2016). Neoangiogenesis-related genes are hallmarks of fast-growing hepatocellular carcinomas and worst survival. 
Results from a prospective study. Gut 65, 861–869. 
Villanueva, A., Portela, A., Sayols, S., Battiston, C., Hoshida, Y., Méndez-González, J., Imbeaud, S., Letouzé, E., 
Hernandez-Gea, V., Cornella, H., et al. (2015). DNA methylation-based prognosis and epidrivers in hepatocellular 
carcinoma. Hepatol. Baltim. Md 61, 1945–1956. 
Wagner, C., Briggs, W.T., and Cook, R.J. (1985). Inhibition of glycine n-methyltransferase activity by folate derivatives: 
Implications for regulation of methyl group metabolism. Biochem. Biophys. Res. Commun. 127, 746–752. 
 Bibliography 
237 
 
Wagner, M., Zollner, G., and Trauner, M. (2008). Nuclear bile acid receptor farnesoid X receptor meets nuclear factor-
kappaB: new insights into hepatic inflammation. Hepatol. Baltim. Md 48, 1383–1386. 
Wagner, M., Choi, S., Panzitt, K., Mamrosh, J.L., Lee, J.M., Zaufel, A., Xiao, R., Wooton-Kee, R., Ståhlman, M., 
Newgard, C.B., et al. (2016). LRH-1 is a critical determinant of methyl-pool metabolism. Hepatol. Baltim. Md 63, 95–
106. 
Waisbourd-Zinman, O., Koh, H., Tsai, S., Lavrut, P.-M., Dang, C., Zhao, X., Pack, M., Cave, J., Hawes, M., Koo, K.A., 
et al. (2016). The toxin biliatresone causes mouse extrahepatic cholangiocyte damage and fibrosis through decreased 
glutathione and SOX17. Hepatol. Baltim. Md 64, 880–893. 
Wakamatsu, T., Nakahashi, Y., Hachimine, D., Seki, T., and Okazaki, K. (2007). The combination of glycyrrhizin and 
lamivudine can reverse the cisplatin resistance in hepatocellular carcinoma cells through inhibition of multidrug 
resistance-associated proteins. Int. J. Oncol. 31, 1465–1472. 
Wang, H., Chen, J., Hollister, K., Sowers, L.C., and Forman, B.M. (1999). Endogenous Bile Acids Are Ligands for the 
Nuclear Receptor FXR/BAR. Mol. Cell 3, 543–553. 
Wang, P., Qiu, W., Dudgeon, C., Liu, H., Huang, C., Zambetti, G.P., Yu, J., and Zhang, L. (2009). PUMA is directly 
activated by NF-kappaB and contributes to TNF-alpha-induced apoptosis. Cell Death Differ. 16, 1192–1202. 
Wang, X.W., Heegaard, N.H.H., and Ørum, H. (2012). MicroRNAs in Liver Disease. Gastroenterology 142, 1431–1443. 
Wasmuth, H.E., Tacke, F., and Trautwein, C. (2010). Chemokines in liver inflammation and fibrosis. Semin. Liver Dis. 
30, 215–225. 
Watanabe, M., Houten, S.M., Wang, L., Moschetta, A., Mangelsdorf, D.J., Heyman, R.A., Moore, D.D., and Auwerx, J. 
(2004). Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c. J. Clin. Invest. 113, 1408–
1418. 
Watmough, N.J., and Frerman, F.E. (2010). The electron transfer flavoprotein: Ubiquinone oxidoreductases. Biochim. 
Biophys. Acta BBA - Bioenerg. 1797, 1910–1916. 
Wei, G., Wang, M., and Carr, B.I. (2010). Sorafenib combined vitamin k induces apoptosis in human pancreatic cancer 
cell lines through RAF/MEK/ERK and c-Jun NH2-terminal kinase pathways. J. Cell. Physiol. 224, 112–119. 
Wei, J.L., Leung, J.C.-F., Loong, T.C.-W., Wong, G.L.-H., Yeung, D.K.-W., Chan, R.S.-M., Chan, H.L.-Y., Chim, A.M.-
L., Woo, J., Chu, W.C.-W., et al. (2015). Prevalence and Severity of Nonalcoholic Fatty Liver Disease in Non-Obese 
Patients: A Population Study Using Proton-Magnetic Resonance Spectroscopy. Am. J. Gastroenterol. 110, 1306. 
Welzel, T.M., Graubard, B.I., Zeuzem, S., El-Serag, H.B., Davila, J.A., and McGlynn, K.A. (2011). Metabolic syndrome 
increases the risk of primary liver cancer in the United States: a study in the SEER-Medicare database. Hepatol. Baltim. 
Md 54, 463–471. 
Wilhelm, S., Carter, C., Lynch, M., Lowinger, T., Dumas, J., Smith, R.A., Schwartz, B., Simantov, R., and Kelley, S. 
(2006). Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat. Rev. Drug Discov. 5, 
835–844. 
Wilhelm, S.M., Carter, C., Tang, L., Wilkie, D., McNabola, A., Rong, H., Chen, C., Zhang, X., Vincent, P., McHugh, 
M., et al. (2004). BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK 
Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis. Cancer Res. 64, 7099–7109. 
Williams, K.T., and Schalinske, K.L. (2007). New insights into the regulation of methyl group and homocysteine 
metabolism. J. Nutr. 137, 311–314. 
Winau, F., Hegasy, G., Weiskirchen, R., Weber, S., Cassan, C., Sieling, P.A., Modlin, R.L., Liblau, R.S., Gressner, A.M., 
and Kaufmann, S.H.E. (2007). Ito cells are liver-resident antigen-presenting cells for activating T cell responses. 
Immunity 26, 117–129. 
Wiśniewski, J.R., Zougman, A., Nagaraj, N., and Mann, M. (2009). Universal sample preparation method for proteome 
analysis. Nat. Methods 6, 359–362. 
Wojtovich, A.P., Smith, C.O., Haynes, C.M., Nehrke, K.W., and Brookes, P.S. (2013). Physiological consequences of 
complex II inhibition for aging, disease, and the mKATP channel. Biochim. Biophys. Acta 1827. 
Wong, R.J., Cheung, R., and Ahmed, A. (2014). Nonalcoholic steatohepatitis is the most rapidly growing indication for 
liver transplantation in patients with hepatocellular carcinoma in the U.S. Hepatol. Baltim. Md 59, 2188–2195. 
Woods, K., Thomson, J.M., and Hammond, S.M. (2007). Direct regulation of an oncogenic micro-RNA cluster by E2F 
transcription factors. J. Biol. Chem. 282, 2130–2134. 
MicroRNAs in liver disease 
238 
 
Wortham, M., He, L., Gyamfi, M., Copple, B.L., and Wan, Y.-J.Y. (2008). The transition from fatty liver to NASH 
associates with SAMe depletion in db/db mice fed a methionine choline-deficient diet. Dig. Dis. Sci. 53, 2761–2774. 
Xia, H., Ooi, L.L.P.J., and Hui, K.M. (2013). MicroRNA-216a/217-induced epithelial-mesenchymal transition targets 
PTEN and SMAD7 to promote drug resistance and recurrence of liver cancer. Hepatol. Baltim. Md 58, 629–641. 
Xia, J.-L., Dai, C., Michalopoulos, G.K., and Liu, Y. (2006). Hepatocyte growth factor attenuates liver fibrosis induced 
by bile duct ligation. Am. J. Pathol. 168, 1500–1512. 
Xu, R., Zhang, Z., and Wang, F.-S. (2012). Liver fibrosis: mechanisms of immune-mediated liver injury. Cell. Mol. 
Immunol. 9, 296–301. 
Xu, R., Wei, W., Krawczyk, M., Wang, W., Luo, H., Flagg, K., Yi, S., Shi, W., Quan, Q., Li, K., et al. (2017). Circulating 
tumour DNA methylation markers for diagnosis and prognosis of hepatocellular carcinoma. Nat. Mater. advance online 
publication. 
Xu, Y., Huang, J., Ma, L., Shan, J., Shen, J., Yang, Z., Liu, L., Luo, Y., Yao, C., and Qian, C. (2016). MicroRNA-122 
confers sorafenib resistance to hepatocellular carcinoma cells by targeting IGF-1R to regulate RAS/RAF/ERK signaling 
pathways. Cancer Lett. 371, 171–181. 
Yamashita, H., Takenoshita, M., Sakurai, M., Bruick, R.K., Henzel, W.J., Shillinglaw, W., Arnot, D., and Uyeda, K. 
(2001). A glucose-responsive transcription factor that regulates carbohydrate metabolism in the liver. Proc. Natl. Acad. 
Sci. U. S. A. 98, 9116–9121. 
Yang, C., Zeisberg, M., Mosterman, B., Sudhakar, A., Yerramalla, U., Holthaus, K., Xu, L., Eng, F., Afdhal, N., and 
Kalluri, R. (2003). Liver fibrosis: insights into migration of hepatic stellate cells in response to extracellular matrix and 
growth factors. Gastroenterology 124, 147–159. 
Yang, H., Huang, Z.Z., Zeng, Z., Chen, C., Selby, R.R., and Lu, S.C. (2001). Role of promoter methylation in increased 
methionine adenosyltransferase 2A expression in human liver cancer. Am. J. Physiol. Gastrointest. Liver Physiol. 280, 
G184-190. 
YANG, H., ARA, A.I., MAGILNICK, N., XIA, M., RAMANI, K., CHEN, H., LEE, T.D., MATO, J.M., and LU, S.C. 
(2008). Expression Pattern, Regulation, and Functions of Methionine Adenosyltransferase 2β Splicing Variants in 
Hepatoma Cells. Gastroenterology 134, 281–291. 
Yang, H., Cho, M.E., Li, T.W.H., Peng, H., Ko, K.S., Mato, J.M., and Lu, S.C. (2013a). MicroRNAs regulate methionine 
adenosyltransferase 1A expression in hepatocellular carcinoma. J. Clin. Invest. 123, 285–298. 
Yang, H., Liu, Y., Bai, F., Zhang, J.-Y., Ma, S.-H., Liu, J., Xu, Z.-D., Zhu, H.-G., Ling, Z.-Q., Ye, D., et al. (2013b). 
Tumor development is associated with decrease of TET gene expression and 5-methylcytosine hydroxylation. Oncogene 
32, 663–669. 
Yang, J.-J., Tao, H., Huang, C., Shi, K., Ma, T.-T., Bian, E.-B., Zhang, L., Liu, L.-P., Hu, W., Lv, X.-W., et al. (2013c). 
DNA methylation and MeCP2 regulation of PTCH1 expression during rats hepatic fibrosis. Cell. Signal. 25, 1202–1211. 
Yanguas, S.C., Cogliati, B., Willebrords, J., Maes, M., Colle, I., van den Bossche, B., de Oliveira, C.P.M.S., Andraus, 
W., Alves, V.A.F., Leclercq, I., et al. (2016). Experimental models of liver fibrosis. Arch. Toxicol. 90, 1025–1048. 
Yee, H.F. (1998). Rho directs activation-associated changes in rat hepatic stellate cell morphology via regulation of the 
actin cytoskeleton. Hepatol. Baltim. Md 28, 843–850. 
Yen, C.-H., Lu, Y.-C., Li, C.-H., Lee, C.-M., Chen, C.-Y., Cheng, M.-Y., Huang, S.-F., Chen, K.-F., Cheng, A.-L., Liao, 
L.-Y., et al. (2012). Functional characterization of glycine N-methyltransferase and its interactive protein 
DEPDC6/DEPTOR in hepatocellular carcinoma. Mol. Med. Camb. Mass 18, 286–296. 
Yeo, E.J., and Wagner, C. (1994). Tissue distribution of glycine N-methyltransferase, a major folate-binding protein of 
liver. Proc. Natl. Acad. Sci. U. S. A. 91, 210–214. 
Yerushalmi, B., Dahl, R., Devereaux, M.W., Gumpricht, E., and Sokol, R.J. (2001). Bile acid-induced rat hepatocyte 
apoptosis is inhibited by antioxidants and blockers of the mitochondrial permeability transition. Hepatol. Baltim. Md 33, 
616–626. 
Yin, X.-M., and Ding, W.-X. (2003). Death receptor activation-induced hepatocyte apoptosis and liver injury. Curr. Mol. 
Med. 3, 491–508. 
Yoshiji, H., Kuriyama, S., Yoshii, J., Ikenaka, Y., Noguchi, R., Hicklin, D.J., Wu, Y., Yanase, K., Namisaki, T., 
Yamazaki, M., et al. (2003). Vascular endothelial growth factor and receptor interaction is a prerequisite for murine 
hepatic fibrogenesis. Gut 52, 1347–1354. 
 Bibliography 
239 
 
Young, M.D., Wakefield, M.J., Smyth, G.K., and Oshlack, A. (2010). Gene ontology analysis for RNA-seq: accounting 
for selection bias. Genome Biol. 11, R14. 
Yu, S.J. (2016). A concise review of updated guidelines regarding the management of hepatocellular carcinoma around 
the world: 2010-2016. Clin. Mol. Hepatol. 22, 7–17. 
Yu, J., and Zhang, L. (2008). PUMA, a potent killer with or without p53. Oncogene 27, S71–S83. 
Yu, C., Wang, F., Jin, C., Huang, X., Miller, D.L., Basilico, C., and McKeehan, W.L. (2003). Role of fibroblast growth 
factor type 1 and 2 in carbon tetrachloride-induced hepatic injury and fibrogenesis. Am. J. Pathol. 163, 1653–1662. 
Yu, C., Bruzek, L.M., Meng, X.W., Gores, G.J., Carter, C.A., Kaufmann, S.H., and Adjei, A.A. (2005). The role of Mcl-
1 downregulation in the proapoptotic activity of the multikinase inhibitor BAY 43-9006. Oncogene 24, 6861–6869. 
Yu, C., Friday, B.B., Lai, J.-P., Yang, L., Sarkaria, J., Kay, N.E., Carter, C.A., Roberts, L.R., Kaufmann, S.H., and Adjei, 
A.A. (2006). Cytotoxic synergy between the multikinase inhibitor sorafenib and the proteasome inhibitor bortezomib in 
vitro: induction of apoptosis through Akt and c-Jun NH2-terminal kinase pathways. Mol. Cancer Ther. 5, 2378–2387. 
Yu, J., Ni, M., Xu, J., Zhang, H., Gao, B., Gu, J., Chen, J., Zhang, L., Wu, M., Zhen, S., et al. (2002). Methylation profiling 
of twenty promoter-CpG islands of genes which may contribute to hepatocellular carcinogenesis. BMC Cancer 2, 29. 
Zangar, R.C., Davydov, D.R., and Verma, S. (2004). Mechanisms that regulate production of reactive oxygen species by 
cytochrome P450. Toxicol. Appl. Pharmacol. 199, 316–331. 
Zeybel, M., Hardy, T., Robinson, S.M., Fox, C., Anstee, Q.M., Ness, T., Masson, S., Mathers, J.C., French, J., White, S., 
et al. (2015). Differential DNA methylation of genes involved in fibrosis progression in non-alcoholic fatty liver disease 
and alcoholic liver disease. Clin. Epigenetics 7. 
Zeybel, M., Luli, S., Sabater, L., Hardy, T., Oakley, F., Leslie, J., Page, A., Moran Salvador, E., Sharkey, V., Tsukamoto, 
H., et al. (2017). A Proof-of-Concept for Epigenetic Therapy of Tissue Fibrosis: Inhibition of Liver Fibrosis Progression 
by 3-Deazaneplanocin A. Mol. Ther. J. Am. Soc. Gene Ther. 25, 218–231. 
Zhai, B., and Sun, X.-Y. (2013). Mechanisms of resistance to sorafenib and the corresponding strategies in hepatocellular 
carcinoma. World J. Hepatol. 5, 345–352. 
Zhai, B., Hu, F., Jiang, X., Xu, J., Zhao, D., Liu, B., Pan, S., Dong, X., Tan, G., Wei, Z., et al. (2014). Inhibition of Akt 
reverses the acquired resistance to sorafenib by switching protective autophagy to autophagic cell death in hepatocellular 
carcinoma. Mol. Cancer Ther. 13, 1589–1598. 
Zhang, X.-Q., Xu, C.-F., Yu, C.-H., Chen, W.-X., and Li, Y.-M. (2014). Role of endoplasmic reticulum stress in the 
pathogenesis of nonalcoholic fatty liver disease. World J. Gastroenterol. WJG 20, 1768–1776. 
Zhang, Y., Ikegami, T., Honda, A., Miyazaki, T., Bouscarel, B., Rojkind, M., Hyodo, I., and Matsuzaki, Y. (2006). 
Involvement of integrin-linked kinase in carbon tetrachloride-induced hepatic fibrosis in rats. Hepatol. Baltim. Md 44, 
612–622. 
Zhou, G., Myers, R., Li, Y., Chen, Y., Shen, X., Fenyk-Melody, J., Wu, M., Ventre, J., Doebber, T., Fujii, N., et al. (2001). 
Role of AMP-activated protein kinase in mechanism of metformin action. J. Clin. Invest. 108, 1167–1174. 
Ziol, M., Handra-Luca, A., Kettaneh, A., Christidis, C., Mal, F., Kazemi, F., de Lédinghen, V., Marcellin, P., Dhumeaux, 
D., Trinchet, J.-C., et al. (2005). Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with 
chronic hepatitis C. Hepatol. Baltim. Md 41, 48–54. 
Zollner, G., and Trauner, M. (2008). Mechanisms of cholestasis. Clin. Liver Dis. 12, 1–26, vii. 
Zollner, G., Wagner, M., Fickert, P., Silbert, D., Fuchsbichler, A., Zatloukal, K., Denk, H., and Trauner, M. (2005). 
Hepatobiliary transporter expression in human hepatocellular carcinoma. Liver Int. Off. J. Int. Assoc. Study Liver 25, 
367–379. 
Zubiete-Franco, I., García-Rodríguez, J.L., Martínez-Uña, M., Martínez-Lopez, N., Woodhoo, A., Juan, V.G.-D., Beraza, 
N., Lage-Medina, S., Andrade, F., Fernandez, M.L., et al. (2016). Methionine and S-adenosylmethionine levels are critical 
regulators of PP2A activity modulating lipophagy during steatosis. J. Hepatol. 64, 409–418. 
(2002). REDUCTION IN THE INCIDENCE OF TYPE 2 DIABETES WITH LIFESTYLE INTERVENTION OR 
METFORMIN. N. Engl. J. Med. 346, 393–403. 
(2017). Cholestasis Treatment & Management: Medical Care, Surgical Care, Consultations. 
